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Stroke is the leading cause of disability for adults and the second leading cause of death 
worldwide. It is characterised by a sudden weakness or numbness of the face, arm or leg, 
most often on one side of the body. The most common type of stroke is an ischaemic stroke, 
the blockage of a cerebral vessel and is causing dementia. Nuclear Factor Erythroid 2 (NF-
E2)-Related Factor 2 (Nrf2) is a transcription factor and master regulator of a battery of 
antioxidant and anti-inflammatory genes such as Heme oxygenase-1 (hmox1), NAD(P)H 
dehydrogenase quinone 1 (nqo1), glutamate-cystine antiporter (xCT; gene slc7a11), 
sulfiredoxin 1 (srxn1). As astrocytes play a central role in the neuroprotective effects of 
boosting Nrf2, the overarching hypothesis of the present work is that boosting the Nrf2 
pathway in astrocytes will prevent oxidative stress and pro-inflammatory damage caused by 
ischaemia/reperfusion and thereby protect neurons from damage and diminish cognitive 
deficits and neurodegeneration that may lead to dementia. 
A mouse model of transient focal cerebral ischaemia was chosen to reproduce ischaemia in 
controlled conditions, by occluding the middle cerebral artery. Modest duration of ischaemia 
(15 minutes) was sufficient to cause ischaemic neuronal damage in the striatum and to 
significantly increase oxidative stress, inflammatory markers and to activate Nrf2-signalling. 
Furthermore, oxidative stress and inflammation were found despite reperfusion and in areas 
spared of neuronal death, suggesting they may still be at risk of cellular damage. Despite 
persistent elevations in oxidative stress, inflammatory glial cells and cytokines 4 weeks after 
ischaemia, there were no alterations to Nrf2-signalling suggesting that boosting Nrf2-
signalling may confer protective effects.  
Nrf2 overexpression in GFAP-expressing astrocytes in a mouse model (GFAP-Nrf2 mice) has 
been shown to confer protection against inflammation and oxidative stress in 
neurodegenerative models. Following ischaemia, GFAP-Nrf2 mice presented a significant 
reduction of neuronal damage, oxidative stress was markedly reduced, and levels of reactive 
astrocytes were increased in the peri-infarct of the cortex. This was paralleled with a 
significant increase of cxcl10 and anti-inflammatory il-4rα cytokine gene expression.  
These promising results led to next study the potential protective effects of boosting Nrf2 in 
astrocytes on cognitive and neurological deficits 4 weeks after ischaemic stroke. In this 
experiment, ischaemia impaired cognitive functions at 4 weeks and this was paralleled with 
oxidative stress and inflammation. Neuronal damage caused by ischaemia was not 
significantly altered between wild-type and GFAP-Nrf2 animals despite upregulated Nrf2-
signalling in GFAP-Nrf2 mice compared to wild-types. Nrf2 overexpression in astrocytes 
increased microglial response and reduced inflammatory c3, but their cognitive functions 
were further impaired compared to wild-types. 
Altogether these studies suggest that Nrf2 exerts different effects after ischaemia depending 
on the severity of stroke and the timepoint analysed. Furthermore, these results suggest that 
there is ongoing signalling between microglia and astrocytes. This work provides an original 
contribution to understanding the potential protective effects of Nrf2 overexpression in 






Lay summary  
Stroke is the leading cause of disability for adults and the second leading cause of death 
worldwide. The first symptom is a sudden numbness of the face, arm or leg, most often on 
one side of the body, and in the long term it can impair cognitive functions, the mental 
processes by which we think, remember, learn and make decisions. These processes depend 
on neurons, the main cell type of the brain, and their environment. The main cause of stroke 
is a blockage of a vessel in the brain, called cerebral ischaemia. It leads to a cascade of 
damaging mechanisms that can cause dysfunction and death of neurons. These damaging 
mechanisms include alterations to the immune defence system called inflammation. Another 
damaging mechanism is called oxidative stress and is characterised by an overproduction of 
toxic molecules called oxidants that can damage cells. The brain normally produces 
antioxidants to balance it out, however after stroke, these defences are reduced and 
overwhelmed. These two features of ischaemia endanger neurons to the point that it might 
lead to their death and cause cognitive decline. Nrf2 is a protein known for its antioxidant 
and anti-inflammatory effects and is thus a promising candidate for treatment of stroke 
patients. In this thesis, the impact of stroke on Nrf2 was studied together with the potential 
protective effect of boosting Nrf2 on neuron damage after stroke. It was found that Nrf2 is 
activated during the first day after stroke and that these changes were associated with 
increased oxidative stress and inflammation. However, four weeks after ischaemia, oxidative 
stress and inflammation persisted whereas the Nrf2 system was no longer activated.  
The protective effects of Nrf2 are dependent on another cell type in the brain called 
astrocytes, that provide a supporting role for neurons that includes providing them with 
antioxidants. A model has been developed in which Nrf2 levels are boosted specifically in 
astrocytes, and other studies have shown that this has beneficial effects in several 
neurodegenerative diseases such as Parkinson’s disease. In the second part of this thesis, the 
effects of boosting Nrf2 in astrocytes was studied in a model of stroke. Boosting Nrf2 in 
astrocytes was shown to modestly decrease damage to neurons and reduce inflammation 
and oxidative stress 1 day after a large stroke. This promising result led on to a second 
experiment to determine if boosting Nrf2 could protect neurons and cognition in the longer 
term (4 weeks) response to a smaller stroke. Interestingly, in this experiment, boosting Nrf2 
in astrocytes did not alter neuronal damage and oxidative stress after ischaemia although 
alterations to inflammation were detected. Surprisingly, it was found that boosting Nrf2 in 
astrocytes impaired cognitive function. Altogether these studies suggest that Nrf2 exerts 
different effects after ischaemia depending on the severity of stroke and the time point 










Non est arbor solida nec fortis nisi quam frequens ventus incursant. Lucius Annaeus Seneca. 
No tree becomes rooted and sturdy unless many a wind assails it, Seneca the younger. 
L’arbre ne devient solide et fort qu’en subissant les assauts répétés du vent. Sénèque le Jeune. 
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1. Introduction  
1.1. General clinical knowledge on ischaemic stroke 
1.1.1. Definition  
1.1.1.1. Acute Symptoms 
Stroke is characterised by the World Health Organisation as sudden weakness or numbness 
of the face, arm or leg, most often on one side of the body. Other symptoms include 
confusion, difficulty speaking or understanding speech; difficulty seeing with one or both 
eyes; difficulty walking, dizziness, loss of balance or coordination; severe headache with no 
known cause; fainting or unconsciousness (reference from WHO; Siegler et al., 2013). 
Clinically, stroke is defined as a sudden onset of focal neurological symptoms or signs that 
should last more than 24 hours, that must be caused by disturbances in cerebral blood flow 
and not explained by other disease processes (Abbott et al., 2017). A mnemonic campaign 
was launched to help recognize signs of a stroke called “FAST” which is defined by Facial 
drooping, Arm weakness, Speech difficulties and Time to call emergency services (Harbison 
et al., 2003). A revised mnemonic was recently proposed with the addition of Balance and 
Eyes termed “BE-FAST” (Aroor et al., 2017).  
 
1.1.1.2. Epidemiology 
Every year, around 14 million people worldwide suffer from a stroke (Johnson et al., 2019). 
Stroke is the leading cause of disability for adults and the second leading cause of death 
worldwide. Over 55 years of age, the risk doubles every 10 years (Rojas et al., 2007). In the 
United Kingdom, there are more than 100 000 strokes each year, and there are currently over 
1.2 million stroke survivors; it is the third leading cause of death in Scotland (Association, 
2018). It has a significant health cost to the United Kingdom economy, estimated to be 




1.1.1.3. Ischaemia or Haemorrhage 
In 87% of cases, stroke is caused by a blockage of a vessel by a thrombus or embolus; this 
event is termed ischaemia (Mozaffarian et al., 2016; Neuhaus et al., 2017). The remaining 
13% of strokes are haemorrhagic, caused by a burst vessel (Fig. 1.1). In both cases, the 
symptoms are similar, and a differential diagnosis must be undertaken using magnetic 
resonance imaging (MRI) techniques. 
 
Figure 1-1 Diagram representing ischaemic versus haemorrhagic stroke in the human brain. 
Cerebral ischaemia is characterised by a blockage of a cerebral vessel. It leads to hypoperfusion of the following 
vessels (in black) and thus hypoxia (in blue) and dysfunction leading to cell death (area in purple). Cerebral 
haemorrhage is a burst of a cerebral vessel which leak blood in the parenchyma and is very toxic for the brain cells 
causing their death (area in purple). 
 
The word ischaemia comes from the ancient greek ἴσχω (pronounced iskho) that means 
“holding back” and αἷμα (pronounced haima) that means “blood”. The vessel is blocked by 
coagulated blood (a blood clot is also named thrombus). Ischaemia can be permanent or 
temporary. During ischaemia, oxygen and nutrient supplies are interrupted; resulting in a 
cascade of events that are detrimental such as excitotoxicity, depolarisation, oxidative stress, 




1.1.1.4. Acute Treatment of Ischaemic Stroke: Reperfusion 
The only drug approved and used for ischaemia since 1996 is called Alteplase; its active 
substance is the recombinant tissue-type plasminogen activator (rtPA; FDA Application 
No.:  103172-Suppl. 1055). It is a serine protease; it cleaves plasminogen into its activated 
form plasmin, which is known for its clot lysis effect. Consequently, it breaks the thrombus 
and liquefies the blood. However, the use of this method is beneficial only during the acute 
period. When first approved, rtPA treatment improved the outcome by 11% if used in the 
first 3 hours after the onset (National Institute of Neurological Disorders and Stroke rt-PA 
Stroke Study Group, 1995). Since then, the therapeutic window has been extended to 4 hours 
and 30 minutes (Hacke et al., 2004). Thrombolysis on patients with unknown time of onset 
has shown beneficial outcomes, when used on a selection of patient (Thomalla et al., 2018). 
In the last years, another technique called mechanical thrombectomy to remove the clot was 
developed using stent retrievers. The first clinical trials showed improved survival and 
functional recovery, but only a few neurosurgeons are trained, and a few centres are 
equipped for this procedure. This new technique can potentially expand the time window 
treatment (Baek et al., 2014; Jovin et al., 2015; Mokin et al., 2018) to 16 or 24 hours after the 
onset for all patient (Albers et al., 2018; Nogueira et al., 2017). 
 
1.1.2. Risk factors  
1.1.2.1. Age and Gender 
As discussed previously, age is an important factor in ischaemic stroke occurrence, for 95% 
of strokes occurred at the age of 45 and older (Grau et al., 2001). Furthermore, the risk of 
having a stroke doubles every 10 years past 55-years old (Rojas et al., 2007).  
Before 70 years old, the risk is higher for men than women. However the prevalence for 
stroke is more elevated for women after 80 years-old compared to men (Andersen et al., 
2010). Two thirds of stroke patients older than 80 years are women; but this result is biased 
as life expectancy for women is greater than men. The reduced incidence of stroke in young 
women is thought to be due to the neuroprotective effect of oestrogen (Honarpisheh & 
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McCullough, 2019; Zhang et al., 2018) or immune system differences (Freitas-Andrade et al., 
2017; Seifert et al., 2017). 
 
1.1.2.2. Comorbidities and risk factors  
As the probability of having a stroke gets greater with age, it also increases the possibility of 
comorbidities. These comorbidities significantly increase the risk of having a stroke and they 
worsen the stroke outcome. These are diabetes, cancer, hypertension, obesity, coronary and 
cardiac diseases (Allen & Bayraktutan, 2008; Gallacher et al., 2018; Moskowitz et al., 2010; 
Rojas et al., 2007). 
Arrhythmia, and notably atrial fibrillation, is a dysregulation of the normal pumping blood 
function of the heart. It leads to stagnation of blood in the heart. It eventually causes blood 
to coagulate forming a blood clot and can be injected in the rest of the vascular system. The 
clot gets bigger with platelet aggregation due to immune detection. It is more likely to block 
vessels that are narrowed; this phenomenon is called stenosis and can happen with 
aggregation of cholesterol (atherosclerosis). With age, blood vessels are weakened and 
harden (arteriosclerosis), this leads to hypertension and increases the risk of cerebral 
ischaemia (Oladiran & Nwosu, 2019; Wolf et al., 1998).  
Atherosclerosis happens more frequently in cases of obesity, hyperlipidaemia, 
hypercholesterolemia or diabetes. Diabetes is characterised by hyperglycaemia caused by 
insulin resistance. Diabetes potentially leads to hypertension, hypercholesterolemia and 
atrial fibrillation. Thus it increases the risk of developing atherosclerosis and ischaemic stroke 
(Béjot & Giroud, 2010; Luitse et al., 2012). Hypertension, notably with blood pressure at 
higher than 140/90, increases vascular diseases and notably is found in 66 to 69% of 
ischaemic patient (Grau et al., 2001; Lewington et al., 2002; McManus & Liebeskind, 2016). 
 
1.1.2.3. Other risk factors 
Studies of stroke prevalence amongst diverse ethnic groups revealed greater risks for black 
and Hispanic people than white, possibly due to higher risk of hypertension and diabetes 
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(Centers for Disease Control and Prevention (CDC), 2001; Kissela et al., 2005; Ohira et al., 
2006; White et al., 2005). These groups showed greater insulin resistance, obesity rates and 
possibly some genetic differences in the fat distribution, lipolysis and metabolic rate 
compared to other ethnic groups (Akinyemi et al., 2019; Caprio et al., 2008; Saab et al., 2015; 
Spanakis & Golden, 2013). To note that modifiable risk factors such as smoking and low 
physical activity are also thought to be generally reduced in those populations, increasing 
obesity (Akinyemi et al., 2019; Caprio et al., 2008; Spanakis & Golden, 2013).  
Smoking is an important risk factor for stroke, with a dose dependent effect with more 
cigarettes smoked per day causing an increased relative risk of stroke (Boehme et al., 2017; 
Hankey, 1999; Thun et al., 2000; Wolf et al., 1988). 
 
1.1.3. Long term effects of ischaemia 
Ischaemia may lead to disability or death within hours. However, advances in the treatment 
and prevention of stroke have produced a decline in mortality (Hankey, 2017; Khandelwal et 
al., 2016), and one consequence is an increased number of stroke survivors (Macrae & Allan, 
2018; Muruet et al., 2018; Pendlebury & Rothwell, 2009); there are currently 1.2 million 
stroke survivors in the UK (Association, 2018). As previously explained, these patients are for 
the most part elderly; and aging impairs recovery (Knoflach et al., 2012; Macciocchi et al., 
1998). After recovery, less than half of the patients regain independence (Hankey, 2017). 
Ischaemic patients may present cognitive decline faster than healthy age-matched people 
(Levine et al., 2015). Around 80% of them will present mild cognitive impairments (Barbay et 
al., 2018). Cognitive impairment may appear immediately or within month or years 
(Pendlebury & Rothwell, 2009, 2019; Zamboni et al., 2017). 
Dementia and cognitive impairment are now recognised to be associated with vascular 
causes (Iadecola, 2013). Ischaemia can contribute mechanistically to dementia including 
vascular cognitive impairment (VCI). VCI is an umbrella term that encompasses any form of 
cognitive deficit associated with and presumed to be caused by cerebrovascular disease 
(O’Brien et al., 2003). As first termed by O’Brien and colleagues (2003), VCI encompasses 
many types of dementia such as multiple-infarct dementia, post-stroke dementia, small 
vessel disease, hereditary vascular dementia CADASIL, Alzheimer’s disease with vascular 
dementia, and more (O’Brien et al., 2003) as seen in Fig 1.2 (Iadecola, 2013). At a National 
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Institute for Neurological Disorders and Stroke (NINDS) workshop, Hachinski et al (2006)  
identified standards for identifying and describing individuals with VCI, notably by 
recommending the development of MRI techniques, psychological assessments and physio-
pathological evidence (Hachinski et al., 2006). Gorelick et al (2011) reviewed the literature 
on VCI and published a statement on vascular contributions to cognitive impairment and 
dementia for healthcare professionals. This statement highlighted the importance of vascular 
contributions to dementia and the importance of detection and control of traditional risk 
factors for stroke and cardiovascular disease for the prevention of VCI (Gorelick et al., 2011).  
VCI commonly features a decline in cognitive functions and cerebrovascular lesion are 
demonstrated with MRI (Gorelick et al., 2016; Rodríguez García & Rodríguez García, 2015). 
The cerebrovascular lesion can comprise strategic infarct (one small to medium infarct), multi 
infarct encephalopathy (several large vessel infarcts), lacunar infarcts (ischaemia of small 
artery), hypoxic-ischaemic encephalopathy (with hypotension or cardiac arrest), cerebral 
haemorrhage, mixed cerebrovascular disease (which is a combination of the above) and 
Alzheimer’s disease with vascular dementia (Rodríguez García & Rodríguez García, 2015). The 
presence of microinfarcts and notably in the white matter (named white matter 
hyperintensities) is highly associated with VCI (Ferro et al., 2019) and the burden of white 
matter hyperintensities is correlated with the extent of cognitive deficits. VCI symptoms are 
heterogeneous depending on the cerebrovascular pathology, and can include  amnesia, 
aphasia (neurological impairment of language), agnosia (neurological impairment of 
visuospatial processing), and executive function (such as planning and making decision) 
impairment to name just a few (Gorelick et al., 2011; Rodríguez García & Rodríguez García, 




Figure 1-2 Vascular cognitive impairment is a nomenclature for diverse cerebro-vascular pathologies (from 
Iadecola, 2013). 
Alzheimer’s disease (AD) is a neurodegenerative disease, which causes memory loss, 
confusion and mood deterioration. Stroke more than doubles the risk of AD in the elderly 
(Vermeer et al., 2003). Stroke pathology is present in one third of AD cases at post mortem 
autopsy (Kalaria, 2000). Stroke was found to enhance amyloid precursor protein and its 
cleavage into Amyloid β (Nihashi et al., 2001; Saido et al., 1994). Amongst the cascade of 
detrimental events triggered by ischaemia, oxidative stress and inflammation are accused of 
leading to Alzheimer’s disease (Daulatzai, 2016; Gorelick et al., 2011; Pluta et al., 2009; Rojas-
Gutierrez et al., 2017). In recent years, the blood-brain barrier and alterations in the integrity 
of astrocytes have been linked to cognitive decline in AD (Avila-Muñoz & Arias, 2014; Chen 





1.2. Cellular biology and pathophysiology of cerebral ischaemia  
1.2.1. Hypoperfusion and penumbra 
Cerebral ischaemia is a reduction in the blood supply to the brain. Any reduction in the blood 
supply is called hypoperfusion and it leads to oxygen and nutrient deprivation in cells. The 
brain accounts for only 2% of the body mass, however, it uptakes 20% of glucose and energy 
(Erbsloh et al., 1958; Klocke et al., 1969; Magistretti & Allaman, 2015; Mink et al., 1981). It is 
the most sensitive organ to glucose and oxygen deprivation due to its high metabolic rate. 
With ischaemia, oxygen and nutrient supplies are suboptimal and can be completely 
interrupted in some areas. It causes brain cell malfunctioning and triggers a cascade of 
pathogenic mechanisms that are detrimental such as excitotoxicity, depolarisation, oxidative 
stress, inflammation, blood-brain barrier leakage and apoptosis (Fig 1.3; Dirnagl et al., 1999; 
Moskowitz et al., 2010), all of which will be reviewed in this section. These pathophysiologic 
events appear at different timepoints after the onset of ischaemia and are proposed to have 
different durations (Fig 1.4).  
During the acute phase of ischaemia, the lesion is divided into two parts: penumbra and core. 
The lesion’s core represents irreversible damage to cells as they die from hypoxia. Whereas 
the penumbra represents a suboptimal irrigated area leading to decrease energy production 
disrupting ion pump (Astrup et al., 1981). The perfusion rate of the penumbra is below 20 
ml/min/100 g and the core below 10 ml/min/100 g whilst normal perfusion is about 55 




Figure 1-3 Simplified diagram of the interrelated pathophysiological mechanisms of cerebral ischaemia. 
The artery occlusion reduces blood supply to the brain and lead to energy deprivation in the cell. Many functions 
of the cell rely on this constant supply on energy to maintain the cell homeostasis, notably mitochondria and ion 
pumps. These dysfunctions are at the beginning of a number of detrimental cascades. Ion pumps failure initiate 
calcium accumulation promote cytotoxic oedema and lead to excitotoxic cell death. Mitochondrial dysfunction 
increases reactive oxygen species (ROS) and reactive nitrogen species (RNS) while antioxidant enzymes are reduced 
resulting in imbalance named oxidative stress that damage cell compounds (lipids, DNA, proteins). Oxidative stress 
initiate cytokines productions that activate immune cells with notably astrocytes and microglia. These cells have 
different response signatures, some are neuroprotective, but others are aggressive and cytotoxic. This 
inflammatory state promotes peripheral immune cell infiltration such as macrophages and leukocytes. Leukocytes 







Figure 1-4 Cascade of damaging events after cerebral ischaemia (from Dirnagl et al., 1999). 
 
The penumbra can be imaged with MRI using perfusion weighted and diffusion weighted 
images (Moskowitz et al., 2010). Diffusion weighted images shows the ischaemic necrosis, 
identifying the core of the lesion. Perfusion weighted image shows the blood flow reduction 
hence the entire area at risk. The mismatch of the perfusion weighted image with the 
diffusion weighted image inform on the penumbra (Fig 1.5). 
 
 
Figure 1-5 The penumbra can be seen with the mismatch or perfusion and diffusion weighted MRI images (From 
Moskowitz et al., 2010). 
 
The longer the duration of hypoperfusion, the larger the infarct (Memezawa et al., 1992). 
Without reperfusion, cells in the penumbra die leading to expansion of core the lesion. 
However, restoration of blood flow in the penumbra is beneficial to a certain extent; the 
infarct volume plateaus between 18 and 24 hours in rodents and cats (Hartings et al., 2003; 
Heiss, 2000; Mulcahy et al., 2003) and thus the penumbra cannot be rescued anymore 
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(Baron, 2018; Hossmann, 2012; Robertson et al., 2015). Reperfusion is beneficial as long as 
the penumbra is still detectable, during the first hours after the onset for humans and mouse 
models (Hossmann, 2012; McCabe et al., 2018; Morris et al., 2018; Paciaroni et al., 2009). 
However, recent advances in the field showed beneficial effects of reperfusion at 16 to 24 
hours after the onset (Albers et al., 2018; Nogueira et al., 2017; Wardlaw & Bath, 2019). 
 
1.2.2. Ischaemic models 
1.2.2.1. In vitro models of ischaemia 
Most commonly undertaken using cell culture of primary neurons from rodents or cell lines, 
in vitro models reduce the use of animals, reduce costs and time, and are mostly used to 
understand mechanisms underlying the response to treatment or drugs and to evaluate their 
toxicity or protective effects. Depending on the protocol used, some in vitro techniques were 
developed to explore the responses of single-cells rather than mixed cell culture and it 
facilitates the use of transfection to knock-in and knock-out (KO) genes and silencing of RNA 
(Engelhardt et al., 2015; Liddelow & Barres, 2017; Lipton, 1999; Mcdonough et al., 2017; 
Pekny & Nilsson, 2005; Shih et al., 2005a). 
Regarding ischaemia/reperfusion research, oxygen and glucose deprivation (OGD) models 
have been used to mimic hypoxic conditions and nutrient deprivation by modifying the 
culture oxygenation and medium (Bell et al., 2011a; Ryou & Mallet, 2018; Shih et al., 2005a). 
Common endpoints include the measure of cell death or cell viability, mRNA and protein 
levels. Ischaemia triggers a cascade of events that can lead to neurotoxicity, such as 
inflammation and oxidative stress. To mimic these events, there are in vitro models of 
inflammation induced by lipopolysaccharide (LPS; Catorce & Gevorkian, 2016; Hoogland et 
al., 2015) and free radicals for oxidative stress injury such as hydrogen peroxide (H2O2; Gille 
& Joenje, 1992; Reddy et al., 2007). 
An important criticism of these models is the discrepancies between cultured cells and in vivo 
cells. Cultured astrocytes tend to have a reactive phenotype with increased antioxidant 
glutathione production (Shih et al., 2003) and cultured neurons present important variations 
of glutathione levels throughout the literature, most likely due to the preparation protocol 
used (Dringen et al., 1999). Discrepancies between in vivo and in vitro models are caused by 
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maturation differences (Desestret et al., 2013; Hellwig et al., 2013). Development of 
organotypic brain slice culture emerged to address this problem (Humpel, 2015; Khalilov et 
al., 1997). Primary culture cells are not developed in terms of structural aspects of the brain 
such as white matter and vascular supply. Stroke research needs a systemic approach with a 
vascular system and a multi-organ context. Recently, an in vitro model reproducing the multi-
cell aspect of the brain was developed (Xue et al., 2013). It consists in 3 layers of primary cell 
culture: neurons, astrocytes and endothelial cells. This model was notably used in hypoxic 
conditions mimicked by ODG techniques (Tian et al., 2016; Zhao et al., 2019). As in vitro 
techniques are limited, more in vivo techniques to mimic stroke have been developed. 
 
1.2.2.2. In vivo models of ischaemia 
To study ischaemic stroke, many models have emerged, each with specific advantages and 
limitations. Depending on the hypothesis, the technique used must be carefully chosen. To 
perform occlusion of a vessel, the approach can be extravascular (external to the vessel) 
using coagulation, clips or ligation; or endovascular (internal to the vessel, through the 
lumen) using intraluminal filament, emboli or photochemical methods (Fluri et al., 2015; 
McCabe et al., 2018). 
All extravascular techniques require a craniotomy that can trigger complications and 
potentially impair food consumption, which is crucial for the recovery after ischaemia. 
Furthermore, advanced surgical skills are necessary for these techniques. However, these are 
highly reproducible and have a high success rate (Fluri et al., 2015; McCabe et al., 2018). 
Electrocoagulation permanently occludes the vessel using diathermy machine (Tamura et al., 
1981). As this model is permanent, an alternative to this model is the use of clip or ligation 
that can be removed to perform a transient ischaemia (Buchan et al., 1992). 
A method that reduces invasiveness and that does not require advanced surgical skills would 
be the injection of endothelin-1, a long-lasting vasoconstrictor (Robinson et al., 1990). Using 
a cannula, it can be used on conscious animals to avoid anaesthetic cross effects (Bogaert et 
al., 2000). However, this technique showed major disadvantages as it triggers astrocytosis 
and axonal sprouting (Uesugi et al., 1998) and the timing of occlusion could not be controlled, 
giving high variability. 
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Two endovascular models of occlusion use injection of either autologous blood or thrombin 
that closely mimics human pathology and are both used to model thrombolysis. Embolic 
methods have very little control over the final site of clot lodgement and limit the control of 
occlusion timing reducing reproducibility (Zhang et al., 2015). Thromboembolic models are 
characterised by injection of thrombin in distal arteries using small craniotomy, that will 
create a fibrin clot (Orset et al., 2007). Due to its superficial location, it creates only small 
infarct, and thus there is low mortality and high reproducibility. Furthermore, it is clinically 
relevant as it mimics a limited time window for alteplase treatment (Orset et al., 2007). 
Another endovascular model is the photo-thrombosis technique that consists of injection of 
Rose Bengal in the blood stream, then illumination of the area chosen for occlusion with light. 
It leads to reactive oxygen species mediated damage to endothelial cells, by activating 
platelets causing their aggregation and thrombi formation (Watson et al., 1985). It is a simple 
technique with low variability due to controlled location of the lesion and is minimally 
invasive. However, it is uncharacteristic of human stroke as it creates an early vasogenic 
oedema and is unsuitable for neuroprotective drug experimentation as it creates very little 
penumbra (Fluri et al., 2015; McCabe et al., 2018). 
The last endovascular technique is the intraluminal filament model, mainly undertaken to 
occlude the origin of the middle cerebral artery (MCA), as it is the most common ischaemic 
location in the human brain (O’Sullivan & Schmitz, 2007). At its origin, the MCA is shaped like 
a “Y” with two downstream branches finer than the upstream one. As the MCA is placed right 
after the common carotid artery, any clot is thus easily driven there and can become trapped 
(O’Sullivan & Schmitz, 2007). 
The insertion of the thread in an artery leads to permanent ligation of that artery afterwards 
in order to reperfuse and avoid haemorrhage. The model used in this thesis utilises unilateral 
common carotid artery occlusion (UCCAo) to enable the thread to be inserted via the internal 
carotid (Hata et al., 1998). Other have performed this surgery by inserting the thread in the 
external carotid (McColl et al., 2004; Morris et al., 2016; Trotman-Lucas et al., 2017). A 
comparison of the two methods demonstrated a lower mortality rate, bigger infarcts and 
more neurological deficits with the insertion of the thread by the external carotid artery 
(Smith et al., 2015). However, insertion of the thread by the external carotid damages the 
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mouth vasculature hence it impairs mastication that is crucial for recovery of post-stroke 
body weight loss (Boyko et al., 2010; Dittmar et al., 2003).  
Insertion of a thread can damage intraluminal vessel wall and increases risk of haemorrhage; 
this problem has been reduced by optimisation of the filament size (Tsuchiya et al., 2003). 
Other limitations are filament diameter not optimal for the vessel and filament misplaced 
(i.e. not being advanced far enough, hence not leading to complete occlusion; Fluri et al., 
2015; Hata et al., 1998; Morris et al., 2016). Knowing these limitations, a short range of 
animal weights was selected to match the filament diameter. This method has controlled 
limitation and many advantages such as reproducibility and high proportion of successful 
procedures, the creation of a penumbra, and control over time of occlusion, furthermore it 
mimics mechanical thrombectomy. 
These models have been performed mainly on rodents, but strain is also a factor to take in 
account in the design of the study. In rats, 5 strains have shown significantly different infarct 
sizes, notably because of hypertension (Cipolla et al., 2018; Duverger & MacKenzie, 1988). 
Age and sex are important variability factor and needs to be duly controlled (Zhang et al., 
2018). In mice, different strains showed different susceptibility regarding ischaemic lesion 
size as some presented bigger infarcts compared with other strains within the same study 
(Barone et al., 1993; Zhang et al., 2018). This is potentially due to anatomical differences 
between strains (Barone et al., 1993; Maeda et al., 1998). The mouse model C57Bl/6J, 
commonly used, also have variability regarding sex and sub-strains (Zhao et al., 2017). 
The model used in this thesis is 15-, 30- or 60-minutes duration ischaemia. This model is 
giving neuronal damage in a defined area with no recovery at 24 hours. These outcomes do 
not mimic the transient ischaemic attack (TIA) that is supposedly leaving no defined lesion 
but possibly small diffuse lesion, difficult to perceive with MRI study or CT scans and 
neurological signs and symptoms disappear 24 hours after the injury (Easton et al., 2009). 
Others have reported that ischaemia for 2.5 to 10 minutes in mice left no discernible lesion 
on MRI, whereas from 12.5 minutes the lesion was visible in either cortex or striatum 
(Pedrono et al., 2010). Recent advancements in high resolution MRI might classify a greater 
number of minor stroke amongst those TIA patient (with symptoms not lasting beyond 24 
hours; Kernan et al., 2014), and research on new biomarkers emerge to help the diagnosis 
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(Dolmans et al., 2019), especially since TIA often lead to greater ischaemia (Coutts, 2017).
   
1.2.3. Alterations in neurological function and cognition in animal models of 
ischaemia 
Ischaemia causes sudden weakness, confusion, loss of balance or coordination. In the long 
term, ischaemic patients might be disabled by hemiparesis, language impairments and 
cognitive decline. Behavioural assessment in preclinical research tests sensorimotor 
functions using notably neurological score (called neuroscore). Many tests have been 
developed around the different sensorimotor functions observed in mice (reviewed by 
Balkaya et al., 2013; Trueman et al., 2017). Ischaemic animals present general sensorimotor 
impairment following the injury but then recover during the first week (Deng et al., 2016; 
Macrez et al., 2011; Omura et al., 2006; Orset et al., 2007; Titova et al., 2011).  
In order to investigate cognitive deficits, tests were developed around learning and memory 
paradigms. The most commonly used test is the Morris water maze, evaluating the spatial 
memory of an animal (Morris, 1984) but it is very stressful for the mice and time consuming 
for the experimenter. Novel object recognition (NOR) memory has been studied in various 
disease models and thus a plethora of protocols have been developed (Antunes & Biala, 
2012). These tasks are based on rodent’s innate preference to explore novel over familiar 
stimuli in their environment and can be used to infer memory for the familiar stimulus 
(Berlyne, 1950; Ennaceur & Delacour, 1988). It is a two-phase test with a familiarisation phase 
in which the animal is left to explore an object and its duplicate, followed by a retention test 
to determine whether the animal remember the familiarised object and thus spent more 
time exploring the novel object. In the context of stroke models, NOR has been used with a 
24 hours retention paradigm showing impairment from 7 to 28 days post-injury (Wang et al., 
2012; White et al., 2012; Yabuki & Fukunaga, 2013; Zhu et al., 2015). Because many tests 
were used for different severity of ischaemia, recommendations by Leger and colleagues 
were used to design the experiment in this thesis (Leger et al., 2013): Handling the animal 
must be done before performing any experiment; ideally, animals should have an habituation 




1.2.4. Vascular system disruption  
1.2.4.1. The neurogliovascular unit (NGVU) 
For the neuron to function, it needs a suitable environment to support it. Neurons together 
with astrocytes, microglia, endothelial cells and pericytes, form the neurogliovascular unit 
(NGVU; Fig 1.6).  
Astrocytes and microglia have crucial roles in this unit as they contribute to the different 
pathological features of ischaemia in beneficial and detrimental cascades (Magaki et al., 
2018). Astrocytes bring essential energy and support to the neuron in homeostatic 
conditions; After an insult, astrocytes adapt their response to maintain neuronal needs 
(Verkhratsky & Nedergaard, 2017; Weber & Barros, 2018). In the same way, microglia 
modulate the neuronal environment for their growth and bring trophic support in a resting 
state; after an insult or in the context of a disease, microglia become activated, changing 
their functions to evolve and adapt to the situation (Butovsky & Weiner, 2018). 
In the NGVU, astrocytes, pericytes and endothelial cells have a role in maintaining a physical 
barrier, controlling exchange between blood from the vessel lumen and parenchyma: the 
blood brain barrier (BBB). It comprises vessel walls, composed by endothelial cells, and on 
the parenchyma side, astrocytes and pericytes surround vessels (Fig. 1.6). To investigate its 
integrity, researchers can either study the proteins of the tight junction between the 
endothelial cell spaces (such as occludin, claudin-5, ZO1), aquaporin-4 (AQP4), a water 
channel on astrocyte end-feet or by analysing leakage of blood to the parenchyma named 
extravasation (Fig. 1.6). 
BBB breakdown is thought to contribute to neurodegenerative diseases (Zlokovic, 2008). 
Following focal cerebral ischaemia (MCAo), BBB permeability is increased from 2 hours post-
injury and is reported to return to baseline after 18 days using Evans Blue extravasation (Wu 
et al., 2014).  
Neurovascular coupling is a system defining vascular adaptation to neuronal activity (Phillips 
et al., 2016). It requires astrocytes to elicit vessel dilatation (Zonta et al., 2003). Cerebral 
ischaemia impacts on neurovascular coupling as it damages endothelial cells and promote 
BBB breakdown (Del Zoppo & Mabuchi, 2003; Salinet et al., 2015). In physiological conditions, 
CBF is maintained to a certain level despite perfusion changes; this phenomenon is called 
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autoregulation and is found at perfusion rate from 50 to 150 mmHg (Kunz & Iadecola, 2009). 
It is possible through vasoconstriction and vasodilatation finely tuned by glia that constantly 
adapt CBF to neuronal demands (Girouard & Iadecola, 2006). However during ischaemia, the 
perfusion rate is too low, and autoregulation is lost (Salinet et al., 2015). 
 
Figure 1-6 The neurogliovascular unit and blood-brain barrier. 
 
1.2.5. Excitotoxicity and depolarisation waves 
One of the acute detrimental events that is triggered by ischaemia and reperfusion is 
excitotoxicity. It was first discovered that injection of glutamate on the retina tissue lead to 
its degeneration; and later on this concept was extended to neurons of the brain (Lucas & 
Newhouse, 1957; Olney, 1969). This concept, later named “excitotoxicity” by Olney, was 
associated with excess influx of calcium via N-Methyl-D-Aspartate (NMDA) receptors after 
ischaemia (Choi, 1988; Tymianski et al., 1993). These authors described the loss of energy of 
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the cell leading to malfunction of the active calcium pumps. Calcium enters the cell via NMDA 
receptors and cannot be ejected causing its accumulation and eventual neuronal death. 
Reducing excitotoxicity is still the focus of ongoing research to develop novel therapies for 
stroke, such as novel compounds that target the NMDA-R signalling pathways (Bano & 
Ankarcrona, 2018; Wu & Tymianski, 2018). 
With ischaemia, the accumulation of calcium and other ions, normally regulated with active 
pumps, leads to the depolarisation of the neurons (Branston et al., 1977). As neurons die, 
their death leads to their fragmentation, liberating excess calcium in the extracellular 
medium. This creates “depolarisation waves” that propagate to the penumbra and induce a 
cascade of detrimental events such as inflammation and apoptosis (Hossmann, 1996; Dirnagl 
et al., 1999; Fig 1.3). 
 
1.2.6. Oxidative stress  
1.2.6.1. Definition 
A reduction of oxygen concentration in the blood is called hypoxia, from the Greek υπό 
(hypo) meaning under and οξύς (oxus) oxygen. Cells in the brain depend on this oxygen to 
function, a mechanism termed as aerobic from the Greek ἀήρ (aero) air and βίος (bios) life. 
The brain is the most sensitive organ to glucose and oxygen deprivation due to its high 
metabolic rate and has poor anti-oxidative defences (Kohen et al., 1988) and is therefore 
more prone to damage caused by oxidative stress (Lebel & Bondy, 1991). Oxidative stress 
occurs when there is an imbalance between the production of oxidants and the cell’s capacity 
to neutralise them through intrinsic antioxidant defences. 
Oxidants are radicals that have at least one unpaired electron, thus they tend to interact with 
other elements to get them paired. By doing so, they are reduced and the element they 
interact with is oxidised. The oxidation of cell elements (such as DNA, proteins or the 
cytoplasmic membrane) leads to their degradation and thus dysfunction of the cell (Sun et 
al., 2018).  
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Some radicals are derived from oxygen and thus are called Reactive Oxygen Species (ROS); 
they are also named free radicals because of their unpaired electron(s). Other free radicals 
are derived from nitrogen; they are called Reactive Nitrogen Species (RNS; see table 1.1).  
 
Table 1-1 Reactive oxygen and nitrogen species with their formula and structure. 
Although elevation of ROS is detrimental, basal level maintenance of ROS is important for 
homeostasis (Angelova & Abramov, 2018; Ye et al., 2015). Particularly fine tuning of ROS 
production and regulation is critical as both high and low ROS levels impact at different time 
point the physiological development of nervous system cells (Olguín-Albuerne & Morán, 
2018; Schippers et al., 2012) notably neurons (Kennedy et al., 2012). Furthermore, ROS are 
essential for vascular homeostasis and function, immune response, haematopoiesis (Vara & 
Pula, 2014). 
 
1.2.6.2. Oxidative stress following ischaemia 
During ischaemia, levels of ROS increase to the extent that they overwhelm endogenous 
scavenging systems. This is hypothesized to be due to mitochondria dysfunction (Sun et al., 
2018; Zhang et al., 2016). In anaerobic conditions, mitochondria cannot provide energy to 
the rest of the cell with the consequence that many physiological mechanisms are 
interrupted. To study oxidative stress in vitro, oxygen and glucose deprivation (OGD) has 
been used to demonstrate that reduced energy causes astrocytes to die (Yager et al., 1994). 
Mitochondrial dysfunction produces ROS and nitric oxide (NO); a second messenger in cells 
that inhibits cellular respiration thus leading to cell death (Cleeter et al., 1994). NO and ROS 
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together generate peroxynitrite (ONOO-), a highly aggressive element (Beckman, 1991). It is 
important to note that following reperfusion, by recanalization of the blocked vessel (mostly 
attain by thrombolysis), there is an exacerbation of ROS production (Enzmann et al., 2018). 
There is also evidence of oxidative stress in human; a meta-analysis showed increased lipid 
peroxidation and equal or decreased levels of antioxidant activities in patient following 
stroke (Cherubini et al., 2005). In the following months after the onset, radicals from 
phagocytes were still increased with equal antioxidant defences contained in the blood 
leading to oxidative damage to lipid following ischaemic stroke in patient compared to 
controls (Alexandrova & Bochev, 2005). Interestingly, patient with MCA occlusion had 
increased oxidative stress biomarkers compared to controls on admission before tPA 
injection, and 1, 2, 12 and 24 hours after tPA injection (Domínguez et al., 2010). Oxidative 
stress was correlated positively with ischaemia severity and recovery as poorly or not 
recovering patient had decreased antioxidant and increased radicals at admission, 6 hours 
after, 1, 3, 5 and 7 days after compared to patient with functional recovery at 2 weeks 
(Cherubini et al., 2000). Reducing oxidative stress using uric acid reduced growth and 
improved functional recovery in hyperglycaemic ischaemic patients (Amaro et al., 2015). 
Cognitive impairments were correlated with higher oxidative stress in patients following 
ischaemic stroke (Wang et al., 2018). Both increased NO and MDA in ischaemic stroke patient 
during the first 48 hours was negatively correlated with neurological score (Ozkul et al., 
2007). 
Many have pointed out that oxidative stress might be the link between ischaemia and these 
types of dementia (Bennett et al., 2008; Luca et al., 2015; Tönnies & Trushina, 2017; 
Tramutola et al., 2017). At early stage of AD, anti-oxidative enzymes are decreased 
(Mangialasche et al., 2009; Nunomura et al., 1999) and radicals are increased (Resende et al., 
2008). Oxidative stress is involved in the generation of amyloid-β and the onset and 
progression of AD (Akbar et al., 2016; Obrenovich et al., 2006; Pratico et al., 2001; Reddy, 
2006). 
Oxidative stress is found also found in VaD patients (Aguilar-Navarro et al., 2016;  Choi & Lee, 
2017; Luca et al., 2015). Ischaemia, AD and VaD share common risk factors such as ageing, 
hypercholesterolemia, hyperglycaemia, smoking, cardiovascular disease, hypertension 
(Vijayan & Reddy, 2016), and these risk factors increases or are increased by oxidative stress 
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(Choi & Lee, 2017). Oxidative stress is found beneath molecular and cellular mechanisms 
underlying VaD (Calabrese et al., 2016; Vijayan & Reddy, 2016). Furthermore, increased 




Inflammation is a mechanism that defines activation of immune defences. Cells that undergo 
an injury produce and release messengers to attract immune cells called damage-associated 
molecular patterns (DAMPs; Shi et al., 2019). In the brain, glial cells respond to those 
messengers, they get activated and respond with production of cytokines (Liu et al., 2017). 
Inflammation is a major detrimental mechanism of cerebral ischaemia; it is closely related to 
other mechanisms of ischaemia-induced damage to neurons. But some inflammatory 
mechanisms are beneficial and thus its modulation could be a potentially target for the 
development of novel therapeutic approaches for the treatment of stroke (Anrather & 
Iadecola, 2016; Shi et al., 2019). Two notable glial cells activated in the parenchyma during 
ischaemia are microglial cells and astrocytes. The messengers can also attract immune cells 
from the blood circulation, such as macrophages and neutrophils. 
Inflammation is found in human patient using blood samples, post-mortem studies and PET 
scans (Shi et al., 2019) in a chronic manner (Narasimhalu et al., 2015) but also in remote 
places to the injury (Shi et al., 2019). Inflammation is associated with cognitive decline in 
ischaemic patients (Kliper et al., 2013). Mild cognitive impairment patients have increased 
inflammation notably pro-inflammatory TNF-α, and its receptor is positively correlated with 
increased cognitive decline (Shen et al., 2019). Inflammation is increased in VCI, VaD and AD 
patients (De Strooper & Karran, 2016; Iadecola, 2013; Wallin et al., 2017). Inflammation is 
found in most cellular mechanisms of VaD such as BBB disruption, white matter damage 
(Albers et al., 2018; Calabrese et al., 2016). Oxidative stress and inflammation are intertwined 
cascades both increasing vascular disruption and participating in promoting neuronal 




1.2.7.2. Glial response following ischaemia 
Astrocytes 
Astrocytes undertake numerous roles in the central nervous system (CNS) to maintain 
homeostasis and modulation of the immune response. Astrocytes have a support role for 
neurons by producing and releasing neurotrophic factors, antioxidants and energy precursor 
glycogen and lactate; they also regulate the neuronal transmission by buffering excessive 
glutamate at the synapse, re-up-take of neurotransmitters, releasing vasoconstrictor or 
vasodilator mediators and modifying the extracellular matrix (Verkhratsky & Nedergaard, 
2017; Weber & Barros, 2018).  
Any brain damaging disease exerts a modification of astrocyte morphology, gene expression 
and thus their functions (Burda & Sofroniew, 2014; Liu & Chopp, 2016; Pekny et al., 2016). In 
this case, astrocytes are reactive, and the global phenomenon is also called astrocytosis. 
Interestingly, it has been found that different injuries lead to heterogeneity of astrocyte 
function and gene expression (Zamanian et al., 2012). In this paper, they showed that LPS-
inflammation challenge upregulated many pro-inflammatory genes in astrocytes whereas 
ischaemia upregulated many anti-inflammatory and antioxidant genes but also 
thrombospondins that promote synaptogenesis (Zamanian et al., 2012). Since this discovery, 
more reports have highlighted an important diversity in the response of astrocytes 
depending on the insult (Matias et al., 2019). Furthermore, as astrocytes could potentially be 
guided toward neuroprotective phenotypes, it became a potential therapeutic target for 
cerebral disease (Pekny et al., 2019).  
One protein commonly used to detect reactive astrocytes is glial fibrillary acidic protein 
(GFAP; Sofroniew, 2009). GFAP is essential for astrocytosis and glial scar formation 
(Herrmann et al., 2008; Pekny & Pekna, 2004). GFAP knockout mice have increased lysosomal 
degradation and inflammatory responses in an Alzheimer’s Disease model (Kamphuis et al., 
2015), increased paralysis and disease severity in a multiple sclerosis model (Liedtke et al., 
1998) and increased inflammation and impaired functional recovery following ischaemia (Li 
et al., 2008; Liu et al., 2014). Altogether, these studies suggest that reactive astrocytes have 
a protective role against these insults. 
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Following cerebral ischaemia, anaerobic conditions lead to a loss of astrocytes (Liu et al., 
1999; Shannon et al., 2007) but also morphological changes for the remaining ones, in and 
around the infarct (Ding, 2014; Lukaszevicz et al., 2002). Astrocytes become elongated in the 
penumbra (Ding, 2014), they develop more extensions, and their processes gets larger (Ding, 
2014; Lukaszevicz et al., 2002; Wagner et al., 2013). Furthermore, astrocytes gain phagocytic 
functions and help clear debris (Koizumi et al., 2018; Morizawa et al., 2017). Importantly, 
astrocytes are known for their antioxidant support to neurons (Baxter & Hardingham, 2016) 
and their neuroprotective role during an oxidative challenge (Drukarch et al., 1997; Kraft et 
al., 2004; Shih et al., 2003). Regarding ischaemia, astrocytes represent a target for the 
development of therapeutic strategies as they modulate the immune response, synaptic 
connectivity, angiogenesis and neurogenesis but also control most of the antioxidant 
production and maintain the BBB (Becerra-Calixto & Cardona-Gómez, 2017; Koizumi et al., 
2018; Liu & Chopp, 2016). Notably, ischaemic tolerance observed after preconditioning was 
found mediated by astrocytes (Hirayama et al., 2015). In this mechanism, one important 
aspect is the upregulation of antioxidant by astrocytes that was found essential for 
neuroprotection following ischaemia (Bell et al., 2011a; Shih et al., 2003; Shih et al., 2005b). 
Overall, neuroprotective effects of reactive astrocytes were associated with improved 
neurological recovery after ischaemia (Sims & Yew, 2017). 
However, in the recent years, potential detrimental roles of reactive astrocytes where found 
and notably through the upregulation of inflammatory cytokines (Becerra-Calixto & Cardona-
Gómez, 2017). As part of the immune system defence, astrocytes can be aggressive and 
neurotoxic (Liddelow et al., 2017). Ben Barres group conducted a transcriptomic study of 
reactive astrocytes and found heterogeneity of reactive astrocytes depending on the injury 
(Zamanian et al., 2012). In 2017, they advanced this work to demonstrate two populations of 
reactive astrocytes (Liddelow et al., 2017). Their main features are their transcriptomic 
differences leading to different cellular behaviour. Using the so-called microglia M1/M2 
phenotype (despite controversy, see Ransohoff, 2016) Barres used this nomenclature for 
astrocytes, naming one phenotype as neuroinflammatory/neurotoxic (A1) whereas the other 
is protectant/neurotrophic (A2). Liddelow et al (2017) showed that an activation of the A1 
phenotype with pro-inflammatory microglia was neurotoxic and led to synapse destruction. 
On the other hand, A2 phenotype upregulates neurotrophic factors (Liddelow & Barres, 
2017). Even though this classification is pertinent and highlights the heterogeneity of reactive 
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astrocytes in different disease states, subsequent in vivo studies tend to show a diversity of 
response (Lin et al., 2017) suggesting that this classification is very reductive.  
Following ischaemia, different publications found either aggressive and neurotoxic 
phenotypes (Villarreal et al., 2016), but also neuroprotective phenotype (Zamanian et al., 
2012), and others found both simultaneously at different areas of the lesion (Rakers et al., 
2018). One critic of Zamanian et al (2012) is the use of very young (P30) mouse brains, which 
could explain discrepancies with the response of adult mice. Furthermore, this paper 
analysed whole brain samples whereas the first paper analysed only one time point after 
ischaemia. Several papers show that ischaemia first leads to increased levels anti-
inflammatory cytokines during the first hours/days and that they later decline, then pro-
inflammatory cytokines are increased (Amantea et al., 2018; Hu et al., 2012; Zhang et al., 
2018). Furthermore, some have found that there are different inflammatory responses  
depending on the location of the lesion (Hu et al., 2012; Perego et al., 2011). As astrocytes 
play an important part in the modulation of inflammation and in the production of these 
cytokines, it suggests that there are heterogenous responses of reactive astrocytes 
throughout the lesion. Rakers and colleagues (2018) recently reported diverse gene 
expression in reactive astrocyte upregulated in the core and in the peri-infarct (Rakers et al., 
2018).  
This heterogeneity in astrocyte gene expression and function is also found in physiological 
conditions through different parts of the brain (Lin et al., 2017; Morel et al., 2018; 
Lanjakornsiripan et al., 2018). There are two main types of astrocytes: protoplasmic found in 
the grey matter and fibrous in the white matter (Miller & Raff, 1984) and it appeared that 
fibrous astrocytes are more sensitive to injury than protoplasmic (Shannon et al., 2007) 
However, others found the opposite (Lukaszevicz et al., 2002). Although diverse injuries exert 
different reactive astrocyte response (Lin et al., 2017), aging was also found to modulate the 
phenotype of reactive astrocytes (Boisvert et al., 2018). 
First discovered in Alzheimer’s disease neuropathology by Alois Alzheimer in 1910, 
(Alzheimer, 1910) astrocytes with lost processes have been observed after ischaemic 
challenges such as OGD and anaerobic glycolysis (Mercatelli et al., 2016). The term 
‘clasmatodendrosis' that defines this phenomenon was first reported in the literature in 1926 
(Google N-gram viewer) and termed “clasmatodendrosis” by Cajal (Penfield, 1928). It defines 
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astrocyte with swelling and vacuolisation in the soma and disintegrated processes (Friede & 
Van Houten, 1961; Hulse et al., 2001; Tomimoto et al., 1997, Davies et al., 1998). The first in 
vitro model to study clasmatodendrocytes has demonstrated that anaerobic glycolysis, 
indicated by increased medium acidity, is a key mechanism of tissue damage (Friede & Van 
Houten, 1961; named here klasmatodendrosis). More recently this concept was associated 
with white matter hyperintensities and cognitive decline found in both human and mouse  
(Chen et al., 2016; Hase et al., 2017; Sahlas et al., 2002). 
 
Microglia 
Microglia are the body of immune cells in the CNS. Microglia modulate the neuronal 
environment and provide trophic support in a resting state; after an insult or in the context 
of a disease, microglia become activated, changing their function and gene expression 
(Hammond et al., 2018). These small cells with short processes can migrate and proliferate. 
As scavenger cells, microglia phagocyte damaged and unused cells or infectious agents (Puig 
et al., 2018). Reactive microglia produce ROS and NO-derived elements that can exacerbate 
oxidative stress (Zhao et al., 2017). They may also promote cell survival and repair via the 
production of anti-inflammatory cytokines and growth factors (Chen & Trapp, 2016). 
One of the challenges in microglia research has been to define their homeostatic phenotype 
and to differentiate them from infiltrated peripheral macrophages (Butovsky & Weiner, 
2018). In physiologic conditions, microglia are in a resting state. This phenotype potentially 
restrains any inflammatory response to maintain homeostasis (Salter & Stevens, 2017). 
However, with an injury, microglia shift to an adaptative phenotype, which depends on the 
injury (Hammond et al., 2018). 
In vitro studies have distinguished different phenotypes of microglia after an injury. 
Depending on the treatment, two main populations have been defined (for review, Zhao et 
al., 2017):  
• M1: classical – pro-inflammatory phenotype: 
They are induced by LPS, IFNγ, TNFα, IL-1β and produce cytokines such as IL-1β, IL-6, TNFα 
and CCL2, but also ROS and NO. This phenotype is believed to be cytotoxic and to promote 
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tissue re-modelling, neurodegeneration, tumour destruction (for review, Zhao et al., 2017). 
• M2: alternative – anti-inflammatory, pro-resolving, quiescent phenotype: 
These are induced by IL-4, IL-13 and IL-10 and produce factor such as IL-10, IL-13, TGFβ1, IL-
4, IGF-1. They are known for phagocytosis, resting signals, survival signals, tumour promotion 
(Puig et al., 2018). 
 
The M1/M2 dichotomy was named after a similar classification of T helper 1 and 2 cells. 
However, this characterisation is very controversial as there are probably a spectrum of 
phenotypes rather than only two and these polarised phenotypes have not been reported in 
vivo (For review: Ransohoff, 2016). Nevertheless, the concept of pro and anti-inflammatory 
microglia is still used as many studies investigate modulators of inflammatory phenotype and 
recent evidence suggested that diseases and injuries had prevalence of one of the two 
phenotypes (Cherry et al., 2014; Tang & Le, 2016). 
Several papers showed that ischaemia first led to increased anti-inflammatory cytokines in 
the first hours/days and that these later declined, after which pro-inflammatory cytokines 
were increased (Amantea et al., 2018; Hu et al., 2012; Zhang et al., 2018). Furthermore, a 
different spatial distribution of diverse microglia/macrophage inflammatory phenotypes 
were observed from 24 hours to 14 days after ischaemia (Hu et al., 2012; Perego et al., 2011). 
Some have found upregulated M2 markers in the core and M1 markers in the peri-infarct 
(Perego et al., 2011). Others found upregulated M2 markers in the peri-infarct from 1 to 7 
days, but then these markers decreased and M1 markers were upregulated from 5 days up 
to 14 days (Hu et al., 2012). These studies used immunohistochemistry and rt-qPCR; thus 
their conclusions are limited as these cytokines and chemokines are produced by different 
cells, and not only microglia/macrophages. To overcome this limitation, cell sorting or single 
cell RNA-sequencing could be used. Studies have suggested that modulating these 
phenotypes following ischaemia is possible (Liu et al., 2017; Zhao et al., 2017) and that 
therapeutic strategies promoting an anti-inflammatory phenotype seem promising (Wang et 




Macrophages and neutrophils infiltration 
After cerebral ischaemia, peripheral immune system cells are detected in brain parenchyma. 
After 30 to 60 minutes of MCAo in mice, neutrophils were found immediately after the onset 
of the ischaemia and peaked between 18 hours to 3 days after the onset (Grønberg et al., 
2013; Vaas et al., 2017). Then, neutrophil number decreased whereas macrophage peak 
infiltration was observed between 3 to 14 days and seemed to decline only after 3 weeks 
(Grønberg et al., 2013). This infiltration of neutrophils and monocyte-derived macrophages 
was reported to be both detrimental and beneficial (Benakis et al., 2015; Enzmann et al., 
2018). 
Neutrophils produce matrix metalloproteinases (MMPs), enzymes that degrade the collagen 
of the extracellular matrix but also cellular components. They notably worsen BBB 
breakdown after stroke by damaging endothelial cells when releasing MMP 9 and 
exacerbating the inflammatory response (Turner & Sharp, 2016). They also participate in ROS 
production, exacerbating oxidative stress in the parenchyma (Matsuo et al., 1995; Satoh et 
al., 1999; Turner & Sharp, 2016). Therapies blocking neutrophil adhesion to endothelial cells 
were found to decrease their infiltration, ameliorate ischaemia and reduce infarct volume 
(Francis & Baynosa, 2017). It is possible that neutrophils may have different inflammatory 
phenotypes as suggested after discovering that their infiltration was associated with the 
production of anti-inflammatory markers (Cuartero et al., 2013). 
Macrophages are morphologically like microglia and express a large number of similar 
markers (Bennett et al., 2016; Satoh et al., 2016). Macrophages may also have both anti- and 
pro-inflammatory phenotypes in the vicinity of an ischaemic lesion (Zrzavy et al., n.d.). 
Macrophages produce neurotoxic factors that worsen the infarction but also have anti-
inflammatory properties; and thus as microglia, they can be classified as the M1/M2 system 
(Benakis et al., 2015). Modification of macrophages from pro-inflammatory phenotype to 
anti-inflammatory phenotypes reduces the production of those neurotoxic factors (Kadl et 







Within weeks, the ischaemic infarct has increased levels of reactive glial cells. Astrocytes, 
microglia and macrophages are found in the lesion, notably in the core. All activated, they 
form an intertwined pattern of cells, named the glial scar (Sofroniew, 2009). It was first 
thought to be neuroprotective because it limits inflammation spreading (Bush et al., 1999; 
Wanner et al., 2013). Signal transducer and activator of transcription 3 (STAT3) is important 
for the glial scar formation and astrocyte activation. In a model of spinal cord injury, selective 
deletion of STAT3 in astrocytes impeded their activation and formation of the scar, leading 
to an expansion of inflammatory cell infiltration, increased lesion size, demyelination, 
delayed and attenuated motor recovery (Herrmann et al., 2008; Okada et al., 2006; Wanner 
et al., 2013). However, the glial scar was found to be permeable, as oedema and neuronal 
damage were observed beyond the scar and were associated with clearance mechanisms 
such as drainage and phagocytosis at the border of the scar (Zbesko et al., 2018). 
Furthermore, it was observed that astrocytes gained phagocytic functions and helped the 
clearing of debris (Koizumi et al., 2018; Morizawa et al., 2017).  
Recent studies also suggested a possible detrimental effect of the glial scar. Reactive 
astrocytes notably produce axonal repair inhibitors (Liu & Chopp, 2016) and studies in human 
suggest that the glial scar can impede neuronal growth and thus repair (Huang et al., 2014). 
This finding is however controversial as further evidence suggested that the glial scar 
produced multiple axonal growth factors; and by preventing the glial scar formation, it 
resulted in the reduction of these growth factors (Anderson et al., 2016). 
 
1.2.8. Apoptosis & necrosis 
Apoptosis is a mechanism of programmed cell death, particularly useful during normal 
development and homeostasis (Geden et al., 2019; Grilo & Mantalaris, 2019). It is composed 
of several steps: condensation of the chromatin and shrinking of the cell, blebbing (which is 
defined by the formation of protrusions around the cell) and fragmenting (Kerr et al., 1972). 
Necrosis is defined as the unprogrammed cell death as opposed to apoptosis. It is composed 
of different steps, such as blebbing, swelling and finally membrane rupture leading to the 
leakage of the cell contents. This leakage triggers an immune response and oedema (Cullen, 
2010; Martin et al., 1998; Snider et al., 1999). Excitotoxicity and oxidative stress lead to 
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apoptosis and necrosis (Dirnagl et al., 1999). Apoptosis is observed after mild injury and 
found in the penumbra of the ischaemic lesion compared to necrosis that is mostly found in 
acute phase of severe injury, and thus mainly found in the core of the ischaemic lesion (Kerr 





1.3. Nrf2 signalling 
1.3.1. An endogenous transcription factor  
1.3.1.1. Definition 
The Nuclear Factor Erythroid 2 (NF-E2)-Related Factor 2 (Nrf2) signalling pathway has been 
identified as a new therapeutic target to prevent damage caused by elevated oxidative stress 
and inflammation (Sandberg et al., 2014). It is a transcription factor of the Cap’N’Collar family 
and the basic leucine zipper sub-family (Chan & Paolo, 1995; Itoh et al., 1995). Nrf2 
upregulates a battery of antioxidant and anti-inflammatory genes that contain an antioxiant 
response element (ARE) on their upstream promotor regions that initiates their transcription  
(ARE; Itoh et al., 1997; Rushmore et al., 1991). 
Nrf2 was discovered in 1994 (Moi et al., 1994) and two years later, its antioxidant properties 
were demonstrated (Venugopal & Jaiswal, 1996). The phase II detoxyfying  enzyme response 
was established by Rushmore in 1991 and relates to antioxiant response elements (ARE) 
upregulated during oxidative challenge (Rushmore et al., 1991). The phase II response was 
found altered with neurologic diseases and its activation was demonstrated to be 
neuroprotective (Zhang et al., 2013; Venugopal & Jaiswal, 1996). Since then, Nrf2 has been 
described as a master regulator of antioxidants, and notably of ARE, and a target for therapy 
in diseases involving elevated levels of oxiditive stress-related disease therapy could be 
developed (Ma, 2013; Ma & He, 2012). 
 
Keap1 – ARE 
In physiological conditions, Nrf2 is sequestered in the cytoplasm by homodimerised Keap1 
(Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1) at two 
sites (Fig 1.7). Nrf2 binding to Keap1, complexed with Cullin 3 (Cul3) and Ring box 1 (RG1), 
leads to Nrf2 ubiquitination (Ub) and thus degradation, ensuring that Nrf2 levels are kept 
low. Oxidation by radicals, alkylation by electrophiles or metal chelation of the cysteine 151, 
273 or 288 changes the conformation of Keap1 that downregulates Nrf2 ubiquitination and 
releases Nrf2 (Yamamoto et al., 2008). Once freed, Nrf2 translocates to the nucleus where it 
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upregulates a battery of over 200 cytoprotective genes by binding to the antioxidant 
response elements (ARE) of certain genes (Fig 1.7; Itoh et al., 1997). 
 
 
Figure 1-7 Conditions for Nrf2-signalling activation. 
Nrf2 is sequestered by Keap1 and degraded in physiological conditions. With oxidative stress, Keap1 conformation 
is changed and Nrf2 is free to translocate to the nucleus where it activates Nrf2-signalling by binding to the 
antioxidant response element (ARE) sequence of more than 200 cytoprotective genes. 
 
Nrf2 detection using immunohistochemistry is limited at present due to a lack of specificity 
of the commercially available antibodies (Kemmerer et al., 2015). In order to analyse Nrf2-
signalling activation, different methods have emerged. Nrf2-signalling activation is 
characterised by its translocation to the nucleus and the upregulation of its related 
downstream genes. Therefore, alternative methods exist such as measuring Nrf2 nuclear 
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fraction compared to Nrf2 cytoplasmic fraction (Chen et al., 2016; Lei et al., 2016; Mao et al., 
2018), or mRNA levels of Nrf2-related genes such as HO1, NQO1 (Dai et al., 2018; Liu et al., 
2019; Yao et al., 2016). 
 
1.3.1.2. Downstream proteins of the Nrf2/ARE pathway  
Heme oxygenase-1 (HO1) 
Heme contains an iron atom, which is cytotoxic, notably by lipid peroxidation which leads to 
DNA damage. Heme oxygenase-1 (HO1) is a heat shock protein (Hsp 32) known to degrade 
heme elements into free ferrous iron, carbon monoxide and biliverdin, which further 
degrades to bilirubin. Both biliverdin and bilirubin have radical-scavenging properties 
(Bergeron et al., 1997; Ryter & Tyrrell, 2000; Stocker et al., 1987). HO1 is induced with Nrf2 
pathway activation (Alam et al., 1999; Zeynalov et al., 2009). HO1 is upregulated in the 
ischaemic lesion and confers neuroprotective effects (Alfieri et al., 2013; Ding et al., 2014). 
HO1 has been described as co-localised with astrocytes at the peri-lesional site from 4 to 72 
hours after reperfusion and with microglia in the core at 72 hours after reperfusion in rats 
after focal cerebral ischaemia (Bergeron et al., 1997; Min et al., 2006). It was also shown that 
HO1 is expressed in the vessels in the perilesional sites (Alfieri et al., 2013).  
 
NQO1 
NQO1 (Nicotinamide adenine dinucleotide phosphate (NADPH) quinone oxidoreductase 1) is 
a downstream protein of the Nrf2 pathway (Lee et al., 2003; McMahon et al., 2001). 
Furthermore, its expression depends on Nrf2 activation, as it is not expressed in Nrf2 
knockout models (Yeager et al., 2009).  
NQO1 is an antioxidant, it catalyses the reduction of NADP (oxidised form) into NADPH 
(reduced form) and is also an electrophile detoxifier. Electrophiles are produced when there 
is increased oxidative stress (Dinkova-Kostova & Talalay, 2010), notably lipid peroxidation 




Sulfiredoxin 1 (srxn1)  
Activation of the Nrf2 pathway also leads to the transcription of sulfiredoxins, notably 
sulfiredoxin 1 (srxn1) a scavenger that protects against hypoxia, excitotoxicity and Amyloid β 
toxicity (Soriano et al., 2008, 2009; Zhu et al., 2012). This effect is particularly interesting 
following ischaemia/reperfusion as Srxn1 knockout increases lesion volume, neurological 
deficits and oxidative stress (Wu et al., 2017).  
The protective effect of sulfiredoxin1 seems to involve peroxiredoxin, an antioxidant that 
exists in six forms (noted from I to VI). Peroxiredoxin can be inactivated by hyper-oxidation 
and srxn1 catalyses the reduction of peroxiredoxin (Soriano et al., 2009, 2008) from 
peroxiredoxin I to IV, but not V and VI (Woo et al., 2005). Peroxiredoxin VI has an ARE 
sequence and thus is upregulated with Nrf2 pathway activation (Chowdhury et al., 2009). 
 
Glutathione system and xCT 
Glutathione (GSH) is an antioxidant mainly produced by astrocytes and released in the 
extracellular space where it can reduce ROS (Drukarch et al., 1998). GSH secretion by 
astrocytes enhances neuronal levels of GSH (Bolaños et al., 1996; Dringen et al., 1999) 
however, neurons cannot uptake GSH directly. GSH derives from cysteine that is unstable in 
the extracellular space and becomes oxidized in cystine (Meister, 1995). There, cystine can 
be taken up by neurons via the glutamate-cystine antiporter (xCT) and then transformed back 





Figure 1-8 Indirect glutathione production from astrocyte increases neuronal glutathione levels (GSH). 
Glutathione expression depends on Nrf2-signalling (McMahon et al., 2001). Gene precursors 
of GSH and xCT both contain ARE sequences and thus are upregulated with Nrf2-signalling 
activation (Sasaki et al., 2002). GSH knockout increases cell death but it is rescued with forced 
expression of xCT by transfection (Mandal et al., 2010). Itself, xCT protects against lipid 
peroxidation, possibly because it reduces extracellular radicals (Banjac et al., 2008). 
Following ischaemia, there was increased oxidative stress in xCT knockout mice and 
aggravated infarct damage (Shibasaki et al., 2009). 
 
1.3.1.3. Cells expressing Nrf2 
Nrf2 is expressed in many organs and systems including the CNS, digestive system, female 
and male-sex organs, skin and endocrine organs and it is highly expressed in the muscles and 
kidney but also in heart, lungs, liver and brain (Fagerberg et al., 2014; Moi et al., 1994). 
In the brain, Nrf2 is produced by neurons in vitro (Habas et al., 2013), but this production is 
repressed in vivo in adult neurons (Bell et al., 2015). Forced Nrf2 expression in neurons during 
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the early days of development leads to reduced synapse density, retarded 
electrophysiological maturation and outgrowth of dendritic arborescence. It was suggested 
that this detrimental effect of Nrf2 was mediated via the reduction of ROS (Bell et al., 2015). 
As ROS-pathways are crucial for synaptogenesis, neuronal differentiation during early life 
development (Bell et al., 2015; Hardingham & Do, 2016), Nrf2 repression in cortical neurons 
is a critical part of their development and synaptogenesis. 
Nrf2 is also expressed in astrocytes (Habas et al., 2013), microglia (Rojo et al., 2010) and 
endothelial cells (Chen et al., 2003) in physiological conditions. After ischaemia, 
immunohistochemical double labelling studies show that Nrf2 is upregulated in microglia, 
astrocytes and neurons (Dang et al., 2012). However, this result is controversial since Nrf2 
detection using immunohistochemistry lacks specificity (Kemmerer et al., 2015). Nrf2 is 
upregulated on the ischaemic side of rat brains (Srivastava et al., 2013) at 4 and 24 hours and 
other studies show an increase of HO1 at 4, 7 and 24 hours (Alfieri et al., 2013). However, 
alterations of Nrf2-signalling in the more chronic response to ischaemia have not been 
defined. 
 
1.3.2. Nrf2 pharmacological activators and genetically modified models  
1.3.2.1. Nrf2-signalling pharmacological activators  
DMF/MMF 
The FDA have approved Dimethyl fumarate (DMF) and its precursor monomethyl fumarate 
(MMF) for the treatment of multiple sclerosis. They exhibit antioxidant effects by activating 
Nrf2-signalling pathway (Scannevin et al., 2012). DMF releases Nrf2 from Keap1 by alkylation 
of several of its cysteines, whereas MMF is less efficient as it only alkylate one of Keap1 
cysteine (Ahuja et al., 2016; Takaya et al., 2012). 
In models of ischaemia, several papers reported a protective effect of DMF through Nrf2 
activation. It reduced neurological deficits and infarct volume, glial activation, oxidative 
stress, BBB breakdown and thus reduced vasogenic oedema and peripheral immune cell 
infiltration (Kunze, 2017; Kunze et al., 2015; Lin et al., 2016; Liu et al., 2019; Yao et al., 2016). 
These effects were lost with in Nrf2 deficient mice (Kunze et al., 2015; Liu et al., 2019; Yao et 
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al., 2016) suggesting that the compound protective effects were dependant on the activation 
of Nrf2-signalling. 
 
tBQH and Sulforaphane 
Sulforaphane and tert-butyl hydroquinone (tBHQ) showed Nrf2-dependant protective effects 
after in vivo ischaemia or an oxidative challenge in vitro (Lee et al., 2003; Mao et al., 2018; 
Shih et al., 2005a). Both compounds are electrophiles that act to downregulate Nrf2 
ubiquitination by reacting on the cysteine 151, 273 and 288 of Keap1 (Abiko et al., 2011; 
Hong et al., 2005; Kobayashi et al., 2006; Zhang & Hannink, 2003). In a model of ischaemia, 
tBHQ reduced infarct and improved neuroscore in a Nrf2-dependant manner (Shih et al., 
2005) and Sulforaphane reduced lesion propagation, BBB breakdown and consequently 
reduced cognitive dysfunction (Alfieri et al., 2013). 
 
Curcumin 
Curcumin has been shown to have protective effects following ischaemia such as modulation 
of inflammation from pro- to anti-inflammatory (Liu et al., 2017), reduction of lesion volume, 
oxidative stress and oedema and improved neurological deficit (Li et al., 2016; Yang et al., 
2009) and these effects were associated with activation of Nrf2 signalling. However, these 
publications did not prove that the protective effects of Curcumin were dependant on Nrf2. 
Curcumin acts via Nrf2-independent mechanisms such as iron-chelating properties (Jiao et 
al., 2009). This could be investigated by examining if the protective effects of curcumin are 
lost in Nrf2 knockout mice.  
 
CDDO 
Bardoxolone-methyl or 1-(2-cyano-3,12-dioxooleana-1,9[11]-dien-28-oyl) imidazole (CDDO-
Im) protects from cell from oxidative stress-induced death in vitro (Bynum et al., 2015), and 
is a very potent activator of Nrf2-signalling (Kensler & Wakabayashi, 2010; Liby et al., 2005). 
However, it also has many Nrf2-independent protective effect (Walsh et al., 2014). 
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Furthermore, triterpenoids, such as CDDO, have cytotoxic effects in high doses (Kensler & 
Wakabayashi, 2010; Liby et al., 2005; Liby et al., 2007; Magesh et al., 2012). 
 
Limitation of these Nrf2-signalling activators 
Many activators of Nrf2-signalling exist but they can also have Nrf2-independent effects. For 
example, DMF is known to additionally  modulate HCAR2 signalling, IκB kinase, transforming 
growth factor-β signalling (Kensler & Wakabayashi, 2010; Liby et al., 2007; Parodi et al., 
2015). Interestingly, inflammation also activates IκB kinase, transforming growth factor-β 
signalling (Amantea et al., 2015; Islam et al., 2018; Kondylis et al., 2017), and they are also 
modulated with oxidative stress (Barcellos-Hoff & Dix, 1996; Korn et al., 2001; Leonardi et 
al., 2000). Electrophiles, such as DMF, Sulforaphane and tBHQ, can react with other proteins 
on the sulfhydryl groups of their cysteine or on amino and hydroxyl group of nucleic acid that 
leads to carcinogenicity and genotoxicity (Abed et al., 2015; Magesh et al., 2012). ARE 
inducers in general have cytotoxic effect in high dose (Dimmock et al., 1999; Kensler & 
Wakabayashi, 2010; Magesh et al., 2012). Finally, a review found that non-natural Nrf2-
pathway activators have oxidative effects (Eggler et al., 2008). 
In conclusion, pharmacological compounds that activate Nrf2-signalling can be limited due 
to their off-target effects and their potential toxicity. 
  
1.3.2.2. Nrf2-repressing models  
In order to investigate the potential protective role of Nrf2 signalling, genetic modification of 
Nrf2 expression levels is a more specific tool than pharmacological compounds that activate 
Nrf2-signalling. The first models developed to study the modification of Nrf2 were designed 
by knock out the gene of interest or its translation to a protein using RNA silencing. 
 
Nrf2 Knock-out 
Following ischaemia, Nrf2 KO animals had increased inflammation and worsened 
neurological deficits compared to wild-type animals (Rojo et al., 2010; Sandberg et al., 2014; 
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Shah et al., 2007). It was also reported that Nrf2 KO mice had increased infarct volume 
compared to wild-type at 24 hours following 90 minutes ischaemia or at 48 hours or 7 days 
following permanent ischaemia (Shah et al., 2007; Shih et al., 2005; Wang et al., 2012). 
However, another paper did not find a detrimental effect on infarct volume in Nrf2 KO mice 
at 24 hours following 60 minutes ischaemia (Narayanan et al., 2015). In Shih et al (2005), Nrf2 
KO mice had greater infarct in the cortex 7 days after permanent distal MCAo but not at 24 
hours (Shih et al., 2005). Altogether, these findings suggest that Nrf2 KO detrimental effect 
on the lesion volume depends on the survival time or duration of ischaemia (see table 1.2). 
In the same manner, neurological deficits were greater in Nrf2 KO mice compared to wild-
types at 24 hours following 90 minutes ischaemia (Shah et al., 2007) whereas it has no effect 
at 1 hour after 90 minutes ischaemia or at 48 hours following permanent ischaemia (Shah et 
al., 2007; Wang et al., 2012). Therefore, the main difference in these papers was due to 
changes in the severity of the ischaemia (60 minutes compared with 90 minutes or 
permanent occlusion) and survival time points (1 hour versus 24 hours, and 24 hours versus 
7 days).  
 
Table 1-2 Infarct volume of Nrf2 knockout mice compared to wild-types following ischaemia. 
In diverse conditions, Nrf2 knock-out mice had either equal or increased infarct volumes compared to wild-types 
(Narayanan et al., 2015; Shah et al., 2007; Shih et al., 2005; Wang et al., 2012). 
 
Lack of Nrf2 from birth might lead to the development of compensatory mechanisms (El-
Brolosy & Stainier, 2017). This finding stimulated the development of alternative methods 
such as conditional knock-out, to allow temporal or spatial control of Nrf2 knockout, or 
silencing models. Furthermore, Nrf2-KO models can be cell specific, allowing a clearer 
understanding of the cell interaction mechanisms at stake. 
Nrf2 knock-out (KO) models have also been used to prove the Nrf2 dependent mechanisms 
of action of pharmacological compounds targeting Nrf2 signalling. For example, DMF, 
Sulforaphane or tBHQ were found protective in models of increased oxidative stress, cerebral 
24 hours 48 hours 7 days References
60 minutes equal Narayanan et al., 2015
90 minutes increased Shah et al., 2007
Permanent equal increased Shih et al., 2005






haemorrhage, hypoxia/ischaemia but not when administered to Nrf2 KO mice (Jakel et al., 
2007; Lin et al., 2016; Scannevin et al., 2012; Zhao et al., 2007). In vitro, Nrf2 KO cells showed 
increased vulnerability to oxidative stress and mitochondria dysfunction (Jakel et al., 2007; 
Lee et al., 2003; Lee et al., 2003b; Narayanan et al. , 2015). 
  
Silencing Nrf2 by interfering with its RNA 
Small interfering RNA (siRNA) and short hairpin RNA (shRNA) have been predominantly used 
in vitro to test whether a drug has protective effects that were dependant on the Nrf2-
signalling pathway. Many drugs lose their protective effects when administered in 
combination with Nrf2 siRNA (Ding et al., 2014; Jing et al., 2013; Kunze et al., 2015; Li et al., 
2018; Ling et al., 2015; Wang et al., 2016). For some compounds, Nrf2 signalling was found 
to act in concert with other signalling pathways to mediate the protective effect of that drug 
(Hao et al., 2013; Hu et al., 2018). 
Some Nrf2 activators showed anti-inflammatory effects, for example by reducing pro-
inflammatory cytokines following LPS treatment, but with Nrf2 silencing, they lose effect 
using microglial or endothelial cell cultures (Li et al., 2018; Wang et al., 2018). Furthermore, 
Nrf2 siRNA increased toxicity and reduced cell viability after oxidative injury (Yang et al., 
2017; Zhang et al., 2010) and LPS-induced decreased BBB proteins (Li et al., 2018). 
Interestingly, in most papers there is no difference in cell viability when comparing an injury 
coupled with Nrf2 siRNA, to the injury alone, meaning that silencing Nrf2 does not worsen 
the injury: One paper did an injection of LPS in vivo on the cardiac muscle cells (Hao et al., 
2013), and the other an OGD in vitro on cortical neurons (Ling et al., 2015). In the same 
manner, inflammatory levels were not worsen following LPS treatment with Nrf2 silencing 
compared to LPS alone (Li et al., 2018; Wang et al., 2018). 
SiRNA has also been used to determine the potential detrimental effect of Nrf2 silencing. In 
an in vivo accelerated senescence model, Nrf2 siRNA increased glial response and worsened 
cognitive functions (Ren et al., 2018). Two papers used Nrf2 silencing in combination with 
MCAo models. Nrf2 siRNA increased pro-inflammatory and pro-apoptotic proteins (Hou et 




The worsening effect of Nrf2 siRNA is found in the in vivo papers working on brain cells (Hou 
et al., 2018; Ren et al., 2018; Xue et al., 2016); whereas the equal cell viability or inflammation 
comparing an injury coupled with Nrf2 siRNA, to the injury alone, is observed either in vitro 
or in vivo on cardiomyocytes (Hao et al., 2013; Li et al., 2018; Ling et al., 2015; Wang et al., 
2018). 
 
1.3.2.3. Models boosting Nrf2 expression  
Injection of Nrf2 adenovirus/lentivirus 
In a mouse model of Alzheimer’s disease, Nrf2 overexpression by adenovirus or lentivirus 
reduced amyloid-β-induced apoptosis, decreased astrocyte activation and improved spatial 
learning (Kanninen et al., 2009, 2008; Wang et al., 2014). Nrf2 overexpression also reduced 
the neuronal lesion caused by mitochondria dysfunction mediated by in vivo injection of the 
mitochondrial complex inhibitor malonate (Calkins et al., 2005; Shih et al., 2005b). 
Furthermore, Nrf2 overexpression by adenovirus or lentivirus reduced cell vulnerability to 
oxidative stress and glutamate toxicity (Dowell & Johnson, 2013; Jakel et al., 2007; Kraft et 
al., 2004; Li et al., 2005; Shih et al., 2005b). 
 
Overexpression of Nrf2 in astrocytes: the GFAP-Nrf2 model 
Astrocytes are known for their support to neurons and especially their production of 
antioxidants (Baxter & Hardingham, 2016). Neurons have very little antioxidant defences and 
notably Nrf2 (Shih et al., 2003). Co-cultured with astrocytes, neurons have greater survival, 
development of branching and are less sensitive to oxidative challenge compared to neurons 
on their own (Shih et al., 2003; Kraft et al., 2004). Indeed, neurons have very little antioxidant 
defences and notably Nrf2 compared to astrocytes (Baxter & Hardingham, 2016; Bronstein 
et al., 1995; Desagher et al. 1996; McNaught & Jenner, 1999; Min et al., 2006; Tanaka et al., 
1999; Shih et al., 2003). Furthermore, neuron survival to an oxidative challenge was improved 
with the presence of astrocytes, an effect that was abolished with depletion of glutathione, 
suggesting a pivotal role for both astrocytes and glutathione production for neuron survival 
(Drukarch et al., 1997). As explained previously, glutathione is an antioxidant that is produced 
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by astrocytes which enhances neuronal levels of glutathione (Bolaños et al., 1996; Dringen 
et al., 1999). Glutathione expression depends on Nrf2-signalling as its precursors and uptake 
receptor have ARE sequences (McMahon et al., 2001; Sasaki et al., 2002). Furthermore, 
activation of Nrf2-signalling with pharmacological compounds predominantly targetted 
astrocytes but not neurons (Eftekharpour et al., 2000; Johnson et al., 2002; Murphy et al., 
2001) and Nrf2 adenovirus is selectively taken up by astrocytes and not neurons (Kraft et al., 
2004).  
Glutamate toxicity can be reduced if neurons are co-cultured with glia; and this protective 
effect is lost if Nrf2 is knocked out (Shih et al., 2003). Nrf2 adenovirus is selectively up taken 
by astrocytes preferentially compared to neurons (Kraft et al., 2004). Furthermore, tBHQ 
treatment increased neuronal survival following an oxidative challenge and this was 
mediated through Nrf2 activity in astrocytes (Kraft et al., 2004). Taken together, these papers 
suggest a pivotal role of astrocytes to rescue neurons during oxidative challenges. 
Furthermore, pharmacological activation of Nrf2-signalling predominantly has effects on 
astrocytes but not neurons (Eftekharpour et al., 2000; Johnson et al., 2002; Murphy et al., 
2001). Neurons have very little Nrf2 and its related proteins compared to glia (Shih et al., 
2003).  
In order to find therapies for ischaemia, the concept of preconditioning emerged. It is defined 
by a brief, sub-lethal injury that can improve the tolerance to neurons to a subsequent, lethal 
injury (Dirnagl et al., 1999). A preconditioning of 90 min OGD performed 24 hours before 
another OGD insult lead to 66% decreased in cell death compared to non-conditioned 
neurons (Bell et al., 2011a). Interestingly this effect was lost in Nrf2 KO cocultures. Bell et al. 
(2011) then went on investigate Nrf2 signalling in preconditioning and found increased 
expression of glutathione system genes both in vivo and in vitro (Bell et al., 2011b). Taken 
together, most of the papers cited above found glutathione as one of the most prominent 
Nrf2-downstream system in the astrocyte neuroprotection. However other studies revealed 
astrocytic neuroprotection with Nrf2 activation via HO1 in the context of ischaemic insults 
and oxidative challenge (Alfieri et al., 2013; Bergeron et al., 1997; Min et al., 2006). 
These discoveries led to the development of a model that overexpressed Nrf2 specifically in 
astrocytes using a GFAP promoter (GFAP-Nrf2). This model has been used to study the 
protective effect of astrocytic Nrf2 overexpression in amyotrophic lateral sclerosis (ALS) 
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models. This disease is characterised by the degeneration of motor neurons during 
adulthood, leading to progressive muscle control loss and eventual death from respiratory 
failure (Kiernan et al., 2011). The most widely used mouse model of ALS is obtained by 
expressing a mutation of superoxide dismutase 1 (SOD1) that causes rapid degeneration of 
motor neurons, paralysis and eventually death (Morrice et al., 2018). Firstly, co-culturing 
motor neurons with primary astrocytes overexpressing Nrf2, motor neuron survival was 
increased, an effect that was lost with glutathione inhibitor or activity. Secondly, by crossing 
the SOD1 ALS mouse model with the GFAP-Nrf2 model, motor neuron degeneration was 
prevented, mouse survival was increased and the onset of disease symptoms was delayed 
compared to ALS mice (Vargas et al., 2008).  
Parkinson’s disease is a progressive neurodegenerative disease that primarily causes tremor 
and then impaired movement, posture, balance and speech. It is characterised by an 
accumulation of misfolded alpha-synuclein proteins that lead to degeneration of 
dopaminergic neurons involved in motor control (Konnova & Swanberg, 2018). Mouse 
models that can reproduce Parkinson’s pathology involve expression of mutant alpha-
synuclein, or injection of the mitochondrial complex inhibitor 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) that damages dopaminergic neurons in the substantia nigra 
(Chen et al., 2009). Nrf2 signalling pathway was increased in the substantia nigra and 
decreased in the striatum 2 days after 5 days injection of MPTP. Furthermore, dopaminergic 
neurons were lost with MPTP injection, and further decreased in Nrf2 deficient mice 
compared with wild type mice (Chen et al., 2009). However, when MPTP was administered 
to GFAP-Nrf2 mice, there was reduced neuronal toxicity compared to wild-type animals. In 
addition, crossing GFAP-Nrf2 mice with the mutated alpha-synuclein model resulted in 
increased mouse survival and motor neuron viability in crossed animals compared with the 
disease model controls. This protective effect was associated with a reduction of alpha-
synuclein accumulation, oxidative stress and glial activation (Gan et al., 2012). 
Alexander’s disease is a neurodegenerative disease due to a mutation in the GFAP gene that 
causes developmental delays, seizures and juvenile death (Brenner et al., 2001; Prust et al., 
2011). A mouse model of Alexander’s disease involving expression of human mutant GFAP 
demonstrates similar pathophysiologic features: increased GFAP protein and mRNA levels, 
neurotoxic astrocytic protein aggregates called Rosenthal fibres, seizures and oxidative 
stress. When mutant GFAP mice were crossed with GFAP-Nrf2 mouse model, there was 
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decreased GFAP protein and mRNA levels, reduced Rosenthal fibres and increased body mass 
(LaPash Daniels et al., 2012).  
Malonate is an inhibitor of mitochondrial function that damages neurons and induces 
oxidative stress and glial activation (Calkins et al., 2010; Calkins et al., 2005; Shih et al., 
2005b). Following instrastrial injection of malonate in vivo, wild-type animals developed a 
small lesion with increased Nrf2 signalling around it. Malonate injection into Nrf2 KO animals 
produced a larger lesion and Nrf2-signalling was minimal (Calkins et al., 2010). However, 
when malonate was injected into GFAP-Nrf2 animals, neuronal damage was decreased, and 
this was paralleled by increased Nrf2-signalling activity around the lesion compared with wild 
type mice. 
Hypoperfusion induced by bilateral common carotid stenosis leads to 40% reduction of 
cerebral blood flow, an impairment in spatial working memory, white matter damage and 
inflammation in the optic tract (Sigfridsson et al., 2018). However, when hypoperfusion was 
induced in GFAP-Nrf2 mice, astrocytic overexpression of Nrf2 improved cognitive deficits, 
reduced white matter damage, dampened microgliosis and astrocytosis and complement 
component C1q and C4 in the optic tract when compared with wild type mice.  
Collectively, these studies suggest that astrocytic overexpression of Nrf2 can reduce 
oxidative stress and inflammation in a diverse range of neurodegenerative models. In vitro 
models that mimic aspects of focal cerebral ischaemia suggest that astrocytic Nrf2 may 
mediate neuroprotective effects, however this has not been investigated in an in vivo model 
of ischaemia. 
 
1.3.3. Beneficial effects of Nrf2-signalling following ischaemia 
Ischaemia/reperfusion is not always possible due to the limited time window, and if 
reperfusion is possible, the oxygen flow can increase ROS (Enzmann et al., 2018). Thus, 
antioxidant and anti-inflammatory therapy has been of an area of research to develop an 
adjunct to thrombolysis or thrombectomy.  
As previously explained, Nrf2-silencing models tend to show a detrimental effect of the lack 
of Nrf2 suggesting a pivotal role of Nrf2 in the endogenous protective response against 
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injuries. Conversely, pharmacological compounds that activate Nrf2-signalling and Nrf2 
overexpressing models protect neurons against oxidative stress, inflammation and 
consequently improved neurological function. The beneficial effects of Nrf2 following 
ischaemia are reviewed in this section. 
 
1.3.3.1. Nrf2-signalling modulation following ischaemia 
Activation of Nrf2 signalling can lead to increased transcription of antioxidant genes such as 
GSH, HO1, srxn1 or NQO1. These Nrf2-dependent genes are found to be upregulated from 4 
hours to 3 days post ischaemia (Alfieri et al., 2013; Bell et al.,  2011a; Bell et al., 2011b; Ding 
et al., 2014; Tanaka et al., 2010; Yang et al., 2009). The gene that encodes Nrf2 itself was also 
upregulated in the lesion 4 to 72 hours after the onset (Alfieri et al., 2013; Lin et al., 2016; 
Srivastava et al., 2013; Zhai et al., 2013) because Nrf2 has an ARE sequence in its gene (Kwak 
et al., 2002; Raghunath et al., 2018), suggesting auto-regulation. At the same time, Keap1 
was decreased from 2 to 72 hours (Ling et al., 2015; Tanaka et al., 2010). Similar finding were 
reported from in vitro studies that demonstrated that OGD increases oxidative stress, which 
in return releases Nrf2 from keap1, permitting the activation of the Nrf2-signalling pathway 
(Itoh et al., 1997). 
Looking closely at the spatial distribution of Nrf2 alterations, it was upregulated in the peri-
infarct of the ischaemic lesion (Alfieri et al., 2013; Dang et al., 2012; Srivastava et al., 2013; 
Tanaka et al., 2010), and has been reported to be upregulated in microglia, astrocytes and 
neurons after ischaemia (Alfieri et al., 2013; Bergeron et al., 1997; Dang et al., 2012; Min et 
al., 2006). 
HO1 and Nrf2 proteins levels peaked during the first week (Alfieri et al., 2013; Lin et al., 2016; 
Mao et al., 2018) and tended to return to baseline at 14 days (Lin et al., 2016). However, no 







Table 1-3 Summary of the modulation of Nrf2, Keap1 and Nrf2-related protein following ischaemia. 
Abbreviated as follow, for the animal and model: SD: Sprague-Dawley rats; 2VO: bilateral common carotid arteries 
occlusion; CCAo: common carotid artery occlusion; tMCAo: transient middle cerebral artery; Perm.: permanent; 
Prot.: protein; h: hours; d: days. 
For the Nrf2-related genes: HO1: heme oxygenase 1; NQO1: NAD(P)H dehydrogenase quinone 1 (gene nqo1), Gclc: 
Glutamate—cysteine ligase catalytic subunit gene; Gclm: glutamate-cysteine ligase modifier subunit gene; 
slc7a11: xCT gene; srxn1: sulfiredoxin1. 
 
1.3.3.2. Antioxidant effect of Nrf2-signalling following ischaemia 
Nrf2 overexpression reduced cell vulnerability to oxidative stress during oxidative challenge 
(Jakel et al., 2007; Kraft et al., 2004; Li et al., 2005; Shih et al., 2005b). This is explained by the 
transcription role of Nrf2 that leads to the upregulation of a battery of cytoprotective genes 
and notably antioxidants such as NQO1, srxn1 and xCT (Banjac et al., 2008; Dinkova-Kostova 
& Talalay, 2010; Soriano et al., 2009; Soriano et al., 2008; Zhu et al., 2012). Repressing Nrf2 
expression increased the vulnerability to oxidative stress, reducing cell viability after 
oxidative injury after ischaemia or oxidative challenge (Zhang et al., 2010; Jakel et al., 2007; 
Lee et al., 2003b; Narayanan et al., 2015). In addition, pharmacological activators of Nrf2-







Yang et al., 
2009
SD rats pMCAo perman. Prot. & mRNA
from 3 h to 
72 h
HO1 is increased from 
3 h to 72 h
Tanaka et al., 
2010
ICR mice tMCAo 60 mins
positive-cell 
count
at 8, 24, 72 h
at 2, 8, 24 
and 72 h




tMCAo 15 mins mRNA
hmox1 and srxn1 
upregulated at 4 h




tMCAo 15 mins mRNA
gclc, gclm, slc7a11 
upregulated at 4 h
Alfieri et al., 
2013
SD rats tMCAo 70 mins
immuno-
reactivity
at 4, 24 but 
not 72 h
HO1 increased at 4, 
24 and 72 h
Srivasta et al., 
2013
SD rats tMCAo 70 mins nuclear Nrf2 at 24 h
Zhai et al., 
2013
SD rats tMCAo 90 mins prot. & mRNA at 24 h
Ding et al., 
2014
SD rats tMCAo 120 mins
prot. & nuclear 
Nrf2
at 48 h HO1 increased at 48 h
Ling et al., 
2015
SD rats tMCAo 60 mins
prot. & nuclear 
Nrf2
at 3 d at 3 d
Lin et al., 2016 SD rats tMCAo 120 mins prot. 
at 3, 7 d but 
not 14 d
HO1 increased at 3 
and 7 d but not 14 d 
Wu et al., 
2017
SD rats tMCAo 60 mins prot. at 24 h
NQO1, srxn1 and prdx 
increased at 24 h
Mao et al., 
2018
SD rats 2VO perman.
prot. & nuclear 
Nrf2
at 3 and 7 d
HO1 increased at 3 
and 7 d





60 mins prot. & mRNA at 6, 12, 24 h
HO1 & NQO1 increased 
at 6, 12, 24 h
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signalling reduced oxidative stress resulting from ischaemia (Alfieri et al., 2013; Li et al., 2016; 
Yao et al., 2016; Jakel et al., 2007; Lin et al., 2016; Scannevin et al., 2012; Zhao et al., 2007; 
Kunze, 2017; Kunze et al., 2015; Liu et al., 2019; Bynum et al., 2015). 
As previously explained in section 1.3.2.3, the neuroprotective effect of Nrf2 is dependent 
on astrocytes and notably through antioxidant upregulation (Shih et al., 2003; Kraft et al., 
2004). Furthermore, activation of Nrf2-signalling with pharmacological compounds 
predominantly targetted astrocytes but not neurons (Eftekharpour et al., 2000; Johnson et 
al., 2002; Murphy et al., 2001) and Nrf2 adenovirus is selectively taken up by astrocytes and 
not neurons (Kraft et al., 2004).  
 
1.3.3.3. Nrf2 and Inflammation 
Nrf2 and its role on polarisation of glial cells 
Besides the production of a battery of antioxidants, Nrf2-signalling has anti-inflammatory 
effects. In response to oxidative stress, Nrf2 can modulate microglial phenotype by elevating 
Nrf2, HO1, srxn1 and thioredoxin1 protein production (Kadl et al., 2010). In presence of heme 
elements, microglia switch to a phenotype that produces more HO1 (Boyle et al., 2012). HO1 
has been discovered to alter the phenotype of macrophages to an anti-inflammatory 
phenotype (Naito et al., 2014). Furthermore, in the absence of Nrf2, pro-inflammatory 
cytokine production is increased and anti-inflammatory cytokines are reduced in a 
Parkinson’s disease model (Rojo et al., 2010). Nrf2-signalling pharmacological activation or 
forced expression lead to decreased pro-inflammatory cytokine production whereas anti-
inflammatory cytokine production is increased (Kobayashi et al., 2016; Liu et al., 2017; Peng 
et al., 2016; Liu et al., 2019).  
 
Nrf2-signalling modifies the glial response following ischaemia  
Following ischaemia, astrocytes and microglia are activated in the lesion and they produce 
pro- and anti-inflammatory cytokines. Interestingly, pharmacological activation of Nrf2-
signalling with Ginseng, DMF or MMF causes a modulation of the glial response to ischaemia 
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(Lin et al., 2016; Liu et al., 2019; Yao et al., 2016). Lin and colleagues (2016) found a 50% 
decrease in microglia/macrophage activation 3 and 7 days after ischaemia in the penumbra 
of mice treated with DMF compared to vehicle treated mice (Lin et al., 2016). Furthermore, 
Yao and colleagues also reported a reduction of GFAP and Iba1-positive cells using DMF and 
MMF (Yao et al., 2016) in a model of ischaemia. More recently, Nrf2-signalling activators 
Ginseng and DMF were shown to alter the glial response after ischaemia, however they found 
different results depending on the time point (Liu et al., 2019), with increased GFAP staining 
and cell number at 24 hours and decreased GFAP staining without an alteration to GFAP-
positive cell number at 6 hours. On the other hand, microglia/macrophage staining Iba1 was 
reduced with both activators at 6 and 24 hours. 
 
BBB leakage, immune cell infiltration and Nrf2 
Nrf2 knockout increases vasogenic oedema and decreases AQP4 expression (Liu et al., 2019; 
Yao et al., 2016), whereas Nrf2 activation reduces vasogenic oedema (Alfieri et al., 2013; 
Clausen et al., 2017; Kunze et al., 2015; Li et al., 2016; Liu et al., 2019; Yang et al., 2009; Yao 
et al., 2016), increases BBB proteins occludin, claudin-5, AQP4 and reduces MMP9 after 
ischaemia (Kunze et al., 2015; Liu et al., 2019). Furthermore, DMF reduced neutrophil and T 
cell infiltration from 3 to 14 days after ischaemia (Lin et al., 2016). 
 
1.3.3.4. Nrf2 and its potential role to ameliorate functional recovery and cognition after 
ischaemia 
Sensorimotor recovery after ischaemia is improved by Nrf2-signalling activation or Nrf2 
overexpression 
Deficiency of Nrf2 in Nrf2-knockout mice or silencing of srxn1 RNA led to neurological deficits 
(Shah et al., 2007, Wu et al., 2017) after ischaemia. Although it has been reported that there 
is an increased infarct volume with knockout of Nrf2, there was no significant difference on 
neurological deficit score (Wang et al., 2012). Furthermore, these authors found that 
trichostatin A, an inhibitor of histone deacetylase, activated Nrf2-signalling, reduced the 
cortical infarct and neurological deficits 2 days after ischaemia. 
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Other studies using pharmacological activators of Nrf2 signalling have demonstrated 
reductions of neurological deficits: lipoxin A4 improved neurological scores at 24 hours (Wu 
et al., 2013), DMF improved neurological score from 3 to 14 days after ischaemia (Lin et al., 
2016) and RS9 improved motor recovery at 24 hours after ischaemia (Yamauchi et al., 2016). 
More importantly, some papers found that the reduction of neurological deficits with Nrf2 
activators DMF, MMF, Ginseng and tBHQ were lost in Nrf2 deficient mice (Liu et al., 2019; 
Shih et al., 2005a; Yao et al., 2016). 
 
Nrf2-signalling activation ameliorates cognitive functions after ischaemia 
Very few papers focus on potential protective effects of Nrf2-signalling on cognitive 
impairment after ischaemia. Of these few, Sulforaphane improved cognitive function after 
ischaemia (Mao et al., 2018) and glutathione improved discrimination in novel object 
recognition (NOR) after ischaemia (Yabuki & Fukunaga, 2013). However, these papers do not 
use RNA silencing or genetic KO to prove the direct and sole effect of Nrf2 signalling on 
cognition. 
Finally, Nrf2 overexpression models using lentiviral Nrf2 transfection showed improved 
spatial memory in AD model (Kanninen et al., 2009; Wang et al., 2014) and Nrf2 
overexpression in astrocytes improved spatial memory following hypoperfusion (Sigfridsson 
et al., 2018). However, the effects of boosting Nrf2 in astrocytes has not been tested on a 
mouse model of focal cerebral ischaemia. 
 
1.4. Summary 
Ischaemia is known to raise the risk of neurodegeneration and dementia. Two major 
mechanisms triggered by cerebral ischaemia may be involved: neuroinflammation and 
oxidative stress. Nrf2-signalling pathway has been highlighted as an important therapeutic 
target as it reduces oxidative stress and inflammation. Nevertheless, there are gaps in the 
literature about the chronic state of this pathway after ischaemia. Furthermore, this pathway 
is upregulated at acute stage after ischaemia because of oxidative conditions. 
Pharmacological activation of Nrf2-signalling can cause “off-target” effects. Astrocytes have 
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an important role in the production of antioxidants to protect neurons. Furthermore, Nrf2-
signalling is preferentially activated in astrocytes during ischaemia or oxidative challenges 
and astrocytes are necessary for the neuroprotective effect of Nrf2. The GFAP-Nrf2 model is 
found to reduce oxidative stress, inflammation and neurodegeneration in a number of 
models of neurodegenerative diseases; it can be used to address specific questions about 
Nrf2 mediated astrocyte-neuronal interactions; however, it has never been used for 
ischaemia. 
 
1.5. Global hypothesis 
This work has been designed to test the hypothesis that boosting the Nrf2 pathway in 
astrocytes will prevent oxidative stress and pro-inflammatory damage caused by 
ischaemia/reperfusion and thereby diminish cognitive deficits and neurodegeneration that 
may lead to dementia. 
 
1.5.1. Aims: 
This thesis will be divided in three parts. Firstly, a characterisation of a mouse model of 
ischaemia will be undertaken to investigate alterations to Nrf2-signalling at acute and chronic 
time points, and how it parallels with alterations in oxidative stress and inflammatory glial 
cell changes. The second chapter will focus on the use of a model where Nrf2 is specifically 
overexpressed in astrocytes (GFAP-Nrf2) to determine if it has neuroprotective effects in the 
acute response to ischaemia. Furthermore, the effects of boosting astrocytic Nrf2 will be 
determined on inflammatory glial cell activation, inflammatory cytokine production and 
oxidative stress. Finally, the effects of boosting astrocytic Nrf2 will be studied in the chronic 
response to ischaemia to determine if there is a protective effect on neurological function, 









2. Material & Methods  
2.1. Mice 
2.1.1. GFAP-Nrf2 mice 
GFAP-Nrf2 transgenic mice were made in Prof. Jeffrey Johnson’s laboratory at the University 
of Wisconsin (Vargas et al., 2008). The mice overexpress Nrf2 under the control of a GFAP 
promoter. This has been achieved by using a pCMVβ plasmid (BD Biosciences) excised of its 
CMV promoter to be replace with a custom multiple cloning site with insertion of hGFAP 
promoter containing the mNrf2 sequence from a pEF-Nrf2. The construct was microinjected 
on fertilised eggs on B6/SJL background which is a cross between a C57BL/6J (B6) female and 
an SJL/J (SJL) male (Calkins et al., 2010; Gan et al., 2012). Transgenic mice were identified by 
genotyping ear or tail biopsies on NaOH-extracted DNA (50 mM at 100°C for 7 minutes) with 
a PCR of 35 cycles as follow: 30 seconds at 95°C, 30 seconds at 54°C and 30 seconds at 72°C; 
and a final extension of 5 minutes at 72°C. The PCR was performed using GoTaq Green Master 
Mix (M7822; Promega) and these primers: Nrf2 Left 5'-GCC TGA GAG CTG TAG GCC C–3', Nrf2 
Right 5'-GGA ATG GAA AAT AGC TCC TGC C-3', GFAP Forward: 5'-CTT CAT AAA GCC CTC GCA 
TC-3' and GFAP Reverse 5'-TCT TGC CTC CAA AGG ATG TC-3'. Nrf2 product is 262 bp and GFAP 
Product is 400 bp. The product was run on 2% agarose gel (v3121; Promega) prepared with 
Tris/Borate/EDTA buffer with an electrophoresis tank (Mini-Sub Cell GT Cell; Bio Rad). Mice 
were genotyped prior to surgery and genotype status was confirmed from tail samples at the 
end of the experiment.  
 
2.1.2. Animal maintenance and use 
Two to four months old male C57Bl/6J mice (Charles River, UK; 25 - 30g) or GFAP-Nrf2 (with 
C57Bl/6J background) were used. Animals were group housed on a 12:12 hr light/dark cycle 
and had access to food and water ad libitum. All experiments were conducted in accordance 
with the Animals (Scientific Procedures) Act 1986 and local ethical approval at the University 
of Edinburgh and were performed under personal and project licenses granted by the Home 
Office. The experiments were performed following the ARRIVE guidelines (Kilkenny et al., 
2010; www.nc3rs.org.uk/arrive-guidelines). All animals were randomly assigned into groups 
using random function in Microsoft Excel. The function generate a number between 0 and 1 
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for each animal, when above 0.5, it was assigned as an ischaemic animal. All data collection 
and analysis were performed by experimenter blind to the group.  
2.2. Focal cerebral ischaemic model  
Animals were subjected to a transient focal ischaemia by an occlusion of the right middle 
cerebral artery (MCAo) for different duration of ischaemia (15, 30 or 60). Mice were initially 
anaesthetised in an induction box with 5% isoflurane in a mix of 30% oxygen and 70% nitrous 
oxide before isoflurane levels were reduced to 1.5-2% during the operation. To induce the 
occlusion, the protocol from Hata and colleagues was followed (Hata et al., 1998). The right 
common carotid (CCA), external carotid (ECA), and internal carotid (ICA) arteries and their 
branches were exposed through a midline cervical incision. A 6–0 silk suture was tied around 
the CCA proximal to the bifurcation of the ECA and ICA and then a second suture tied around 
the ECA distal to the superior thyroid artery (STA). The STA and occipital artery (OA) were 
closed by electrocoagulation. A silicone-coated monofilament (diameter 220 μm) was 
introduced into the CCA via a small incision and advanced 10mm distal to the carotid 
bifurcation to occlude the MCA (Monofilament 6-0 medium A MCAO suture L34 PK10; 
Doccol). The sham procedure involved the operation without the insertion of the thread. To 
withdraw the thread, mice were re-anaesthetised with isoflurane anaesthesia as before. 
After wound was sutured, the anaesthesia was discontinued, and mice received 0.5ml saline 
(0.9%) subcutaneously by injection before being transferred to an incubator (30 C) for 2 
hours. The mice were weighed and monitored every day in order to assess the severity of the 
ischaemia injury.  All ischaemia surgery was undertaken by Dr Jill Fowler who was blinded as 
to genotype. Aseptic techniques were used. 
 
2.2.1. Inclusion/exclusion criteria 
Animals that underwent MCA occlusion but had no evidence of ischaemic neuronal damage 
were excluded from the study. In addition, animals were excluded if their weight loss 
exceeded 25%, if they had a poor response to the procedure or if they presented signs of 
infarction, which is defined pan necrosis of cells and a cluster of infiltrated cells and glia in an 




2.3. Histology  
Recipes for all reagents and buffers used are defined in the Appendix section 8.1. (i.e. 
phosphate buffer (PB), phosphate buffer saline (PBS), tris buffer (TB) and paraformaldehyde 
(PFA)) 
After 24 hours or 4 weeks of survival since the onset of ischaemia, animals were re-
anaesthetised with 5% isoflurane in a mix of 30% oxygen and 70% nitrous oxide then 
transferred to a face mask where anaesthesia was maintained with 3% isoflurane during the 
operation. In order to perfuse the brain, the animals were transcardially perfused-fixed. The 
heart was exposed by dissection of the animal’s thorax, accessed by cutting the skin below 
the sternum and the diaphragm. Once the needle was placed in the left ventricle, mice were 
perfused with  20 ml of 0.9% heparinised phosphate buffered saline followed by 20 ml of 4% 
paraformaldehyde (PFA) prepared in phosphate buffer (PB; made with mono-sodium 
phosphate NaH2PO4 and di-sodium phosphate Na2HPO4, purchased from Sigma). Shortly 
after the beginning of the perfusion, the right atrium was opened to allow for bleeding and 
to wash the blood from the body. The perfusion pump (PHD Ultra Syringe Pump, Harvard) 
infused solution at a rate of 2.1 ml/min. Animals were then decapitated and heads post-fixed 
in PFA 4% made in PB for 24 hours, followed by a further 2 hours in PFA 4%  once the brain 
was dissected from the skull. Brains were then transferred to 30% sucrose in PBS for three 
days before freezing them in isopentane at -42 °C for 2 minutes. Twenty-µm sections were 
cut with a cryostat (CM1950. Leica) and retained in cryoprotective solution (30% glycerol, 
30% Ethylene glycol in PB).  
 
2.3.1. Lesion volume assessment 
2.3.1.1. Haematoxylin and eosin (H&E) 
Sections were washed in PBS and then dehydrated through a series of increasing 
concentrations of ethanol baths (70% for 2mins, 90% for 2 mins, 100% for 5 mins) to 
delipidise sections, then immersed in a xylene bath for 15 minutes followed by decreasing 
concentrations of ethanol baths (100% for 5 mins, 90% for 2 mins, 70% for 2 mins). The 
sections were incubated in haematoxylin (Harris) for 3 mins then differentiated in 1% acid 
alcohol (1% HCl in 70% ethanol) for 10 seconds. After 2 minutes in Scott’s tap water substitute 
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(0.35% Sodium bicarbonate NaHCO3 and 2% magnesium sulphate MgSO4 in distilled water), 
the sections were placed in eosin (Shandon Eosin Y Alcoholic) for 1 minute. Finally, the 
sections were de-hydrated in increasing concentration of ethanol baths (70%, 90%, and 
100%) for 15 minutes, 5 minutes and 5 minutes, placed in xylene for 10 minutes and 
coverslips mounted with DPX (Thermo Fisher). 
 
2.3.1.2. Analysis of the lesion volume 
Infarct volume (mm3) was assessed using haematoxylin and eosin (H&E) stained sections, in 
addition to MAP2 and NeuN immunostaining. Nine coronal brain levels were used to 
calculate infarct volume (coordinates from Bregma +2.58; +1.54; +0.98; +0.74; -0.10; -1.06; -
2.06; -2.92; -4.48 mm). Lesion area was mapped onto each coronal level on a line diagram 
(Fig. 2.1) and area (mm2) calculated with Image J (Fiji, NIH). Lesion volume (mm3) was 
calculated using area under the curve in GraphPad Prism (v7). 
 
Figure 2-1 Nine coronal brain levels were used to map the infarct area. 






2.3.2.1. Immunohistochemistry study of the quantifiable markers for light microscopy  
Immunohistochemistry was performed on 3 sections of each brain representing three 
different levels of the brain (Bregma +0.98; -0.10; -2.06; Fig 2.2). After washing off the 
cryoprotective solution with phosphate buffer saline (PBS; PB with sodium chloride NaCl, 
purchased from Sigma; pH 7.4; 3 washes for 15 mins each), and tris buffer (TB; made with 
Trizma HCl and Trizma Base, purchased from Sigma; pH 7.6; 2 washes for 15 mins each) 
sections were floated out in Tris buffer and mounted on Superfrost slides (J1800AMNZ; 
Thermo fisher). To delipidise sections, slides went through a series of increasing 
concentrations of ethanol baths (70% for 2mins, 90% for 2 mins, 100% for 5 mins and 100% 
for 10 mins) and a xylene bath for 10 minutes. This was followed by two baths of 100% 
ethanol for 10 minutes and 5 minutes and a methanol and 3% H2O2 bath for 30 minutes to 
block endogenous peroxide activity. Sections were then blocked for 1 hour with 0.5% BSA 
(Sigma) and normal horse or goat serum (Vector) depending on the secondary antibody 
species. Triton X 0.3% was incorporated in the block to permeabilise sections for HO-1 
staining. Then primary antibodies (see table 1) were diluted in the appropriate blocking 
solution and incubated overnight at 4 °C. A negative control omitting the primary antibody 
was used. 
 
Figure 2-2 Three coronal level were selected to perform the immunohistology studies.  
(Bregma +0.98; -0.10; -2.06; Scale: one square is 1mm²). 
Sections were then washed two times for 10 minutes with PBS and incubated with the 
appropriate secondary antibodies (biotinylated-horseradish peroxidase-conjugated; 
purchased from Vector) used at 1:100 for 1 hour (see table 2.1). After another two times 10 
minutes wash with PBS, the signal was amplified with an ABC kit (Vectastain, Vector, 
California) for 1 hour at room temperature. Finally, after a further two 10 minutes washes 
with PBS, the sections were stained with 3,3’-diaminobenzidine (DAB) in the presence of 
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hydrogen peroxide for 3 minutes (DAB Peroxidase Substrate kit, Vector, California). Slides 
were then rehydrated by different ethanol dilution baths (70% for 2mins, 90% for 2 mins, 
100% for 5 mins and 100% for 5 mins) and a xylene bath for 10 minutes and hard mounted 
in DPX (Thermo fisher) with 1µm thick coverslips (VWR). 
 
Table 2-1 Antibodies used for immunohistochemistry study. 
Microglia and macrophages were stained with Iba1 (Ionised calcium binding adapting 
molecule 1) antibody, reactive astrocytes were immunostained with a GFAP (Glial Fibrillary 
Acidic Protein) antibody, oxidative stress was evaluated via the study of peroxynitrite 
generation with 3-Nitrotyrosine (3-NT). To investigate neuronal damage, anti-MAP2 
(microtubules associated protein 2) and anti-NeuN were used. The use of anti-NeuN required 
a 10 minutes citric acid heat-retrieval before the contact with the primary antibody. the sThe 
SJC-neutrophil antibody was kindly provided by Drs. Daniel Anthony and Sandra Campbell, 
University of Oxford, UK. 
 
2.3.2.2. Immunofluorescence on mounted sections and free-floating sections 
Microglia and macrophages were both stained with Iba1 antibody. To investigate the 
infiltration of macrophages in the parenchyma, the antibody anti-TMEM-119 was used (see 
table 2). The co-labelling of these markers was performed on free-floating sections of level 5 
(Bregma -0.10) for each animal. Sections were washed 3 times 10 minutes in PBS to clear 
them from cryoprotectant. Then the sections were pre-treated with PBS-Triton X 0.1% for 15 
minutes. The sections were blocked for two hours with 10% donkey serum and 10% horse 
serum in PBS at Room temperature. The primary antibodies were prepared in the block and 
left overnight at 4 °C overnight. 
 
Target Host M/P Brand Reference Dilution Secondary Reference
GFAP Rat Monoclonal Invitrogen Cat13-300 1:500 to 1000 Goat anti-rat BA 9401
Iba1 Rabbit Polyclonal Menarini MP 290 CR05 1:250 to 1000 Horse anti-rabbit BA 1100
3-NT Mouse Monoclonal Abcam Ab61392 1:800 Horse anti-mouse BA 2001
HO1 Rabbit Polyclonal αDiagnosic ADI PSA 895 1:1000 Horse anti-rabbit BA 1100
MAP2 Mouse Monoclonal Sigma M9942 1:2000 Horse anti-mouse BA 2001
NeuN Mouse Monoclonal Merck MAB377 1:8000 Horse anti-mouse BA 2001




Table 2-2 Antibodies used for free-floating immunofluorescence. 
The following day, sections were washed three times 10 minutes in PBS. Iba1 antibody was 
detected with biotinylated horse anti-goat at 1:100 prepared in PBS for an hour at room 
temperature. After a further three times wash with PBS, the fluorescent secondary 
antibodies were applied for an hour at room temperature. Before mounting, the sections 
were washed 10 minutes with PBS and two times 10 minutes with PB. Sections were mounted 




Images from immunofluorescence were captured using a Zeiss confocal microscope 
(LSMZ10). Light microscopy of the immunostaining was undertaken with a Zeiss Axio Scope 
A1 microscope. For each section, an image of the cortex and the striatum in the peri-infarct 
and the core of the ischaemic lesion was taken (Figure 2.3). The peri-infarct was defined as 
the closest area of the lesion with no neuronal damage. The core of the lesion was inside the 
neuronal damage area. Images from an equivalent region in the contralateral hemisphere 
was also captured. Images were analysed using the software Image J (Fiji, NIH) after cropping 
the images to a region of 0.285mm2 and transformation into 8-bit images. In order to use a 
threshold, the background was subtracted with 50 pixels rolling ball radius. For Iba1 and 
GFAP immunostained sections, the %area was calculated automatically on Image J (Fiji, NIH) 
with the selection of the specific staining by an auto-threshold (Triangle method). An average 
of the three sections in either the striatum or the cortex was calculated.  
  
Figure 2-3 Depending on the lesion size, the pictures for peri-infarct and core were selected in the cortex and 
striatum in the same area. 
Target Host M/P Brand Reference Dilution Secondary Reference
Horse anti-goat biotinylated (1:100) BA9500
Then streptavidin anti-biotin AF546 (1:100) S11225
TMEM119 Rabbit Monoclonal Abcam Ab209064 1:500 Donkey anti-rabbit AF488 (1:500) A21206
1:250Iba1 Goat Polyclonal Abcam Ab107159
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For HO1 and 3NT staining, the area of immunostaining was mapped onto each coronal level 
and area (mm2) calculated with Image J (Fiji, NIH). Area were delineated by stained 
parenchymal cell bodies only. Volume of HO1 or 3NT immunostaining (mm3) was calculated 
using area under the curve in GraphPad Prism (v7).  
 
2.4. qRT-PCR 
To evaluate gene expression, mRNA was quantified with quantitative real-time reverse 
transcriptase polymerase chain reaction (qRT-PCR). Brains were dissected immediately after 
dislocation of the animal neck. Three 2 mm sections of the brains were collected (Fig. 2.4). 
For each section, the striatum and the cortex of the ipsilateral and contralateral hemisphere 
were collected. Tissue was frozen in liquid nitrogen and stored at -80 °C. RNA extraction was 
undertaken using the RNAeasy Lipid tissue kit (Qiagen). The samples were homogenised in a 
2 ml Eppendorf tube with 1 ml of Quiazol reagent (Qiagen) and shaken with a metal bead for 
two times 2 minutes using a tissue ruptor at 20 Hertz (Qiagen). RNA extraction was conducted 
with the Qiazol kit (RNeasy Lipid Tissue) according to manufacturer instructions: 
Homogenised samples were mixed with 200 µl of chloroform then centrifuge for 15 minutes 
at 4 °C to separate the different phases. The upper phase was collected and mixed with 70% 
ethanol. The sample was then filtered in a spin column at 8000 rpm for 15 seconds. The 
sample was then mixed with 700 µl RW1 and centrifuged at 8000 rpm for 15 seconds then 
mixed with 500 µl RPE and centrifuged at 8000 rpm for 15 seconds twice. After a final 
centrifuge for 14000 rpm, RNA was eluted in 40 µl of RNA grade water. 
 
Figure 2-4 Schematic of the mouse brain dissection for biochemistry cohorts. 
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The RNA concentration was measured with a nanodrop machine (NanoDrop One, Thermo 
Scientific) in duplicates of 1 µl. To remove genomic DNA, the extracted RNA was then purified 
with DNAse I treatment (Thermo Scientific). One µg of the RNA was mixed with 1 µl of DNAse 
and 1 µl of magnesium chloride (MgCl2), mixed with PCR-grade water to get a final volume of 
10 µl. This mix was incubated at 37 °C for 30 minutes. Then, 1 µl of 50 mM EDTA was added 
to the mix and incubated at 65 °C for 10 minutes. The extracted RNA was then reverse 
transcripted into complementary DNA (cDNA) with the Roche cDNA synthesis kit 
(Transcriptor First Strand cDNA Synthesis Kit) and a PCR machine (10 minutes at 25 °C, 30 
minutes at 55 °C and 5 minutes at 85 °C). The kit was composed of Transcriptor Reverse 
Transcriptase; Transcriptor RT Reaction Buffer; 5x concentrated, Protector RNase Inhibitor; 
dNTP Mix, PCR Grade; Anchored Oligo (dT)18 Primer; Random Hexamer Primer and PCR-grade 
water. 
Samples were diluted to a concentration of 3 ng/µl for qRT-PCR. cDNA (5.76ul) was mixed 
with the primers at 0.4 µmol/L (see table 2.3), then 7.4 µl of SyBr Green (Dynamo flash SyBr 
green, Roche) was added together with 5.3 µl of PCR-grade water. Samples were then 
pipetted onto a 96 well plate and placed in a PCR machine (CFX96, BioRad) for 40 cycles. Each 
primer was used with its optimal cycle’s programs: When the annealing temperature was 60 
°C, the protocol was as follows: Denaturation for 30 seconds at 95 °C, annealing for 40 
seconds at 60 °C, and elongation for 30 seconds at 72 °C. For an annealing temperature was 
62.5 or 65 °C, the protocol was as follows: denaturation for 10 seconds at 95 °C, annealing 
for 30 seconds at the temperature stated in table 3, and elongation for 30 seconds at 72 °C. 
Gene expression was normalised to a housekeeping gene (18s), and data were normalised as 
fold change of sham or wild type sham expression. For each pair of primers, the annealing 
temperature was optimised and tested to get efficiency close to 100% (±10%). Two negative 
controls were used, one with water to replace the sample and one with a sample that was 




Table 2-3 Forward end reverse strand of the primers used for the qPCR.  
In brackets the name of the protein if different from the gene name. 
 
2.5. Behaviour  
To investigate the effects of ischaemia and overexpression of Nrf2 in astrocytes on cognition 
and neurological function, behavioural tests were undertaken on mice that survived for 4 
weeks after ischaemia. Cognitive functions, notably memory, were tested with a Novel 
Object Recognition task (NOR) 1 week and 4 weeks after ischaemia. For each behaviour test, 
the mice were moved to the behavioural room 30 minutes prior to the experiment. The light 
of the room was homogenous to avoid shadows and dimly lit (13 to 16 lux). Each trial/test 
was video recorded. 
 
2.5.1. Neuroscore 
Neurological deficits were assessed at 1, 3, 7, 10, 14, 21 and 28 days post-ischaemia using a 
neuroscore test based on a protocol from Clark et al., 1997; De Simoni et al., 2003 and Orsini 
et al., 2012. Scores range from 0 to 36, with a score of 0 indicating no deficit and a score of 
36 indicating maximal impairment. The score represents the sum of the results obtain in 
diverse categories to assess grooming (hair, eyes and coat), sensorial response (whisker 
Gene Forward Reverse Annealing
18S GTGGAGCGATTTGTCTGGTT CAAGCTTATGACCCGCACTT 60, 62.5 or 65
nfe2l2  (Nrf2) CAGCTCAAGGGCACAGTGC GTGGCCCAAGTCTTGCTCC 65
hmox1 AGCACAGGGTGACAGAAGAG GGAGCGGTGTCTGGGATG 60
nqo1 ACCTTGCTTTCTATCACCACTG TGAATCGGCCAGAGAATGAC 60
srxn1 GACGTCCTCTGGATCAAAG GCAGGAATGGTCTCTCTCTG 60
Slc7a11  (xCT) ATACTCCAGAACACGGGCAG AGTTCCACCCAGACTCGAAC 65
keap1 AAGGACCTTGTGGAAGACCA CCCTGTCCACTGGAATTGAT 65
gfap TCCTGGAACAGCAAAACAAG CAGCCTCAGGTTGGTTTCAT 60
aif1  (Iba1) GTCCTTGAAGCGAATGCTGG CATTCTCAAGATGGCAGATC 60
il-6 ACAACCACGGCCTTCCCTACTT CACGATTTCCCAGAGAACATGTG 62,5
il-1β GGGCCTCAAAGGAAAGAATC TACCAGTTGGGGAACTCTGC 65
cxcl10 AAGTGCTGCCGTCATTTTCT GTGGCAATGATCTCAACACG 60
il-4ra TCACGTGGTACAACCACTTCC TGCTGAAGTAACAGAACAGGCA 60
complement3 AGCTTCAGGGTCCCAGCTAC GCTGGAATCTTGATGGAGACGC 65
amigo2 GAGGCGACCATAATGTCGTT GCATCCAACAGTCCGATTCT 65
stat3 GCCCCGTACCTGAAGACCAA ACACTCCGAGGTCAGATCCA 60
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stimulation), posture and gait, spontaneous activity, symmetry, circling and gripping. The 
score was evaluated by an experimenter blinded to the groups. 
 
Table 2-4 Neuroscore test with score ranging from 0 indicating no deficit to 36 indicating maximal impairment. 
Section Observation Score
neat/clean 0
piloerection and dirty nose/eyes 1
piloerection and dirty coat 2
laterally & behind, straightening with noise 0
laterally, react to noise 1
laterally and don't react 2
open and clear 0




prominent. No response on one side 2
absent on one side and slow response ctrltl 3
absent bilaterally 4
upright, parallel, stabilise 0
humpbacked, lowers during rocking 1
head or part of the trunk lies in the palm 2
reclines on one side 3
alert & explore 0
seems alert but calm & quiet, start and stop exploring 1
listless, sluggish moves, no exploration 2
lethargic or stuporous, barely moves for 60sec 3
trunk elevated, fore and hind limbs beneath, tail straight 0
asymmetry: leans on one side & tail slightly bent 1
moderate: leans on one side, limbs stretched out, tail bent 2
flexible, symmetric & quick 0
stiff, inflexible, humpbacked, slower 1
limping with asymmetric movements 2
severe limping, drifting, falling with obvious deficits 3
no spontaneous walk, (stimulation) no more than 3 steps 4
absent 0
predominantly one-sided 1
circles to one side, not constantly 2
circling constantly 3
forelimb extended towards the bench & move actively 0
light. Contralateral forelimb not extended 1
marked. Ctrltl forelimb extend towards trunk, body bent on side 2
prominent. Contralateral forelimb adheres to trunk 3
slight asymmetry. No body/limb movement 4
absent. Extension both forelimbs 0
both forelimbs extended but circling 1
circles on one side and slower motion 2
pivots to one side sluggishly, not rotate in full circle 3
grasps the grid firmly and tries place hind paws 0
less power, slight pull 1























2.5.2. Novel Object Recognition in a Y maze  
Prior to the experiment, mice were handled in order to habituate them. To avoid the stress 
of open spaces, Novel Object Recognition (NOR) was performed in a rat Y-maze (arms 49 cm 
long, 17 cm wide and walls 32 cm; Easter Roads Plastics Ltd, Edinburgh). Because this 
apparatus was too big for mice, it was modified for the experiment (Fig 2.5). One unmodified 
arm was the “starting arm” (49 cm long), was closed and used to place the animal at the 
beginning of the experiment and during the habituation phases. The two other arms were 
closed mid-length and were used to place the objects (24 cm long; Fig 2.6). 
 
Figure 2-5 Schematic of the modified rat Y-maze for mouse novel object recognition. 
 
 
Figure 2-6 Objects used for the NOR. 
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Habituation of 10 minutes per animal were carried out 48 and 24 hours prior to 
familiarisation in the “starting arm” closed. Objects were bigger than the mouse and stable, 
such as upside-down glass, decorative pear, Lego© construction, upside down light bulb, 
plant pot. They were placed at the centre of the two “object arms”. Objects were cleaned 
with ethanol between the tests of two different animals. Objects used and arms selected for 
first new object were randomised. Trials were video recorded with ANY-maze software. The 
analysis was based on the time spent exploring the objects. A pilot test showed that the 
animals were interested in the object mainly during the 3 first minutes. As a result, the 3 first 
minutes of exploration were used. A discrimination index (DI) has been used to normalise the 
time spent on the new arm on the total time spent in the apparatus. 
An animal that did not explore the objects during the 3 minutes of familiarisation would be 
excluded. In the study, one animal was excluded following this rule. 
𝐷𝐼 =
(Time on Novel object − Time on Familiarised Object)
(Time on Novel object + Time on Familiarised Object)
 
 
2.6. Laser Speckle imaging to determine cerebral blood flow 
A semi-quantitative measure of cerebral blood flow was undertaken by using laser speckle 
imaging (Moor FLPI2 Speckle Contrast Imager, Moor Instruments, UK) before surgeries (for 
the baseline) and 4 weeks after the surgeries. Mice were anesthetised with 5% isoflurane in 
a mix of 30% oxygen and 70% nitrous oxide before transfer to stereotaxic frame where they 
were maintained with2.5 to 3 % isoflurane during the operation. Body temperature was 
monitored throughout the experiment using a rectal probe and maintained within the range 
of 36.5–37.5 °C using a heat blanket. The head was fixed in place using ear and tooth bars 
and an incision was made over the midline. The scalp was retracted, the skull was cleaned of 
fur and a thin layer of ultrasound gel applied to prevent the skull drying. Images were 
captured from the MCA territory of the ipsilateral hemisphere of the ischaemia and 
normalised to the contralateral hemisphere of the ischaemia. Speckle contrast images were 
analysed using MoorFLPI-2 Review software (version 4.0). Blood flow was expressed as a 





Data were expressed mean ± S.E.M. and statistical analysis was performed using GraphPad 
Prism software (v7.0). For parametric analysis on the wild-type study in chapter 3, unpaired 
t-test or one-way analysis of variance (ANOVA) followed by post-hoc Bonferroni test to 
correct for multiple comparisons. Mann-Whitney U test or Kruskal-Wallis Test were 
performed for non-parametric analysis. Normality of the distribution was tested with 
Shapiro-Wilk test. 
In chapter 4 and 5, to compare the genotype and the surgery effect, statistical analysis was 
undertaken on the four groups with a two-way ANOVA followed by post-hoc Bonferroni test 
for multiple comparisons. In chapter 5, to analyse neuroscore, two-way ANOVA with 
repeated measures were performed. To analyse discrimination and preference for the novel 
object in the NOR test, one-sample t-test was used to compare the results to zero, (i.e. no 
preference). 
Correlation between total lesion volume and GFAP or Iba1 immunostaining %area was 
assessed with Spearman R. 





3. Characterisation of acute and chronic cerebral ischaemia and its 
impact on Nrf2-signalling pathway 
3.1. Introduction  
Ischaemic stroke is a leading cause of disability and the second leading cause of death 
worldwide, affecting 15 million people per year. Ischaemia can contribute to dementia 
including both vascular cognitive impairment (VCI) and Alzheimer’s disease (AD), however 
there is no therapy to date. Cerebral ischaemia can be modelled in rodents in vivo with 
endovascular techniques, to allow disease mechanisms to be studied and to investigate novel 
therapeutic approaches. As outlined in the introduction, a number of different techniques 
can be used in rodents to induce focal cerebral ischaemia. One of the most commonly used 
techniques involves transient intraluminal thread occlusion of the origin of the MCA with a 
thread introduced via the ligated external carotid artery. Hata et al (1998) developed a 
technique to occlude the MCA that involves thread insertion via the common carotid artery, 
which is permanently ligated. Therefore, this technique involves unilateral common carotid 
artery occlusion in combination with transient middle cerebral artery occlusion. This paper 
showed that this model produces an infarct core with a depletion of ATP and a penumbra 
where protein synthesis was reduced, acidity increased, ATP levels were preserved. They also 
used MRI techniques to highlight the difference between diffusion and perfusion weighted 
imaging, used to distinguish the penumbra from the core. This model has been previously 
characterised, showing astrocyte reactivity and microglial activation from 12 hours to 7 days 
following ischaemia (Alawieh et al., 2015; Petrovic-Djergovic et al., 2012; Strecker et al., 
2011), however glial cell activation at later time points than 7 days have not been defined 
using this model. 
Following ischaemia, neuronal damage is caused by initially by hypoxia but also with 
oxidative stress and inflammation. Due to its high metabolic rate and poor anti-oxidative 
defences, the brain is prone to oxidative stress (Kohen et al., 1988; Lebel & Bondy, 1991). 
Radicals and notably ROS oxidise cell elements such as DNA, proteins or the cytoplasmic 
membrane, leading to their degradation and thus dysfunction of the cell (Sun et al., 2018). 
For many decades, Ischaemic research was predominantly focused on neurons but there is 
now a growing interest on glial cells  and their response after ischaemia as a target for stroke 
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treatment (Liu & Chopp, 2016; Xia et al., 2015). Microglia are immune cells that phagocyte 
damaged and unused cells or infectious agents. Astrocytes support neurons in many ways 
(production and release of neurotrophic factors, antioxidants and energy precursors) but 
additionally regulate neuronal transmission, glutamate levels, homeostasis and 
vasomodulation (Sofroniew & Vinters, 2010). With an injury, microglia become activated and 
astrocytes become reactive; they exert morphological and transcriptomic changes. These 
changes can be classified in two main populations, one aggressive and potentially neurotoxic 
and the other anti-inflammatory and neurotrophic. After ischaemia both phenotypes were 
to be found in the vicinity of the lesion (Liddelow & Barres, 2017; Zamanian et al., 2012; 
Zhang et al., 2018; Zhao et al., 2017). Microglia and astrocytes contribute to ongoing 
inflammation and oxidative stress and may exacerbate neuronal damage (Block et al., 2007; 
Liddelow et al., 2017; Villarreal et al., 2016) or provide neuroprotection by producing anti-
inflammatory cytokines, anti-oxidant and neurotrophic factors (Becerra-Calixto & Cardona-
Gómez, 2017; Chen & Trapp, 2016). 
Nrf2-signalling is a potential therapeutic target in diseases involving oxidative stress and 
inflammation. This transcription factor drives the production of cytoprotective genes such as 
heme oxygenase-1 (HO1; gene hmox1), NAD(P)H dehydrogenase quinone 1 (NQO1; gene 
nqo1), sulfiredoxin 1 (SRXN1, gene srxn1) and glutamate-cystine antiporter (xCT; gene 
slc7a11), reducing cellular oxidative damage and inflammation. Nrf2 is upregulated in 
microglia, astrocytes and neurons after ischaemia (Dang et al., 2012). Even modest durations 
of ischaemia (15 minutes) can lead to the activation of the Nrf2 signalling pathway at 4 hours 
(Bell et al., 2011). Upregulation of Nrf2-related genes has been reported from 4 hours to 3 
days post ischaemia (Alfieri et al., 2013; Bell et al., 2011a; Bell et al., 2011b; Ding et al., 2014; 
Tanaka et al., 2010; Yang et al., 2009) however, more chronic time points have not been 
examined. Therefore, a characterisation of ischaemia at the cellular level coupled with an 
investigation of alterations to the Nrf2 pathway was carried out in the present chapter. This 
study will test the hypothesis that activation of Nrf2 signalling is associated with oxidative 






The aim of the current study was to characterise the acute and chronic effects of ischaemia 
on inflammatory glial cells, oxidative stress and Nrf2 signalling. 
I. To characterise inflammatory glial cell changes and determine how Nrf2 signalling is 
altered in the acute response to focal cerebral ischaemia in mice. 
a. To study inflammatory glial cell changes (reactive astrocytes and 
microglia/macrophages) and oxidative stress following increasing durations (15, 
30 and 60 minutes) of ischaemia. 
b.  To determine how Nrf2-related genes are altered in response to ischaemia. 
 
II. To characterise glial cell changes and determine how Nrf2 signalling is altered in the 
chronic response to focal cerebral ischaemia in mice. 
a. To determine inflammatory glial cell changes and oxidative stress in the chronic 
response to ischaemia. 




3.2.1. Mice and experimental groups 
To address these aims, three experiments were designed. Three to four-month-old male 
C57Bl/6J mice underwent middle cerebral artery occlusion (MCAo) or sham surgery and their 
brains harvested at acute (24 hours) or chronic (4 weeks) time points.  
The first experiment was designed to study cellular responses to increasing duration of 
ischaemia (15-60 minutes; n=6-8 per group) at acute time points (24 hours after injury) using 
histology and immunohistochemistry techniques. The second experiment was developed to 
study Nrf2-related genes and inflammatory-related genes after modest duration ischaemia 
(15 minutes) at three early time points after injury (2, 4 and 24 hours; n=5-6 per group) using 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). In the last 
experiment, the impact of chronic ischaemia (4 weeks post-injury) was studied after modest 
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duration ischaemia (15 minutes) with a histology and immunohistochemistry cohort (n=7-9) 
and a qRT-PCR cohort (n=7-9). Mice were allocated to groups in a randomised fashion. 
 
3.2.1.1. Inclusion/exclusion criteria 
In the histology acute cohort, three animals in ischaemic group did not present neuronal 
damage and thus have been excluded and three animals from the ischaemic group were 
culled early due to a poor response to the procedure. In the histology chronic cohort, two 
animals from the ischaemic group were culled due to either a poor response to the procedure 
or weight loss, and one animal was excluded due to the presence of an infarction defined by 
a cluster of infiltrated cells and glia in an atrophied lesion. For the biochemistry cohorts, one 
sham and one ischaemic animal were excluded due to poor response to the procedure. 
 
 
Table 3-1 Summary of the group size of each group for the histologic and the biochemistry cohorts. 
Histologic cohorts and the biochemistry cohorts depending on the surgery and the duration of occlusion and the 




Duration Initial size Final size Initial size Final size
sham 6 6 7 7
15 min 9 6 12 9
30 min 10 8
60 min 7 6
Histochemistry cohorts
24 hours 4 weeks
Survival Initial size Final size Initial size Final size
sham 6 5 7 7
2 hours 5 5
4 hours 5 5
24 hours 6 6
4 weeks 10 9
Biochemistry cohorts
24 hours 4 weeks
93 
 
3.2.2. Focal cerebral ischaemia model 
Male mice were subjected to a transient focal ischaemia by an occlusion of the right middle 
cerebral artery (MCAo) for differing durations of ischaemia (15, 30 or 60) minutes under 
anaesthesia with 5% isoflurane in a mix of 30% oxygen and 70% nitrous oxide before and 1 
to 1.5% isoflurane during the operation.  
As previously explained in the section 2.2 of the Materials & Methods chapter, a 
monofilament was introduced into the CCA via a small incision and advanced 10mm distal to 
the carotid bifurcation to occlude the MCA (Monofilament 6-0 medium A MCAO suture L34 
PK10; Doccol). Sham experiments involved the same procedure, including unilateral common 
carotid artery ligation, however but the thread was not inserted into the CCA. To withdraw 
the thread, mice were re-anaesthetised with isoflurane anaesthesia. Mice received 0.5ml 
saline (0.9%) subcutaneously by injection and transferred to an incubator (30 C) for 2 hours. 
The mice were weighed daily and monitored at least twice a day for the first 72 hours, and 
then daily, in order to assess the severity of the ischaemia injury. All ischaemia surgery was 
undertaken by Dr Jill Fowler. Aseptic techniques were used. 
 
3.2.3. Histology  
Histology and immunohistochemistry techniques were performed as described in section 
2.3. Lesion volume was assessed by drawing areas of ischaemic neuronal death assessed in 
haematoxylin and eosin (H&E) stained sections from 9 coronal levels as outlined in section 
2.3. The assessment of lesion volume in mice that survived for 1 month was undertaken with 
H&E stained sections as well as MAP2 immunostained sections because loss of neurons after 
4 weeks was harder to detect with H&E stained sections alone. There was a loss of dendrites 
in MAP-2 immunostained sections as previously described (Dawson & Hallenbeck, 1996; 
Popa-Wagner et al., 1999). Oxidative stress was detected using 3-nitrotyrosine antibody and 
then mapped at 3 coronal levels and the volume of oxidative stress was determined as 
outlined in section 2.3. Microglia/macrophages and astrocytes were studied using Iba1 and 
GFAP immunostaining respectively and quantified with %area as outlined in section 2.3. 
Neutrophils and microglia were labelled with a specific antibody (SJC-Neutrophil antibody 
and TMEM119 respectively) and quantified as described in section 2.3. Finally, HO1 
immunostaining was used to assess HO1 upregulation as an index of Nrf2-signalling 
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activation and the area of HO1 immuno-positive staining was quantified at 3 coronal levels 
as outlined in section 2.3. All experiments were conducted by an experimenter blinded to the 
groups. 
 
3.2.4. Analysis  
Images of GFAP and Iba1 immunostained sections were taken with a Zeiss microscope 
(LSMZ10) at 20x magnification. For each section, an image of the cortex and the striatum in 
the peri-infarct and the core of the ischaemic lesion was taken, using the lesions maps to 
determine the peri-infarct and core areas. They were analysed using the software Image J 
(Fiji, NIH) after cropping the images to a region of 0.285mm2 and transformed into 8-bit 
images. Images were captured from 3 coronal levels (Bregma +0.98; -0.10; -2.06) and the 
final result was expressed as an average of these three sections for either the striatum or the 
cortex. 
For Iba1 and GFAP immunostained sections, the %area was calculated automatically using 
Image J (Fiji, NIH) with the selection of the specific staining by an auto-threshold (Triangle 
method) on inverted images. For 3-nitrotyrosine staining, the area of immunostained cells 
was mapped onto three coronal levels and area (mm2) calculated with Image J (Fiji, NIH). 
Lesion volume (mm3) was calculated using area under the curve in GraphPad Prism (v7).  
 
3.2.5. qRT-PCR  
To study gene expression, qRT-PCR was undertaken as explained in the methods section 2.4. 
For this first study, inflammation and glial response were assessed by investigated alterations 
to gfap, aif1, cxcl10 and il-1β mRNA levels. For Nrf2-related gene expression, alterations to 
nfe2l2, hmox1, nqo1, srxn1 and slc7a11 genes were investigated. For each animal, the level 
of expression was normalised to the housekeeping gene 18S and normalised to levels of 






Data were expressed mean ± S.E.M. using GraphPad Prism software. For parametric analysis, 
unpaired student’s t-test or one-way analysis of variance (ANOVA) followed by post-hoc 
Bonferroni test were performed for multiple comparison. P<0.05 was deemed statistically 
significant. Mann-Whitney U test was performed for non-parametric analysis. Normality of 






3.3. Characterisation of ischaemic cell death with increasing occlusion duration 
3.3.1. Increased neuronal damage with increasing duration of occlusion 
 
Figure 3-1 Neuronal damage was detected with Haematoxylin & Eosin staining, 24 hours after ischaemia. 
(A)  Morphologically normal appearing cells and neurons (white arrow) in shams.  
(B) Damaged tissue in the core of the lesion in the cortex displays shrunken neurons with an eosinophilic cytoplasm 
and triangular perikarion (blue arrow). Scale bar 100 μm. 
The ischaemic lesion was detected with haematoxylin and eosin (H&E) staining. In the lesion, 
the tissue appeared vacuolated and ischaemic neurons appeared shrunken with a triangular 
perikarion and eosinophilic cytoplasm (Fig 3.1 B) whereas undamaged tissue contained round 
cell bodies and no vacuolisation (Fig 3.1 A). Areas of tissue containing ischaemic neurons 














Figure 3-2 Increased duration of ischaemia increases neuronal damage in cortex and striatum, 24 hours after 
ischaemia. 
(A) Representative line diagram with ischaemic neuronal damage in black from median animals (coordinates from 
Bregma +2.58; +1.54; +0.98; +0.74; -0.10; -1.06; -2.06; -2.92; -4.48 mm). 
(B) Quantification of neuronal damage mapping showed significant differences between groups in total lesion (F(3, 
22)=16.31, p<0.0001), cortex (F(3, 22)=17.88, p<0.0001) and striatum (F(3, 22)=30.49, p<0.0001). There was a 
significant increase in every region with 30 or 60 minutes of ischaemia (p<0.0001). Interestingly, after 15 minutes 
of ischaemia, the lesion was increased in the striatum (p=0.0024) but not the cortex (p>0.05). 
Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc comparisons with Bonferroni (N=6 to 8 
per group). **p<0.01, ***p<0.001.  
 
No ischaemic cell death was observed in sham animals. There was a significant difference 
between the groups in total lesion (F(3, 22)=16.31, p<0.0001), cortex (F(3, 22)=17.88, p<0.0001) 
and striatal lesion F(3, 22)=30.49, p<0.0001) with an increase in the lesion volume with 
increasing duration of ischaemia (p<0.0001 for all groups; Fig 3.2 A and B). Post-hoc 
comparisons revealed differences in the lesion volume after 30 and 60 minutes in the total 
lesion and cortex compared to shams (p<0.0001, Fig 3.2 B) and from 15, 30 and 60 minutes 
ischaemia in the striatum compared with shams (p=0.0024, Fig 3.2 B). Therefore with longer 
occlusion, the there was an increase in lesion volume (Fig 3.2 B) as reported in the literature 
(Popp et al., 2009). Given these results, the lesion seems to extend from striatum to cortex 
with increasing duration of ischaemia. 
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3.3.2. Increased cortical oxidative stress with increasing duration of occlusion 
Ischaemia and reperfusion can induce oxidative stress via increased reactive oxygen species 
and nitric oxide (Iadecola et al., 1995; Olmez & Ozyurt, 2012). Together, they form 
peroxynitrite (Radi et al., 1991) that nitrates tyrosine residues in proteins. This phenomenon 
can be detected with 3-Nitrotyrosine (3NT) immunohistochemistry (Giannessi et al., 2010). 
There was minimal 3NT immunostaining in the shams, whereas 3NT labelled cells were 
detected in the ischaemic animals (Fig 3.3 A). Morphologically, the staining appeared similar 
with increasing duration of ischaemia. 
Quantification of areas containing 3NT labelled cells was assessed by the mapping the 
immunostaining observed in 3 coronal sections (Bregma +0.98, -0.10. -2.06). There was a 
significant difference between groups in the total lesion (F(3, 22)=17.28, p<0.0001), cortical (F(3, 
22)=12.92, p<0.001) and striatal lesion (F(3, 22)=25.11, p<0.0001). Post hoc comparisons showed 
significant increase in 3NT staining with all durations of ischaemia. A modest duration of 
ischaemia (15 minutes) significantly increased 3NT immunostaining at 24 hours in the total 
ipsilateral hemisphere, cortex and striatum compared to shams (p=0.0008, p=0.0097 and 
p<0.0001 respectively; Fig 3.3 B). With 30 minutes ischaemia and 60 minutes ischaemia, 3NT 
immunostaining was significantly increased in the total ipsilateral hemisphere, cortex and 
striatum (p<0.0001 for every region for both group; Fig 3.3 B). 
This result suggests the presence of oxidative stress in the lesion after ischaemia. 
Interestingly, 24 hours after 15 minutes ischaemia, the cortex contained minimal ischaemic 
neuronal death (Fig 3.2 B) but had elevated 3NT staining (Fig 3.3 B). Therefore, the area of 
3NT immunostaining was compared with area of neuronal damage area for animals that 
underwent 15 minutes of ischaemia (Fig 3.3 C). The blue line represents area of tissue 
containing 3NT immunostained cells on the three coronal sections whereas black line 
represents area of tissue containing ischaemic neuronal damage in the same three coronal 
sections. This comparison demonstrated that there is a greater area of 3NT expression 
compared to the neuronal damage area on these three coronal levels for both cortex and 
striatum (Fig 3.3 C). It is important to note that oxidative stress was found beyond the area 





Figure 3-3 Increased duration of ischaemia increases oxidative stress in cortex and striatum, 24 hours after 
ischaemia. 
(A) Representative images of 3-Nitrotyrosine (3NT) immunostaining showing peroxide nitrite generation in the 
cytoplasm of cells in cortex and striatum after ischaemia and minimal staining in shams.  
(B) Quantification of 3NT staining by mapping the positive immunostaining. There was a significant difference 
between groups in the total ipsilateral hemisphere (F(3, 22)=17.28, p<0.0001), cortex (F(3, 22)=12.92, p<0.001) and 
striatum F(3, 22)=25.11, p<0.0001). There was a significant increase in every region with 15 minutes or longer 
ischaemia (**p<0.01, ***p<0.001). Interestingly, even after 15 minutes of ischaemia, there was increased 
oxidative stress increased in the cortex (p=0.0097) despite minimal ischaemic neuronal damage in that region.  
(C) Profile area of 3Nt immunostaining compared to the area of neuronal damage in three coronal sections of the 
15 minutes ischaemia group demonstrated that 3NT expression extended beyond the lesion site. The blue line 
represents area of tissue containing 3NT immunostained cells on the three coronal sections whereas black line 
represents area of tissue containing ischaemic neuronal damage in the same three coronal sections. 
Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc comparisons with Bonferroni (N= 6 to 8 
per group). **p<0.01, ***p<0.001.  
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3.3.3. Astrocytic response to acute ischaemia 
To investigate how reactive astrocytes are altered by ischaemia, glial fibrillary acidic protein 
(GFAP) immunostaining was undertaken. In shams, 15- and 30-minutes ischaemic animals, 
astrocytes had small cell bodies and long and thin processes with many branches (Fig. 3.4 A). 
In 60-minutes ischaemic animals, processes were fragmented in the peri-infarct and were 
not detectable in the core. In both locations after 60 minutes of ischaemia, cell bodies were 
bigger (Fig. 3.4 A).  
Quantification of the GFAP immunostaining using %area revealed a significant difference 
between groups for the four locations: cortex peri-infarct (F(3, 22)=8.498, p=0.0006), cortex 
core (F(3, 22)=3.455, p=0.033), striatum peri-infarct (F(3, 22)=6.011, p=0.0035) and striatum core 
(F(3, 22)=10.26, p=0.0002; Fig 3.4 B). Post hoc tests revealed no significant differences between 
shams and any duration ischaemia in the cortex core (p>0.05). In the striatum core, GFAP 
%area was decreased in the core of the lesion in the striatum following 30- and 60-minutes 
ischaemia compared to shams (p=0.0318 and p=0.0012). This might be linked to astrocytic 
death observed early on after ischaemic injury (Liu et al., 1999). In the peri-infarct, post hoc 
test revealed a significant increase between sham and 60 minutes ischaemia for the cortex 
and striatum (p=0.0019 and p=0.0025 respectively; Fig. 3.4 B). Other comparisons were not 
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← Figure 3-4 Increased duration of ischaemia modifies reactive astrocytes assessed with GFAP in the cortex and 
the striatum, 24 hours after ischaemia. 
(A) Representative images of GFAP immunostaining showing an increase in the peri-infarct for the cortex and the 
striatum after ischaemia compared to shams for the 60 minutes ischaemia group. However, 15 minutes ischaemia 
did not modify GFAP immunostaining.  
(B) Quantification of GFAP staining assessed by %area showed significant differences between groups in the cortex 
peri-infarct (F(3, 22)=8.498, p=0.0006), the cortex core (F(3, 22)=3.455, p=0.033), the striatum peri-infarct F(3, 22)=6.011, 
p=0.0035) and the striatum core (F(3, 22)=10.26, p=0.0002). There was a significant increase of GFAP 
immunostaining following 60 minutes of ischaemia in the peri-infarct of the cortex and striatum (p=0.0019 and 
p=0.0025 respectively) compared to shams. In the striatum core, GFAP immunostaining was decreased 
significantly following 30 and 60 minutes of ischaemia (p=0.0318 and p=0.0012 respectively). For the other 
comparisons, there was no statistical difference between ischaemic animals and shams. 
Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc comparisons with Bonferroni (N= 6 to 8 
per group). *p<0.05, **p<0.01. 
 
To build on these findings, GFAP mRNA level was investigated in a cohort of animals that 
received 15 minutes of ischaemia and 24 hours survival. Levels of gfap gene expression were 
significantly increased at 24 hours in the striatum and the cortex (p<0.0001 for both; Fig 3.5). 
Taken together, these results show that ischaemia modifies GFAP at protein and gene level 
and that there are increased levels of reactive astrocytes in peri-infarct regions. 
 
 
Figure 3-5 Increased gene expression for gfap in the cortex and striatum, 24 hours after ischaemia. 
GFAP gene gfap mRNA expression (normalised to 18s) was significantly increased in both cortex (t(9)=8.092, 
p<0.0001) and striatum (t(9)=7.409, p<0.0001) 24 hours after 15 minutes of ischaemia compared to shams. 
Data presented as mean ± S.E.M. Student’s t-test for gene expression study (N= 5 to 6 per group). ***p<0.001. 
 
 





























































































3.3.4. Increased microglia/macrophage density in the acute response to ischaemia  
Ischaemia triggers morphological alterations and recruitment of the microglia/macrophages 
at the core and peri-infarct regions of the ischaemic lesion (Fumagalli et al, 2015; Morrison 
& Filosa, 2013; Ito et al., 2001). The morphological modification appears when 
microglia/macrophages are activated after hypoxia and during inflammation (Bachiller et al., 
2018; Hirbec et al., 2017; Hoogland et al., 2015; Patel et al., 2013). Iba1 immunostaining of 
resident microglia and infiltrated macrophages (Ito et al., 2001) was undertaken and % area 
of immunostaining was quantified in the cortex and striatum.  
Sham animals had Iba1-positive cells with small cell bodies and small and thin processes. 
Following ischaemia, Iba1-positive cells had larger, darker cell bodies and the processes were 
thicker and more intensely stained (Fig 3.6 A). For some Iba1-positive cells, the processes 
were lost, giving then an amoeboid shape as reported previously (Giulian, 1987; Schilling et 
al., 2003). 
Quantification of the %area of Iba1 immunostaining with revealed a significant effect of the 
ischaemia in every locations: cortex peri-infarct (F(3, 22)=21.51, p<0.0001), cortex core (F(3, 
22)=11.56, p<0.0001), striatum peri-infarct F(3, 22)=22.28, p<0.0001) and striatum core (F(3, 
22)=16.01, p<0.0001; Fig 3.6 B). Post hoc comparisons with Bonferroni revealed a significant 
increase in the striatum core and peri-infarct following 15 minutes ischaemia (p<0.0001). 
Following 30 minutes ischaemia, Iba1 %area was significantly increased compared to shams 
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← Figure 3-6 Increased duration of ischaemia modifies microglia/macrophage marker Iba1 in the cortex and 
the striatum, 24 hours after ischaemia. 
 (A) Representative images of Iba1 immunostaining showing an increase in the density of cells in the peri-infarct 
and core of the cortex and the striatum after ischaemia compared to shams. Following ischaemia, cells were larger, 
with thicker, darker processes. 
 (B) Quantification of Iba1 staining by %area showed significant differences between groups in the cortex peri-
infarct (F(3, 22)=21.51, p<0.0001), the cortex core (F(3, 22)=11.56, p<0.0001), the striatum peri-infarct F(3, 22)=22.28, 
p<0.0001) and the striatum core (F(3, 22)=16.01, p<0.0001). Post hoc comparisons revealed no significant 
differences between 15 minutes ischaemia and shams in the cortex peri-infarct (p=0.979) and cortex core 
(p=0.156). There was a significant increase in the striatum with 15 minutes (p<0.0001). With 30 minutes ischaemia, 
Iba1 %area was significantly increased compared to shams for every location (p<0.0001). There was a significant 
increase of the Iba1 % area after 60 minutes ischaemia in the peri-infarct cortex and striatum (both p<0.0001), in 
the cortex core (p=0.0037) and in the striatum core (p=0.0088). For the other comparisons, there was no statistical 
difference between ischaemic animals and shams. 
Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc comparisons with Bonferroni (N= 6 to 8 
per group). **p<0.01, ***p<0.001. 
 
To further investigate alterations to microglia/macrophages, Iba1-positive cell counts were 
undertaken to assess recruitment at the lesion site. Quantification of cell counts revealed a 
significant alteration of Iba1-positive cells for all durations of ischaemia compared with 
shams (cortex peri-infarct F(3, 22)=17.97, p<0.0001, cortex core F(3, 22)=5.491, p=0.0054, 
striatum peri-infarct F(3, 22)=9.591, p=0.0003 and striatum core F(3, 22)=3.552, p=0.0301; Fig 3.7 
A).  
Post hoc comparisons with Bonferroni revealed a significant increase in the striatum peri-
infarct with 15 minutes ischaemia (p=0.0076) but not in the cortex peri-infarct, cortex core 
or striatum core (p=0.893, p=0.358 and p=0.254 respectively; Fig 3.7 A). With 30 minutes 
ischaemia, Iba1-positive cells were significantly increased compared to shams in the cortex 
peri-infarct and core (p=0.0002 and p=0.0034 respectively) and striatum peri-infarct 
(p=0.0002) but not in the striatum core (p=0.154; Fig 3.7 A). There was a significant increase 
of Iba1-positive cells in the peri-infarct for both cortex and striatum compared to shams after 
60 minutes ischaemia (p<0.0001 and p=0.0058) but not in the striatum peri-infarct or core 
(p>0.999 for both; Fig 3.7 A). 
To further investigate Iba1 alterations, levels of the Iba1 gene aif1 were investigated. At 24 
hours, there was no significant difference in Iba1-gene aif1 levels between the shams and 
ischaemic animals in the striatum (p=0.585) and in the cortex (p=0.081; Fig 3.7 B).  
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In the peri-infarct, Iba1 %area and Iba1-positive cell counts are both significantly increased 
for the same groups, suggesting that microglia/macrophages migrate to the lesion site. 
However, in the core of the lesion, Iba1 %area increase is not paralleled with an increased 
number of positive cells, suggesting that the morphology has changed in this area compared 






Figure 3-7 Increased duration of ischaemia increases Iba1-positive cells in the cortex and the striatum but not 
Iba1 gene aif1 expression, 24 hours after ischaemia. 
(A) Quantification of the number of Iba1-positive cells.  There were significant differences in the number of Iba1 
immunostained cells in the cortex peri-infarct (F(3, 22)=17.97, p<0.0001), the cortex core (F(3, 22)=5.491, 
p=0.0054), the striatum peri-infarct F(3, 22)=9.591, p=0.0003) and the striatum core (F(3, 22)=3.552, p=0.0301). 
There was a significant increase in the striatum peri-infarct with 15 minutes ischaemia (p=0.0076). With 30 
minutes ischaemia, Iba1-positive cells were significantly increased compared to shams in the cortex peri-infarct 
and core (p=0.0002 and p=0.0034 respectively) and striatum peri-infarct (p=0.0002). There was a significant 
increase of Iba1-positive cells in the peri-infarct for both cortex and striatum compared to shams after 60 minutes 
ischaemia (p<0.0001 and p=0.0058). For the other comparisons, there was no statistical difference between 
ischaemic animals and shams. 
(B) There was no significant difference in mRNA expression of the Iba1 gene aif1 in the cortex (t(9)=1.962, p=0.081) 
and striatum (t(9)=0.566, p=0.585) 24 hours after 15 minutes of ischaemia compared to shams.  
Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc comparisons with Bonferroni (N= 6 to 8 
per group). Student’s t-test for gene expression study (N= 5 to 6 per group).  **p<0.01, ***p<0.001. 
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3.3.5. Increased cxcl10 expression in the striatum 24 hours after 15 minutes 
ischaemia 
Cytokines are produced by neurons, glial cells and immune cells and serve as messengers 
that induce and modulate glial activation and response. Recruitment of glial cells at the injury 
is possible via increased production of chemokines. Interleukin 1 beta (Il-1β) is a cytokine 
found in the pro-inflammatory environment that can promote activation of microglia (Rider 
et al., 2011; Fogal et al., 2005). C-X-C motif chemokine 10 (CXCL10) is produced by microglia, 
astrocytes, neurons, leukocytes, macrophages and T cells (Chai et al., 2015; Harikumar et al., 
2014; Klein et al., 2005; Nakamichi et al., 2004; Singh et al., 2008). It is notably expressed by 
reactive astrocytes and is known to promote microglia recruitment (Cross & Woodroofe, 
1999; Rappert et al., 2004).  
In the cortex, cxcl10 and il-1β levels were not significantly altered when comparing ischaemia 
and sham groups (Mann–Whitney U=6 p=0.125 and Mann–Whitney U=9 p=0.329 
respectively; Fig. 3.8). In the striatum, cxcl10 mRNA expression was significantly increased 
compared to sham following ischaemia (Mann–Whitney U=0 p=0.0043; Fig. 3.8), whereas 
there was no significant difference in the levels of il-1β mRNA expression compared to shams 






Figure 3-8 Inflammatory gene cxcl10 was upregulated in the striatum 24 hours after 15 minutes of ischaemia. 
(A) In the cortex, cxcl10 and il-1β levels were not significantly altered ischaemia and sham groups (Mann–
Whitney U=6 p=0.125 and Mann–Whitney U=9 p=0.329 respectively). 
(B) In the striatum, cxcl10 mRNA expression was significantly increased compared to sham (Mann–
Whitney U=0 p=0.0043). Study of il-1β mRNA expression showed no significant differences compared to shams 
(Mann–Whitney U=11 p=0.536). 
Data presented as mean ± S.E.M. Student’s t-test or Mann-Whitney U test n1 = 5 and n2 = 6, two-tailed (N= 5 to 6 
per group).  **p<0.01. 
 
3.3.6. Peripheral immune cells infiltrate 24 hours after ischaemia 
Ischaemia is associated with peripheral immune cell infiltration through the blood brain 
barrier (BBB). The previous result demonstrated that the gene that encodes the chemokine 
CXCL10 was upregulated and Iba1 staining was increased. Therefore, infiltrating peripheral 
immune cells were examined. Neutrophils and peripheral macrophages can be studied with 
immunostaining.  
Neutrophil staining was performed on this cohort and was detected in ischaemic brains (Fig 
3.9 A). To quantify neutrophils, their presence or absence was determined in the 
experimental groups (Fig 3.9 B). Neutrophils were absent in sham controls. Neutrophils were 
detected in the cortex and striatum of ischaemic animals. Interestingly, only one animal of 
the 15 minutes ischaemia group contained neutrophils. After verification, this animal had the 
biggest lesion within this group (Fig 3.9 B). The probability of neutrophil infiltration to the 
parenchyma occurring following ischaemia was unchanged with 15-minutes ischaemia 



































































































































































(p>0.999) and increased with 30- and 60-minutes ischaemia (p=0.0003 and p=0.0022, Fisher’s 
exact test). In the cortex, the probability was unchanged with 15 minutes ischaemia 
(p>0.999) and increased with 30- and 60-minutes ischaemia (p=0.0047 and p=0.0022). In the 
striatum, the probability was unchanged with 15-minutes ischaemia (p>0.999) and increased 
with 30- and 60-minutes ischaemia (p=0.0097 and p=0.0152). 
 
 
Figure 3-9 Ischaemia increases neutrophil infiltration, 24 hours after ischaemia. 
(A) Representative images of neutrophil immunostaining in the cortex after 60 minutes ischaemia. No neutrophils 
were to be found in the shams. Nuclei were counterstained with DAPI, in blue, and neutrophil in brown (green 
arrows). Scale bar 100 μm. 
(B) Quantification of the presence of neutrophils revealed only one animal of the 15 minutes ischaemia group had 
neutrophil infiltration. On the contrary, every animal receiving 30 minutes or longer ischaemia had neutrophils. 
 
The infiltration of neutrophils suggested that peripheral macrophages may also infiltrate the 
brain. Since Iba1 immunostaining cannot discriminate between innate microglia and 
infiltrated macrophages, another marker was investigated. TMEM 119 is expressed by 
resident microglia but not peripheral macrophages (Bennett et al., 2016; Satoh et al., 2016). 
In order to distinguish them, Iba1 and TMEM 119 co-labelling was undertaken. 
MCAo
Sham 15 minutes 30 minutes 60 minutes Sham 4 weeks
Ispilateral 0 of 6 1 of 6 8 of 8 6 of 6 1 of 7 3 of 9
Cortex 0 of 6 1 of 6 7 of 8 6 of 6 0 of 7 2 of 9







In sham animals, each Iba1-positive cell co-labelled with TMEM 119 suggesting the presence 
of microglia but not macrophages (Fig 3.10 and 3.11). Furthermore, these cells had a 
comparable morphology to the immunostaining studied previously (Fig 3.6 A). After 
ischaemia, Iba1-positive cells were bigger and processes thicker or lost in the lesion as seen 
previously (Fig 3.6 A). This activated resident microglia had reduced TMEM staining. This 







Figure 3-10 Representative images of TMEM119 and Iba1 co-immunostaining in the cortex, 24 hours after 
ischaemia. 
In sham animals, Iba1-positive cells were co-labelled with TMEM119, suggesting they are microglia and not 
macrophages (white arrows). With ischaemia, Iba1-positive cells had bigger cell bodies and thicker processes, 
notably after 15- and 30-minutes ischaemia, and some Iba1-positive cells had an amoeboid form with no 
processes, notably after 60-minutes ischaemia. TMEM119 was co-labelling most of the Iba1-positive cells, 













































Figure 3-11 Representative images of TMEM119 and Iba1 co-immunostaining in the striatum, 24 hours 
after ischaemia. 
In sham animals, Iba1-positive cells were co-labelled with TMEM119, suggesting they are microglia and not 
macrophages (white arrows). With ischaemia, Iba1-positive cells had bigger cell bodies and thicker processes, 
notably after 15- and 30-minutes ischaemia, and some Iba1-positive cells had an amoeboid form with no 
processes, notably after 60-minutes ischaemia. TMEM119 was reduced or not observable in some Iba1-positive 












































In order to quantify these results, microglia (Iba1-positive/TMEM-positive cells; 
Iba1+/TMEM+) and macrophages (Iba1-positive/TMEM-negative cells; Iba1+/TMEM-) were 
counted. Counting of Iba1+/TMEM- cells (dots on the graph) revealed no significant difference 
between groups in the cortex peri-infarct (F(3, 22)=2.01, p=0.1419) and core (F(3, 22)=1.098, 
p=0.3709; Fig 3.12). There was significant differences in the striatum peri-infarct (F(3, 
22)=5.561, p=0.0054) and post hoc comparison revealed there was a significant increase of 
Iba1+/TMEM- cells in the 15, 30 and 60 minutes ischaemia group compared to shams 
(p=0.0117, p=0.0027 and p=0.0478 respectively; Fig 3.12). There was also a significant 
increase in Iba1+/TMEM- cells in the striatum core of ischaemic animals and post hoc 
comparison showed that there was a significant increase (F(3, 22)=6.849, p=0.0020) in the 15- 
and 30-minutes ischaemia group compared to shams (p=0.048 and p=0.0007 respectively) 
but not with 60-minutes ischaemia when compared with shams (p=0.417; Fig 3.12). This 
result showed there is an alteration of TMEM staining that might be attributed to resident 
microglia modification and/or macrophage infiltration.  
 
Figure 3-12 Ischaemia increases microglia/macrophage cells in the cortex and striatum, 24 hours after 
ischaemia. 
Counting of Iba1-positive/TMEM-negative cells (Iba1+/TMEM-; dots) revealed significant differences in the 
striatum peri-infarct (F(3, 22)=5.561, p=0.0054) with a significant increase of Iba1+/TMEM- cells in the 15, 30 and 60 
minutes ischaemia group compared to shams (p=0.0117, p=0.0027 and p=0.0478 respectively). A significant effect 
of the ischaemia in the striatum core (F(3, 22)=6.849, p=0.0020) showed significant differences for 15 and 30 minutes 
ischaemia group compared to shams (p=0.048 and p=0.0007 respectively). There was no significant difference 
between groups in the cortex peri-infarct (F(3, 22)=2.01, p=0.1419) and core  (F(3, 22)=1.098, p=0.3709). 
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Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc comparison with Bonferroni (N= 6 to 8 
per group).  *p<0.05, **p<0.01, ***p<0.001 comparing infiltrating macrophages (Iba1+/TMEM-; dots) for 15-, 30- 
or 60-minutes ischaemia to shams 
3.3.7. Nrf2 signalling during the acute response to ischaemia 
Nrf2 detection using immunohistochemistry is limited at present due to a lack of specificity 
of the commercially available antibodies (Kemmerer et al., 2015). Consequently, to assess 
Nrf2-pathway activation, downstream genes or proteins of this pathway were studied. The 
following immunohistochemical study is based on heme oxygenase-1 (HO1), one of the most 
upregulated protein of Nrf2-pathway activation, previously shown to be upregulated with 
ischaemia (Alfieri et al., 2013). 
HO1 immunostaining was minimal in shams and after 15 minutes ischaemia; however, levels 
were upregulated in the cortex and striatum, in both peri-infarct and core of the lesion after 
30- and 60-minutes of ischaemia (Fig 3.13 A). Quantification of  %area of HO1 
immunostaining revealed a significant difference in the cortex peri-infarct (F(3, 22)=10.21, 
p=0.0002), the cortex core (F(3, 22)=11.08, p<0.0001), striatum peri-infarct (F(3, 22)=3.96, 
p=0.021) but not the striatum core (F(3, 22)=2.88, p=0.0585). 
Post hoc comparisons with Bonferroni showed no differences between 15-minutes ischaemia 
and shams in the cortex peri-infarct and core (p>0.999 for both), in the striatum peri-infarct 
and core of the lesion (p=0.347 and p=0.496 respectively; Fig 3.13). After 30-minutes 
ischaemia, HO1 immunostaining was significantly increased in the peri-infarct cortex and 
striatum (p=0.0044 and p=0.0157 respectively) but not in the core cortex and striatum 
(p=0.158 and p=0.311 respectively; Fig 3.13). HO1 was significantly increased with 60 minutes 
of ischaemia in the peri-infarct for both cortex and striatum (p=0.0004 and p=0.0269 
respectively) and in the core for both cortex and striatum (p<0.0001 and p=0.0228 





Figure 3-13 Increased duration of ischaemia increases heme oxygenase-1 in the cortex and the striatum, 24 
hours after ischaemia. 
 (A) Representative images of heme oxygenase-1 (HO1) immunostaining showing increased levels in the cortex 
and the striatum after 60 minutes ischaemia but not in shams.  
 (B) Quantification of HO1 immunostaining by %area showed significant differences between groups in the cortex 
peri-infarct (F(3, 22)=10.21, p=0.0002), the cortex core (F(3, 22)=11.08, p<0.0001), striatum peri-infarct (F(3, 22)=3.96, 
p=0.021) but not the striatum core (F(3, 22)=2.88, p=0.0585). There was a significant increase in peri-infarct cortex 
with 30- and 60-minutes ischaemia (p=0.0044 and p=0.0004 respectively). In the striatum peri-infarct, HO1 was 
significantly increased with 30- and 60-minutes ischaemia (p=0.0157 and p=0.0269 respectively). In the core of the 
lesion, HO1 immunostaining was increased with 60 minutes ischaemia in the cortex (p<0.0001) and striatum 
(p=0.0228). 
Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc comparisons with Bonferroni (N= 6 to 8 
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Nrf2 is a transcription factor and thus leads to the expression of downstream proteins via an 
upregulation of their genes by binding on their ARE sequences. Nrf2-related gene expression 
has been measured with qRT-PCR on a cohort of animals that received 15 minutes ischaemia 
or sham surgery, with collection of brain samples at 24 hours. The downstream protein genes 
chosen were as follow: heme oxygenase-1 (hmox1), NADPH quinone oxidoreductase 1 
(nqo1), sulfiredoxin 1 (srxn1), xCT (slc7a11). Furthermore, Nrf2 gene nfe2l2 expression was 
also measured. 
There were no differences between the groups for nfe2l2 in the cortex (F(3, 17)=1.892, 
p=0.169), however there was a significant difference in the striatum (F(3, 17)=3.831, p=0.0290). 
Post hoc comparisons however did not show any differences between shams and 2-, 4- or 
24-hours survival (p=0.257, p>0.999, and p=0.0561 respectively; Fig 3.14). 
There was a significant difference between the groups for hmox1 in the cortex (F(3, 17)=3.991, 
p=0.0254), and in the striatum (F(3, 17)=27.93, p<0.0001). Post hoc comparisons revealed a 
significant increase of hmox1 4 hours after ischaemia compared to shams in the cortex 
(p=0.0135) and 24 hours after ischaemia in the striatum p<0.0001; Fig 3.14). Other 
comparisons did not reveal any statistical difference. 
There was a significant difference between the groups for nqo1 in the cortex (F(3, 17)=3.532, 
p=0.0374), however there was no difference in the striatum (F(3, 17)=0.583, p=0.633). Post hoc 
comparisons with Bonferroni a significant increase of nqo1  24 hours after ischaemia in the 
cortex (p=0.0175; Fig 3.14) and no statistically significant difference between shams and the 
other timepoints (p > 0.05). 
There was a significant difference between the groups for srxn1 in the cortex (F(3, 17)=9.534, 
p=0.0006), and in the striatum (F(3, 17)=8.211, p=0.0013). Post hoc comparisons revealed a 
significant increase of srxn1 4 hours after ischaemia compared to shams in the cortex 
(p=0.001) and at 24 hours for both cortex and striatum (p=0.0023 and p=0.0016; Fig 3.14). 
Other comparisons did not reveal any statistical difference. 
There was a significant difference between the groups for slc7a11 in the cortex (F(3, 17)=7.679, 
p=0.0019), and in the striatum (F(3, 17)=18.8, p<0.0001). Post hoc comparisons revealed a 
significant increase of slc7a11 24 hours after ischaemia compared to shams in the cortex and 
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striatum (p=0.0007 and p<0.0001; Fig 3.14). Other comparisons did not reveal any statistical 
difference. 
Taken together, these results show that Nrf2-pathway was activated at 4 and 24 hours after 






Figure 3-14 Nrf2 gene and its related genes were upregulated 24 hours after ischaemia. 
mRNA expression of Nrf2 gene (nfe2l2) and its related genes in the cortex showed a significant difference in the 
striatum for nfe2l2 (F(3, 17)=10.21, p=0.0002) for hmox1 in the cortex (F(3, 17)=3.991, p=0.0254), and in the striatum 
(F(3, 17)=27.93, p<0.0001) for nqo1 in the cortex (F(3, 17)=3.532, p=0.0374), for srxn1 in the cortex (F(3, 17)=9.534, 
p=0.0006), and in the striatum (F(3, 17)=8.211, p=0.0013)  for slc7a11 in the cortex (F(3, 17)=7.679, p=0.0019), and in 
the striatum (F(3, 17)=18.8, p<0.0001).  
Dotted line indicates average sham level. Data presented as mean ± S.E.M. One-way ANOVA followed by post hoc 
comparisons with Bonferroni (N= 5 to 6 per group). *p<0.05, **p<0.01, ***p<0.001. 
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3.4. Long term ischaemia and Nrf2 activation 
A modest duration of ischaemia (15 mins) induced ischaemic neuronal death, oxidative 
stress, activation of microglial cells and these changes were paralleled by activation of Nrf2 
signalling. To determine if oxidative stress and inflammation were present and Nrf2-signalling 
was activated at a chronic time point after stroke, a cohort of mice underwent 15 mins of 
focal cerebral ischaemia and mice survived for 4 weeks.  
 
3.4.1. Modest duration ischaemia increases neuronal damage in the striatum at 
chronic time point 
Lesion volume was mapped out onto line diagrams of coronal anatomical levels using H&E 
stained sections coupled with microtubule associated protein 2 (MAP2) immunostained 
sections (Fig 3.15 A, B and C).  
High magnification images of H&E showed evidence of vacuolisation in the lesion, loss of cells 
with the morphological appearance of neurons, and the tissue was shrunken. MAP2 staining 
was performed to help the distinction (Fig 3.15 A). MAP2 immunostaining showed 
homogenous staining in the healthy tissue. After ischaemia, the lesion had reduced MAP2 
immunostaining (Fig 3.15 B). 
No neuronal damage was observed in the sham groups. With 15 minutes of ischaemia, the 
lesion was mainly contained in the striatum at 4 weeks post-injury. Quantification of lesion 
volume revealed a significant increase in the total ipsilateral hemisphere and striatal lesion 
compared to shams at 4 weeks after the ischaemia (t(14)=4.552, p=0.0005 and t(14)=5.046, 
p=0.0002; Fig 3.15 D). There was no significant difference in the volume of neuronal damage 







Figure 3-15 Ischaemia increases neuronal damage in the striatum but not the cortex 4 weeks after 15 minutes 
ischaemia. 
(A) Representative image of neuronal damage outlined in black on haematoxylin and eosin staining (H & E) and 
high magnification images of H&E showed vacuolisation in the lesion and tissue was shrunken compared to the 
healthy tissue. Scale bar 100 μm. 
(B) Representative image of neuronal damage outlined in black with microtubule-associated protein 2 (MAP2) and 
high magnification images of MAP2 immunostaining showed homogenous staining in the healthy tissue. After 
ischaemia, the lesion had reduced MAP2 immunostaining. Scale bar 100 μm. 
(C) Representative line diagram with ischaemic neuronal damage in black from median animals (coordinates from 
Bregma +2.58; +1.54; +0.98; +0.74; -0.10; -1.06; -2.06; -2.92; -4.48 mm). 
(D) Quantification of neuronal damage mapping revealed a significant difference between shams and 15-minute 
ischaemia in the total lesion (t(14)=4.552, p=0.0005) and the striatal lesion (t(14)=5.046, p=0.0002). There was no 
differences in the cortex when comparing shams and 15 minutes ischaemia (t(14)=1.534, p=0.147). 
Data presented as mean ± S.E.M. Student’s t-test for gene expression study (N= 7 to 9 per group). ***p<0.001.  







































































3.4.2. Modest duration ischaemia increases the oxidative stress marker 3NT in the 
chronic phase  
Oxidative stress, observed using 3NT immunostaining, was detected 4 weeks after 15 
minutes of ischaemia whereas minimal immunostaining was detected in shams (Fig 3.16 A). 
Quantification of the volume of 3NT immunostaining showed that there was a significant 
increase in the total ipsilateral hemisphere and the striatum compared to the sham group 
(t(14)=5.001, p=0.0002 and t(14)=5.17, p=0.0001 respectively; Fig 3.16 B). In the cortex, 3NT 
expression was not significantly different from the sham (t(14)=1.086, p=0.296; Fig 3.16 B).  
The area of 3NT immunostaining was mapped and compared with the area of neuronal 
damage (Fig 3.16 C). Four weeks after the ischaemia, the area of 3NT immunostaining 
mirrored the lesion area (Fig 3.16 C). These results indicate that oxidative stress was still 




Figure 3-16 Modest duration ischaemia increases oxidative stress in the striatum but not the cortex 4 weeks 
after 15 minutes ischaemia. 
(A) Representative images of 3-Nitrotyrosine (3NT) immunostaining showing peroxide nitrite generation in the 
striatum after ischaemia but not in the cortex or in shams four weeks after 15 minutes ischaemia. There was 
minimal 3NT immunostaining in shams and in the cortex after ischaemia. 
(B) Quantification of 3NT staining by mapping the positive staining showed significant differences between shams 
and 15 minutes ischaemia in the total ipsilateral hemisphere (t(14)=5.001, p=0.0002) and the striatum (t(14)=5.17, 
p=0.0001). There was no differences in the cortex between shams and 15 minutes ischaemia (t(14)=1.086, p=0.296). 
(C) Profile of the staining area and the neuronal damage area in three coronal sections of the 15 minutes ischaemia 
group showed 3NT expression mirroring lesion area. 
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3.4.3. Astrocytic response to chronic ischaemia 
Reactive astrocytes were examined with GFAP immunostaining. There were minimal levels 
of GFAP immunostained cells in the cortex and striatum of sham controls. In this study, peri-
infarct and core were homogenous and indistinguishable hence they gave the same results 
(see Appendix fig 8.1). Following ischaemia, there were increased levels of reactive astrocytes 
and individual cells were observed to be darker and more abundant in the ischaemic brains 
compared to shams in the cortex. In contrast, in the striatum there was a marked elevation 
of GFAP immunostaining however individual cells and their processes were no longer visible, 
and instead a glial scar was evident (Fig 3.17 A; Bush et al., 1999; Faulkner et al., 2004; 
Sofroniew, 2009).  
Quantification of GFAP immunostaining by assessing %area revealed significant differences 
between shams and 15 minutes of ischaemia in the cortex (t(14)=2.362, p=0.0332) and the 
striatum (t(14)=4.116, p=0.0010; Fig 3.17 B).  
To build on these findings, levels of GFAP gene were investigated. There was a significant 
difference between shams and ischaemia for gfap mRNA levels for both cortex (t(9)=4.199, 
p=0.0009) and striatum (t(9)=5.634, p<0.0001, Fig 3.17 C) 4 weeks after 15 minutes of 
ischaemia compared to shams. Taken together, these results showed that modest duration 
ischaemia upregulates GFAP at protein and gene levels in the chronic response to ischaemia 





Figure 3-17 Astrocytic marker GFAP was increased in striatum and cortex 4 weeks after 15 minutes ischaemia.  
(A) Representative images of GFAP immunostaining showing increased expression in the striatum and cortex after 
ischaemia compared to shams four weeks after 15 minutes ischaemia.  
(B) Quantification of GFAP immunostaining by assessing %area revealed significant differences between shams 
and 15 minutes ischaemia in the cortex (t(14)=2.362, p=0.0332) and the striatum (t(14)=4.116, p=0.0010).  
(C) There was a significant elevation of GFAP in mRNA both cortex (t(9)=4.199, p=0.0009) and striatum (t(9)=5.634, 
p<0.0001) 4 weeks after 15 minutes of ischaemia compared to shams. 























































































































































































3.4.4. Microglia/macrophage response 4 weeks after ischaemia 
Sham animals presented immunostaining of Iba1 similar to the shams in the 24-hour survival 
cohort, cell bodies were small, and processes were thin. After ischaemia, there was a similar 
pattern of immunostaining in the cortex compared to shams. In the striatum, Iba1-positive 
cells were darker, however they no longer had distinct processes and appeared amoeboid in 
the ischaemic brains compared to shams at 4 weeks (Fig 3.18 A).  
Quantification of Iba1 immunostaining by investigating %area of immunostaining showed 
significant differences between shams and 15 minutes ischaemia in the striatum (t(14)=2.677, 
p=0.0181) but not the cortex (t(14)=1.751, p=0.1018; Fig 3.18 B). 
Counting of Iba1-positive cells revealed that there was a significant increase in the striatum 
compared to shams (t(14)=4.187, p=0.0009) but not in the cortex (t(14)= 1.837, p=0.0875; Fig 
3.18 C).  
To further investigate alterations to Iba1, levels of the gene encoding Iba1, aif1 were 
determined. At 4 weeks, aif1 was increased in both cortex (t(9)=2.218, p=0.0436) and striatum 
(t(9)=3.363, p=0.0046) compared to shams (Fig 3.18 D).  
Taken together, these results show that modest duration ischaemia causes a chronic 
upregulation of Iba1 protein and gene levels. Therefore, the increase in %area of Iba1 
immunostaining sections was partly due to an increase in the number of 




























































































































































































































































← Figure 3-18 Modest duration ischaemia (15 minutes) increases microglia/macrophage marker Iba1 4 weeks 
post injury.  
(A) Representative images of Iba1 immunostaining showing small cell bodies and thin processes in shams in the 
cortex after 15 minutes of ischaemia at 4 weeks. In the striatum after ischaemia, Iba1-positive cells were darker, 
bigger and overlapping with each other. 
 (B) Quantification of Iba1 immunostaining by %area showed significant differences between shams and 15 
minutes ischaemia in the striatum (t(14)=2.677, p=0.0181) but not the cortex (t(14)=1.751, p=0.1018). 
(C) There were significantly increased levels of Iba1 gene aif1 both cortex (t(9)=2.218, p=0.0436) and striatum 
(t(9)=3.363, p=0.0046) 4 weeks after 15 minutes of ischaemia compared to shams. 
(D) Counting Iba1-positive cells revealed that there were significantly increased numbers of cells in the striatum 
(t(14)=4.187, p=0.0009) but not the cortex (t(14)= 1.837, p=0.0875). 
Data presented as mean ± S.E.M. Student’s t-test (N= 7 to 9 per group). *p<0.05, **p<0.01.  
 
3.4.5. Genes il-1β and cxcl10 were increased 4 weeks after modest duration of 
ischaemia 
Interleukin 1 beta (Il-1β) and C-X-C motif chemokine 10 (CXCL10) are cytokines produced 
during inflammation (Chai et al., 2015; Hu et al., 2014; Rider et al., 2011). Genes encoding 
the cytokines cxcl10 and il-1β were investigated at 4 weeks post injury. The data did not 
follow a normal distribution, thus statistical differences were investigated using Mann-
Whitney test. In the cortex, there was a significant increase in cxcl10 mRNA levels in 
ischaemic cortex (Mann–Whitney U=2, p=0.0007; Fig 3.19 A) compared to shams, but no 
significant difference for il-1β (Mann–Whitney U=13, p=0.0549; Fig 3.19 A). In the striatum, 
cxcl10 mRNA expression was significantly increased compared to shams, (Mann–
Whitney U=0, p=0.0002). Similarly, il-1β mRNA expression was significantly increased 




Figure 3-19 Inflammatory gene cxcl10 and il-1β were upregulated 4 weeks after 15 minutes of ischaemia.  
(A) There was a significant increase in cxcl10 mRNA levels in ischaemic cortex (Mann–Whitney U=2, p=0.0007) 
compared to shams, but no significant difference for il-1β (Mann–Whitney U=13, p=0.0549). Genes of interest 
were normalised to 18S levels. 
 (B) In the striatum, cxcl10 mRNA expression was significantly increased compared to shams, as cxcl10 results did 
not follow normal distribution; Mann-Whitney test was used. (Mann–Whitney U = 0, p=0.0002). Similarly, il-1β 
mRNA expression was significantly increased compared to shams (Mann–Whitney U=4, p=0.0021). 




3.4.6. Peripheral immune cells infiltrate 4 weeks after modest duration ischaemia 
Neutrophil infiltration was studied in this cohort of 4 weeks survival after 15 minutes 
ischaemia. Neutrophils were found in three ischaemic brains and one sham animal (Fig 3.20 
A and B) and their presence was sparse as demonstrated in the striatum (Fig 3.20 A).  
The probability of neutrophil infiltration occurring 4 weeks following 15 minutes ischaemia 
was unchanged in the ipsilateral hemisphere (p=0.585), unchanged in the cortex (p=0.475) 
and unchanged in the striatum (p=0.212), Fisher’s exact test. 
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Figure 3-20 Modest duration ischaemia increases neutrophil infiltration 4 weeks after 15 minutes ischaemia.  
(A) Representative images of neutrophil immunostaining after ischaemia but not in shams. Nuclei were 
counterstained with DAPI, in blue, and neutrophil in brown (green arrow). Scale bar 100 μm. 
(B) Quantification of the presence of neutrophils revealed presence of neutrophils in the parenchyma in one sham 
animal and in 3 out of 9 animals of the 15-minute ischaemia group. 
 
In order to evaluate macrophage infiltration and distinguish them from resident microglia, 
the microglia/macrophage marker Iba1 was co-stained with the microglia-specific marker 
TMEM 119. In sham animals, ba1-positive cells were co-labelled with TMEM 119 suggesting 
the presence of microglia but not macrophages (Fig 3.21 A and B). After ischaemia, cortical 
Iba1-positive cells were larger and had thicker processes. Furthermore, TMEM 119 staining 
was decreased and sometimes not detectable on some Iba1-positive cells (Fig 3.21 A). In the 
striatum, there was a marked increase in Iba1-positive cells that had an amoeboid shape and 
TMEM119 was reduced or not observable in many Iba1-positive cells. 
Counting of Iba1+/TMEM- cells (dots) revealed significant differences in the striatum 
(t(14)=8.397, p<0.0001) but not the cortex (t(14)=1,959, p=0.0704) between ischaemia and 
















































































































































← Figure 3-21 Ischaemia increases microglia/macrophage cells with reduced TMEM119 expression 4 weeks 
after 15 minutes ischaemia.  
 (A) Representative images of TMEM119 and Iba1 co-immunostaining in the cortex. In sham animals, both markers 
were expressed revealing resident microglia population (white arrows). Following ischaemia, Iba1-positive cells 
were bigger and had thicker processes; TMEM119 was reduced or not observable in some Iba1-positive cells (blue 
arrows). 
(B) Representative images of TMEM119 and Iba1 co-immunostaining in the striatum. In sham animals, both 
markers were expressed revealing resident microglia population (white arrows). Following ischaemia, there was 
a marked increase of Iba1-positive TMEM119 was reduced or not observable in some Iba1-positive cells (blue 
arrows). 
 (C) Counting of Iba1-positive/TMEM-negative cells (Iba1+/TMEM-; dots) revealed significant differences in the 
striatum (t(14)=8.397, p<0.0001) but not the cortex (t(14)=1,959, p=0.0704) between ischaemia and shams, four 
weeks after 15 minutes ischaemia. 
Data presented as mean ± S.E.M. Student’s t-test (N= 7 to 9 per group). ***p<0.001. comparing infiltrating 
macrophages (Iba1+/TMEM-; dots) for 15-minutes ischaemia to shams 
 
Taken together, these results suggest that 15 minutes of ischaemia has caused modest levels 
of neutrophil infiltration in a minority of animals, increased levels of Iba1-positive cells with 
possibly an infiltration of peripheral macrophages at 4 weeks after injury. 
 
3.4.7. Nrf2 signalling was not activated in chronic ischaemia 
HO1 immunostaining and Nrf2-related gene expression were investigated to assess Nrf2 
signalling pathway activation. In both sham and ischaemic animals, HO1 staining was minimal 
(Fig 3.22 A). After quantification by %area, it was confirmed that HO1 staining was not 
significantly different from shams in the cortex and striatum (t(14)=0.7996, p=0.4373 and 





Figure 3-22 Modest duration ischaemia (15 minutes) does not modify heme oxygenase-1 four weeks post injury.  
(A) Representative images of heme oxygenase-1 (HO1) immunostaining showing minimal staining in ischaemic 
animals and shams 4 weeks after 15 minutes ischaemia.  
(B) Quantification of HO1 immunostaining by %area revealed that there were no significant differences between 
shams and 15 minutes ischaemia in the cortex (t(14)=0.7996, p=0.4373) or the striatum (t(14)=1.762, p=0.0999). 
Data presented as mean ± S.E.M. Student’s t-test (N= 7 to 9 per group).  
 
Expression of hmox1, nqo1, srxn1 and Slc7a11 genes were not significantly altered in the 
cortex compared to shams 4 weeks after the ischaemia (hmox1 (t(14)=0.763, p=0.457), nqo1 
(t(14)=0.479, p=0.638), srxn1 (t(14)=1.17, p=0.261) and xCT gene slc7a11 (t(14)=0.312, p=0.759.; 
Fig 3.23). However, Nrf2 gene nfe2l2 was significantly upregulated at 4 weeks (t(14)=2.247, 
p=0.0413). 

























































































In the striatum, nfe2l2, hmox1, nqo1 and slc7a11 gene expression was not altered (nfe2l2 
(t(14)=1.717, p=0.1081), hmox1 (t(14)=0.211, p=0.835), nqo1 (t(14)=0.3895, p=0.702) and xCT 
gene slc7a11 (t(14)=0.5271, p=0.6064; Fig 3.23). However, srxn1 expression was significantly 
downregulated compared to shams (t(14)=3.693, p=0.0024). Interestingly the striatum results 
are more variable than the cortex results. 
In conclusion Nrf2 signalling was not activated 4 weeks after 15 minutes of ischaemia. 





Figure 3-23 Nrf2 related genes were no longer upregulated 4 weeks after 15 minutes ischaemia.  
There was a significant increase in Nrf2 mRNA levels (nfe2l2) in the cortex 4 weeks after 15-minute ischaemia 
(t(14)=2.247, p=0.0413). Nrf2-related genes were not significantly altered when comparing ischaemia and shams 
animals in the cortex 4 weeks after the ischaemia with hmox1 (t(14)=0.763, p=0.457), nqo1 (t(14)=0.479, p=0.638), 
srxn1 (t(14)=1.17, p=0.261) and xCT gene slc7a11 (t(14)=0.312, p=0.759).  
In the striatum there was no significant differences for nfe2l2 (t(14)=1.717, p=0.1081), hmox1 (t(14)=0.211, p=0.835), 
nqo1 (t(14)=0.3895, p=0.702) and xCT gene slc7a11 (t(14)=0.5271, p=0.6064) 4 weeks after 15 minutes of ischaemia 
compared to shams. Interestingly, there was a significant reduction of srxn1 compared to shams in the striatum 
(t(14)=3.693, p=0.0024). 
Dotted line indicates average sham level. Data presented as mean ± S.E.M. Student’s t-test for gene expression 
study (N= 7 to 9 per group). *p<0.05, **p<0.01. 
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To conclude, cellular oxidative stress and inflammation were detected at 24 hours after 
ischaemia and significantly increased with increasing duration of occlusion compared to 
shams. This was paralleled with a significant upregulation of the Nrf2-related genes hmox1, 
nqo1, slc7a11 and srxn1. Four weeks following ischaemia, there was a significant increase in 
oxidative stress and inflammation; however, hmox1, nqo1 and slc7a11 were not significantly 
altered whereas srxn1 was decreased compared to shams. This finding contradicts the initial 
hypothesis that Nrf2-signalling activation would be activated chronically after stroke and 
associated with oxidative stress and inflammation. 
 
3.5.1. Cerebral ischaemia causes neuronal loss and increase duration of ischaemia 
increases the damaged area 
Increased duration of ischaemia increases the volume of ischaemic neuronal damage. The 
lesion was mainly contained in the striatum after 15 minutes of ischaemia and was found in 
the cortex after 30 and 60 minutes of ischaemia (Fig 3.2) and as previously reported with 30 
minutes ischaemia and longer (Popp et al., 2009). Neuronal damage was also observed in the 
thalamus and hypothalamus in the 60 minutes ischaemia group (Fig 3.2). This is consistent 
with the literature (Hata et al., 1998; Kanemitsu et al., 2002; McColl et al., 2004). 
Interestingly, these anatomical regions are not supplied by the MCA. This damage may be 
due to a direct ischaemia of these regions (Kanemitsu et al., 2002) caused by an incomplete 
circle of Willis (see Fig 3.24; McColl et al., 2004). Variability can be resolved by optimising the 
filament and by choosing a narrow range of animal age and weight to match the filament 
diameter (Hata et al., 1998; Tsuchiya et al., 2003). Overall, MCAo occlusion by insertion of a 
thread is still an adequate model to mimic ischaemic pathology from cell death to glial 






Figure 3-24 Incomplete circle of Willis in C57Bl/6J (from McColl et al., 2004). 
In his study, McColl and colleagues found that lesion volume variability after MCAo in C57Bl/6J could be explained 
by a large variability in cerebro-vasculature of the circle of Willis. Out of 10 animals, only one presented a complete 
circle of Willis. 
With abbreviated: ICA: internal carotid artery; MCA: middle cerebral artery; PcomA: posterior communicating 
artery. 
 
The striatum and a part of the cortex are mainly perfused by the middle cerebral artery (MCA) 
in rodents (Feekes & Cassell, 2006; Scremin, 1995). In human anatomy, lenticulostriate 
arteries, a set of branches that supply important parts of the basal ganglia (striatum and 
lenticular nucleus notably), derive from the MCA and many branches perfusing the cortex in 
temporal, parietal and Rolandic areas mainly (Damasio, 1983). These areas have specific 
functions that are known to be impaired after a stroke:  
- the temporal lobe is important for speech and memory; therefore, stroke patients might 
have aphasia and agnosia;  
- the parietal lobe is associated with sensory inputs such as touch, hearing and vision;  
- the Rolandic fissure (AKA the central sulcus) is surrounded by primary motor and 
somatosensory cortex, controlling movement outputs and receiving touch inputs 
respectively, stroke patients might show signs of apraxia, astereognosis and hemiparesis 
(Laurence, 2005). 
Most ischaemic strokes are located in the middle cerebral artery due to a Y-shape origin with 
two small branches transformation from the internal carotid, but other important infarct 
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subtypes have to be considered for neurodegeneration such as transient ischaemic attack 
(TIA) and lacunar stroke. New methods are being developed to study these, such as 
cholesterol crystals or autologous blood clot injection, but they are less reproducible due to 
a large variability in areas covered. Other models exist such as electrocoagulation of the 
vessel that is permanent or application of endithelin-1 but this method cannot reproduce 
complete perfusion (Fan et al., 2017; Fluri et al., 2015).  
Another limitation is that the model comprised transient MCAo and permanent unilateral 
common carotid artery occlusion (UCCAo; Hata et al., 1998), one focal and one global 
ischaemia model respectively (Liu & Mccullough, 2011). It has been reported that UCCAo 
decreased anti-inflammatory cytokines and increased pro-inflammatory cytokines with 
increased Iba1 staining (Yoshizaki et al., 2008); others have found increased %area and 
density for both Iba1 and GFAP with hypoperfusion in the short term (Zuloaga et al., 2016). 
A recent MRI study carried out by Lizi Hegarty and Jill Fowler revealed hypoperfusion in the 
sham UCCAo (Fig 3.25). However, their results suggest that the sham animals did not present 
a difference in levels of GFAP or Iba1 immunostaining when comparing the hemisphere 
ipsilateral to the stroke with the normally perfused, contralateral hemisphere. It would be 
interesting to add another control group which did not undergo UCCAo (i.e. a naïve group) 






Figure 3-25 Magnetic resonance imaging used determine striatal cerebral blood flow. 
 (A) Representative T2 and ASL images of sham and MCAo mice 24 hours after surgery. (ii) Ipsilateral striatal blood 
flow was reduced by ~56% 24 hours post-sham surgery, and ~59% post-MCAO surgery (B) Representative T2 and 
ASL images of sham and MCAO mice 1-month post stroke. (ii) Ipsilateral striatal blood flow was reduced by ~35% 
1-month post-sham surgery and 16% post-MCAO surgery. Two-way ANOVA with post hoc Bonferroni ***p<0.001, 
****p<0.0001.  
 
Today, most ischaemic stroke cases achieve reperfusion with emergency services 
improvements. Studying the intraluminal monofilament insertion is therefore very relevant 
as it mimics a new technique named thrombectomy that is used to remove the clot by stent 
retriever devices (Wardlaw & Bath, 2019; Zerna et al., 2018). This method is particularly of 
interest as it could extend the time window for treating patient (Baek et al., 2014; Jovin et 
al., 2015; Mokin et al., 2018).  
 
3.5.2. Ischaemia produces oxidative stress environment that persist over time 
Oxidative stress is a key pathophysiological mechanism of stroke-induced brain injury 
(Alexandrova & Bochev, 2005). It is associated with increased level of ROS and NO. Together, 
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(Raina et al., 2000; Smith et al., 1997). This phenomenon is detected by 3-Nitrotyrosine (3NT; 
Giannessi et al., 2010) and was detected in the cortex and striatum at 24 hours for all 
durations of ischaemia (Fig 3.3). This is confirmed by other publications showing increased 
3NT, 8-Hydroxydeoxyguanosine (8OHDG) that is formed by oxidative stress injury to nucleic 
acids hence DNA damage, malondialdehyde (MDA) that derives from ROS damage to 
polyunsaturated lipids and 4-Hydroxynonenal (4-HNE) produced by lipid peroxidation; and 
decreased antioxidant enzyme activities of superoxide dismutase (SOD) at 24 hours (Wu et 
al., 2017; Zhai et al., 2013). Oxidative stress can be found as early as 4 hours after the onset 
of a permanent MCAo with increased 8OHDG and 4HNE (Imai et al., 2003). 
Immunostaining of 3NT was expressed beyond the lesion in the 15 minutes ischaemic group, 
notably in the cortex (Fig 3.3 C). This is confirmed by upregulation of Nrf2-pathway 
downstream genes hmox1, nqo1, slc7a11, srxn1 (Fig 3.14). This might denote a modest 
hypoperfusion in the penumbra. 
Finally, 3NT immunostaining was found at 4 weeks after 15 minutes ischaemia (Fig 3.16), but 
only within the lesion compared to the 24 hours-time point where it was present in the cortex 
without neuronal damage (Fig 3.3 C) suggesting that the penumbral regions recover from the 
oxidative stress observed at 24 hours, and this may be partly due to the activation of Nrf2 
signalling. Previous publications showed oxidative stress until 16 weeks after modest 
duration ischaemia (Fujioka et al., 2003). A review from Alexandrova and Bochev (2005) 
showed there were many disturbances related to chronic oxidative stress in ischaemic 
patients several weeks to months after ischaemia: decrease of ascorbic acid (Hume et al., 
1982) and SOD activity (Wehr et al., 2000), damage due to oxidative stress (Alexandrova et 
al., 2003) with long-lasting increased ROS (Mackensen et al., 2001). 
One limitation of the work presented here was that only one indirect marker of oxidative 
stress was used. For detection of oxidative stress other markers could be used such as lipid 
peroxidation with 4-hydroxynonenal (4-HNE) and DNA damage with 8-OHDG. The 
antioxidant defences of the cell can also be studied by measuring Glutathione (GSH) / 
Glutathione disulphide (GSSG) ratio, but also tagging HO1 and SOD1 (Cherubini, et al., 2005). 
Antibodies targeting 4-HNE and 8OHDG markers were experimented but did not show results 
consistent with the literature.  
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3.5.3. Ischaemia creates an inflammatory environment via modification of glia and 
infiltration of peripheral immune cells 
Twenty-four hours after ischaemia, two distinct regions of the lesion were observed: core 
and peri-infarct. In the chronic study, this distinction was not possible. The border of the glial 
scar was abrupt, peri-infarct and core were homogenous and indistinguishable hence they 
gave the same results and the peri-infarct was difficult to delineate (see appendix Fig 8.1 and 
8.2). Images were taken for the peri-infarct but were not included in this final work. 
 
3.2.1.2. Increased long-lasting astrocytosis 
The modification of astrocyte morphology demonstrated in the present study such as 
hypertrophy denotes of their activation, known as reactive astrogliosis or astrocytosis, and 
was detected at 24 hours post-injury for 30 minutes ischaemia or longer (Fig 3.4 A). It explains 
the increase in the quantification of GFAP immunostaining found in the peri-infarct (Fig 3.4 
B) Previous studies also indicate altered astrocyte morphology such as enlargement, with 
more and thicker processes (Lukaszevicz et al., 2002; Wagner et al., 2013).  
The time course of astrocyte activation after ischaemia may depend on the model and 
duration of the CBF reductions: other studies have shown elevated levels of reactive 
astrocytes 3 hours after 30 minutes OGD (Shannon et al., 2007), 6 hours in the penumbra of 
permanent MCAo (Liu et al., 1999), 7 hours after the onset of a 3 hours transient MCAo 
(Dihné & Block, 2001). In the present study, it was demonstrated that 15 minutes of 
ischaemia does not modify astrocyte morphology at 24 hours (Fig 3.4). Interestingly 
astrocytosis was detected in the cortex 4 weeks after ischaemia despite minimal neuronal 
damage (Fig 3.17). The %area of GFAP immunostaining in the cortex core was not correlated 
with larger neuronal lesions (see Appendix 8.2.2, Fig 8.3) suggesting there is no relation 
between increased astrocytosis and lesion size. Other studies have suggested upregulation 
of reactive astrocytes at 3 days post-injury for the striatum and 6 days post-injury in the 
cortex under similar conditions (Hirayama, Ikeda-Matsuo, et al., 2015). Another publication 
found no reactivity of astrocytes before 48 hours after 30 minutes MCAo (Dirnagl et al., 
1999). In rats, increased levels of reactive astrocytes were found at 5 days post-injury 
following 30 minutes of ischaemia but not following 15 minutes of ischaemia, however, no 
neuronal damage was observed under these conditions (Park et al., 2018). The increased 
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astrocytosis in the cortex of the present study, in the absence of neuronal damage might be 
due to waves of depolarisation in the peri-infarct (Hossmann, 1996; Umegaki et al., 2005). 
They have been linked to astrocyte activation, increased gfap expression (Rakers et al., 2017; 
Yamashita et al., 1996) and can be reproduced by cortical spreading depression that elicits 
astrocytic activation without causing any neuronal damage (Matsushima et al., 1998). 
Although glial activation is found in preconditioning protocols that exert no neuronal damage 
(Hirayama, Ikeda-Matsuo, et al., 2015). 
With an injury, astrocytes become reactive; they exert morphological and transcriptomic 
changes. These changes have been classified in two main populations, one aggressive and 
potentially neurotoxic (named A1) and the other anti-inflammatory and neurotrophic (A2; 
Liddelow et al., 2017), although this classification is controversial. After ischaemia both 
phenotypes are reported to be found in the vicinity of the lesion (Liddelow & Barres, 2017; 
Zamanian et al., 2012; Rakers et al., 2018).  
The massive activation of astrocytes and their entanglement in the lesion area in the striatum 
in the long term suggests that it has formed part of a glial scar. Associated with microglia, 
astrocytes then form a barrier thought to be protective (Bush et al., 1999; Wanner et al., 
2013). It might avoid leakage of cytokines and thus limit the inflammation spreading as found 
with STAT3 deletion that impedes astrocyte activation and formation of the scar, leading to 
an expansion of inflammatory cell infiltration, increased lesion, demyelination, delayed and 
attenuated motor recovery (Herrmann et al., 2008; Okada et al., 2006; Wanner et al., 2013). 
However, the glial scar is permeable permitting oedema and neuronal damage beyond the 
scar. This is associated with clearance mechanisms such as drainage and phagocytosis at the 
border of the scar (Zbesko et al., 2018). Furthermore, astrocytes gain phagocytic functions 
and help the cleaning of debris (Koizumi et al., 2018; Morizawa et al., 2017). Reactive 
astrocytes can also develop a neurotoxic phenotype with age, inflammation and ischaemia 
(Clarke et al., 2018; Liddelow et al., 2017; Villarreal et al., 2016), these proliferate and migrate 
quickly but also induce activation of resting astrocytes (Villarreal et al., 2016). Several papers 
showed that ischaemia first leads to increased anti-inflammatory cytokines for the first 
hours/days and that later it declines, and pro-inflammatory cytokines were then increased 
(Amantea et al., 2018; Hu et al., 2012; Zhang et al., 2018). Taken together, it might suggest 
that during the chronic response to ischaemia, glia will produce pro-inflammatory cytokines 
and thus the population of astrocytes may be neurotoxic. In order to test this hypothesis, 
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astrocyte could be isolated and mixed with primary neuronal cultures to infer on their 
neurotoxicity by testing neuronal viability as previously done (Villarreal et al., 2016), or by 
sequencing their RNA to analyse their cytokines expression. 
In the core of the lesion following 60 minutes of ischaemia, a loss of astrocyte staining was 
observed in the striatum, which is likely due to their death (Fig 3.4 A and B). Astrocytes have 
been shown to die quickly in ischaemic conditions, 1 hour after 30 minutes OGD or 3 hours 
after permanent MCAo (Liu et al., 1999 and Shannon et al., 2007 respectively). This was 
confirmed by structural alteration and severe degradation determined 1 hour after 
permanent MCAo revealed with electron microscopy (Lukaszevicz et al., 2002). For transient 
ischaemia, GFAP immunostaining was found decreased in the core of the lesion 5 days after 
30 minutes of ischaemia (Park et al., 2018). 
Gene expression of gfap was increased with 15 minutes ischaemia at 24 hours and 4 weeks 
(Fig 3.5 & 3.17). In a study by Liu et al., (1999), gfap mRNA was decreased in the cortex at 12 
hours (Liu et al., 1999). This difference might be due to permanent MCAo model as they 
report an increase in both mRNA and protein of GFAP at the peri-infarct. Altogether, these 
findings suggest that astrocyte reactivity and death depend on the ischaemia duration and 
reperfusion. Astrocytes seem highly sensitive to death in anoxic conditions (complete 
depletion of oxygen level) and their reactivity requires hypoxia (reduction of oxygen level) or 
reperfusion after short anoxia. The increase of gfap mRNA might predict astrocytic changes 
found at later time point. 
Complexity in the response of astrocytes might be due to a broad range of responses as 
explained here but also because of their heterogeneity. There are two different kinds of 
astrocytes: protoplasmic found in the grey matter and fibrous in the white matter (Miller & 
Raff, 1984). Fibrous astrocytes are more sensitive to injury than protoplasmic (Shannon et 
al., 2007) but were not studied here as the focus of this study was on cortex and striatum; 
thus it would be interesting to study their activation. Further studies carried out in Fowler 
lab by Lizi Hegarty revealed increased levels of reactive astrocytes in the substantia nigra and 
the internal capsule 4 weeks after ischaemia that were not present 24 hours after ischaemia 
(presented in a poster, 2019). It would be interesting also to count astrocytes in order to 
analyse migration or proliferation. 
144 
 
New studies show heterogeneity in astrocyte function at the synapse (Dallérac et al., 2018) 
but also in their diverse protein production in different anatomical regions, which is related 
to different functions (Lin et al., 2017; Morel et al., 2018). This phenomenon would imply on 
differential response to ischaemia, depending on the area of damage. Importantly, GFAP 
protein is not expressed by every astrocytes but only a subset of them; moreover, alterations 
to non-GFAP astrocytes are not well known and the use of a pan-astrocytic marker would be 
interesting such as ALDH1L1 (Cahoy et al., 2008).  
 
3.2.1.3. Ischaemia triggers microglia/macrophage activation and recruitment  
With ischaemia, Iba1 immunostaining was darker, stained cells became larger and the 
number of cell bodies was increased (Fig 3.6 A). The ischaemic lesion leads to activation of 
microglia, also named microgliosis, and was associated with morphological changes 
(Fumagalli et al, 2015; Morrison & Filosa, 2013). Other studies have reported 
microglia/macrophage activation as early as 3.5 hours after 1.5 hours MCAo (Ito et al., 2001). 
Iba1 immunostaining was increased in the striatum 24 hours after 15 minutes or longer of 
ischaemia and in the cortex with 30 minutes or longer ischaemia as seen with %area 
quantification (Fig 3.6 B). This result mimics the neuronal damage result. This result agrees 
with previously published findings of microgliosis detected 24 hours after 15 minutes of 
MCAo in the striatum and not in the cortex (Hirayama, Ikeda-Matsuo, et al., 2015). In rats, 
microgliosis was detected 5 days after 30 minutes of ischaemia but not with 15 minutes 
ischaemia, however, no neuronal damage was observed in this condition (Park et al., 2018). 
No activation of microglia/macrophage was observed in the contralateral side in this chapter 
and later quantified by Lizi Hegarty finding no differences; however, a study has found 
microgliosis in the contralateral cortex and hippocampus 7 days after permanent MCAo and 
in the spinal cord at 5 weeks (Morioka et al., 1993). 
Counting of Iba1-positive cell bodies showed an increase in the striatum peri-infarct with 15 
minutes or longer ischaemia, and in the cortex peri-infarct with 30 minutes or longer 
ischaemia as found in the literature (Fig 3.7 A; Ito et al., 2001). In the core of the lesion, cell 
counts were increased only in the cortex with 30 minutes of ischaemia.  
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In the peri-infarct, Iba1 %area and Iba1-positive cell counts are both significantly increased 
for the same groups, suggesting that microglia/macrophages migrate to the lesion site (Fig 
3.6 B and 3.7 A). However, in the core of the lesion, Iba1 %area increase is not paralleled with 
an increased number of positive cells (Fig 3.6 B and 3.7 A), suggesting that the morphology 
has changed in this area compared to shams. Images from this area showed shape 
modification as Iba1-positive cells were larger and thicker in the ischaemia (Fig 3.6 A). It has 
been reported that microglia/macrophage become modified at 3.5 hours and increase their 
cell number at the lesion at 48 hours (Ito et al., 2001). The increase in number can be 
explained by both recruitment and proliferation as reported in the literature (Lalancette-
Hébert et al., 2007; Remington et al., 2007). However, these publications found proliferation 
at 48 and 72 hours after ischaemia (Lalancette-Hébert et al., 2007). It would have been 
interesting to study density as differences in the %area and the counting were reported in 
the current study (notably in the core of the lesion striatum) and could imply a different 
morphology of cells. 
Iba1 gene aif1 was unchanged 24 hours after 15 minutes ischaemia (Fig 3.7 B). This finding 
supports the idea that the number of microglia/macrophages is the same and that they do 
not proliferate at this early time point. Upregulation of the %area of Iba1 immunostaining 
but not of its gene at 24 hours suggests either a migration of the existing 
microglia/macrophages and/or morphological evolution of the microglia/macrophage in the 
lesion. As depicted in Fig 3.6 A, microglia/macrophages underwent morphological 
modification due to their activation (Fumagalli et al, 2015; Morrison & Filosa, 2013). And as 
seen in the counting result, there is an increase of the Iba1-positive cells at the lesion (Fig 3.7 
A). Taken together, these results suggest that ischaemia triggers activation and recruitment 
of microglia/macrophages at 24 hours. 
In the long term, alterations to Iba1 were maintained in the lesion. Iba1-positive cells were 
darker and larger in the lesion, and some had an ameboid shape devoid of processes. In 
contrast to the appearance of Iba1 stained cells from the 24-hour survival study, by 4 weeks 
some of the cells had overlapping processes (Fig 3.18 A). After 15 minutes of ischaemia, 
%area was increased in the striatum but not the cortex at 4 weeks (Fig 3.18 B). Interestingly, 
Iba1 immunostaining %area was correlated to the lesion volume in the cortex at 4 weeks (see 
Appendix 8.2.2, Fig 8.4). Counting also revealed an increase of Iba1-positive cells in the 
striatum but not the cortex at 4 weeks (Fig 3.18 C). At 4 weeks, the lesion area was atrophied, 
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and peri-infarct and core were homogenous, the lesion was abruptly delineated. Study of the 
peri-infarct images gave similar results to the core. A glial scar was formed as explained 
previously. As found in humans, the glial scar can impede neuronal growth and thus repair 
(Huang et al., 2014). 
Counting microglia/macrophage in the core of the lesion at 4 weeks was difficult because of 
the morphological changes to the cells. An alternative that would overcome this problem is 
PU.1 marker that stains the nucleus of the microglia/macrophages (Smith et al., 2013). 
Iba1 gene aif1 was upregulated in the cortex and striatum 4 weeks after 15 minutes 
ischaemia (Fig 3.18 D). Iba1 is necessary for activation of microglia/macrophages (Imai & 
Kohsaka, 2002) and deletion of its gene aif1 reduced multiple sclerosis onset, leukocyte 
infiltration and demyelination and gave resistance to acquired arthritis mouse model that is 
also an autoimmune condition (Casimiro et al., 2013; Chinnasamy et al., 2015). As aif1 is 
upregulated following 4 weeks after ischaemia, it might be part of a defence mechanism that 
reinforces the glial scar and/or exacerbate deleterious pro-inflammatory conditions. A new 
model lacking microglia/macrophage has been developed and could be used to study the 
contribution of microglia/macrophages in the glial scar formation (Rojo et al., 2019). 
Reactive glia can be protective due to the release of anti-inflammatory cytokines, thus 
limiting the extension of inflammation and upregulation antioxidant molecules. But it can 
also be deleterious by releasing pro-inflammatory cytokines, increasing peripheral 
infiltration, inhibiting repair, increasing ROS and NO production (Ekdahl et al., 2009; Lucas et 
al., 2006; Swanson et al., 2004). 
There is a broad range of microglia and macrophages response and thus phenotypes. 
Furthermore, the distinction cannot be made by morphological studies (Boche et al., 2013; 
Minett et al., 2016). Immunohistology studies can however test different proteins that are 
linked to a function, for example CD68 is a marker of microglial lysosome study (Boche et al., 
2013). Single-cell transcriptomic studies of the microglia revealed diverse responses to 
different injuries (Frigerio et al., 2019; Hammond et al., 2019).  
A limitation of this study of microglia/macrophage is that only the cortex and striatum were 
studied. Further experiments carried out in the lab by Lizi Hegarty revealed increased 
microglia/macrophage activation in the internal capsule at 24 hours and in the substantia 
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nigra and internal capsule 4 weeks after ischaemia (presented in a poster at the ARUK 
conference, 2019).    
 
3.2.1.4. Ischaemia increases pro-inflammatory cytokines cxcl10 and il-1β 
Expression levels of the il-1β gene were not modified at 24 hours after 15 minutes of 
ischaemia however it was increased significantly in the striatum at 4 weeks compared with 
shams (Fig 3.8 and 3.19). This was in contradiction with publications finding il-1β mRNA 
increased very early (15 minutes and 2 hours) after permanent MCAo in the rat (Buttini et 
al., 1994; Zhai et al., 1997). In a mouse model, IL-1β mRNA and protein were not detected at 
4 hours but were significantly increased at 24 hours after 60 minutes ischaemia (Dénes et al., 
2008). Collectively, it suggests that Il-1β is upregulated early after longer durations of 
ischaemia. 
IL-1β is expressed by microglia and macrophages (Clausen et al., 2008) in a NFκB-dependant 
manner (White et al., 2017). After ischaemia, Il-1β is colocalised with astrocytes and the 
increase in IL-1β was dampened by CX3CR1 KO, a receptor for a chemokine that attract 
leukocytes and is important for microglia and macrophages activation (Dénes et al., 2008).  
IL-1β promotes recruitment of macrophages in hypoxic conditions in vitro (Rider et al., 2011). 
IL-1β is not neurotoxic itself but it increases hypoxia-induced neuronal death (Fogal et al., 
2005) and blocking its receptor IL-1ra reduces lesion volume in ischaemic conditions (Pradillo 
et al., 2012; Savard et al., 2013). Increase of il-1β at 4 weeks in the striatum denotes a pro-
inflammatory environment. It would have been interesting to study protein level of IL-1β in 
these conditions and the cellular location of its expression. 
Despite its key role in pro-inflammatory mechanisms, a few papers report a protective role 
for IL-1β. IL-1β treatment or combined with TNFα or C1q (both promoting neurotoxicity) 
upregulated A2 anti-inflammatory/neuroprotectant phenotype in vitro (Liddelow et al., 
2017). Mesenchymal stem cells primed with IL-1 reduced LPS-induced inflammation 
(Redondo-Castro et al., 2017). Infusion of Il-1β onto human spinal cord astrocytes induced 
reactive astrocytosis and transcriptome analysis suggested a protective phenotype (Teh et 
al., 2017). In the case of ischaemia preconditioning, IL-1β is anti-inflammatory (Shin et al., 
2009). In this paper, IL-1β protein level expression was greater following ischaemia than in 
148 
 
preconditioning. It supports the hypothesis that there might be a dose effect or a threshold 
which defined protective or detrimental effects of IL-1β.  
Increased levels of cxcl10 in the striatum at 24 hours and in the cortex and striatum at 4 
weeks post-ischaemia might also predict astrocytic and microglial changes. This result was in 
accordance with the literature (Mcdonough et al., 2017). CXCL10 is produced by microglia, 
astrocytes, neurons, leukocytes, macrophages and T cells during inflammation (Chai et al., 
2015; Harikumar et al., 2014; Klein et al., 2005; Nakamichi et al., 2004; Singh et al., 2008). 
Furthermore it is increased in pro-inflammatory conditions and following glial activation (Yu 
et al., 2018). Reactive astrocytes produce CXCL10 and it attracts microglia (Cross & 
Woodroofe, 1999; Rappert et al., 2004) but also macrophages and leukocytes through the 
CRCX3 receptor (Biber et al., 2002; Boztug et al., 2002; Klein et al., 2005; Rappert et al., 2002). 
However, the CXCR3 receptor is also present on astrocytes and neurons (Xia et al., 2000). 
CXCL10 KO mice have impaired migration of CD8-positive T cells after intratracheal 
instillation (Campanella et al., 2006) and in a multiple sclerosis model it diminished the 
accumulation CD4-positive lymphocytes and mildly reduced demyelination and clinical 
deficits (Mills Ko et al., 2014). It would be interesting to study CXCL10 protein level to assess 
precisely their role and colocalization with different cell markers would be important in order 
to understand its activity.  
Several papers showed that ischaemia first increased anti-inflammatory cytokines for the 
first hours/days and that they later it decline, followed by elevations of pro-inflammatory 
cytokines (Amantea et al., 2018; Hu et al., 2012; Zhang et al., 2018). Furthermore, a different 
spatial distribution of diverse microglia/macrophage inflammatory phenotypes for the same 
time point after ischaemia was observed (Hu et al., 2012; Perego et al., 2011). Some have 
found upregulated M2 markers at the core and M1 markers at the peri-infarct (Perego et al., 
2011). Others found upregulated M2 markers in the peri-infarct from 1 to 7 days, then these 
markers decreased and M1 markers were upregulated (from 5 days up to 14 days; Hu et al., 
2012). However, this study is limited by the method, as most cytokines are produced by 
diverse cells, and their modulation only partly support this theory. RNA sequencing is a much 




3.2.1.5. Increased peripheral-cell infiltration after ischaemia 
Upregulation of il-1β, cxcl10 and aif1 suggests an upregulation of pro-inflammatory pathways 
and may be part of the mechanism that mediates peripheral immune cell infiltration. 
Neutrophil immunostaining showed infiltration in all groups apart from the shams and only 
in one animal at 24 hours after 15 minutes ischaemia (Fig 3.9 and 3.20). Previous studies 
report neutrophil infiltration at 48 and 72 hours following 60-minutes of ischaemia and 
following 30-minutes of ischaemia animals that resulted in cortical damage. Furthermore, 
this paper found that neutrophils were surrounded by Iba1-cells suggesting phagocytosis 
(Denes et al., 2007). Another paper found neutrophil infiltration in the parenchyma from 24 
hours after 60 minutes ischaemia and detected increased level of circulating neutrophils 
from 1.5 hours in both ischaemic animals and shams (Vaas et al., 2017). Knowing the harm 
that neutrophils can do, their detection in the parenchyma has been pinpointed as extremely 
harmful and may increase neuronal death (Iadecola & Alexander, 2001). 
A recent review from Enzmann and collaborators (2018) warned of possible 
misunderstandings made due to the detection of neutrophil in the parenchyma. Indeed, after 
ischaemia in rodent or human, neutrophils tend to stay in the neurovascular unit and the 
subarachnoid space. The glia surrounding the neurovascular unit might prevent any harm 
creating a barrier called the glia limitans (Enzmann et al., 2018). Thus, labelling neutrophil 
now require co-staining with glial cells or vascular staining to locate them more precisely. 
The neutrophil infiltration and chemokine upregulation raised the possibility of macrophage 
infiltration in the parenchyma after ischaemia. Iba1 is a protein expressed by resident 
microglia and infiltrated macrophages. The distinction of these two cells is important 
regarding inflammation, BBB breakdown and neurotoxicity. Macrophages were observed 
from day 2 to day 14 after 30 minutes ischaemia but it was impossible to distinguish them by 
their morphology (Schilling et al., 2003). In order to do so, labelling one or the other by 
genetic modification seems to be the most reliable technique way so far using CD163, 
expressed by microglia but not macrophages, or CD169 and lysozyme M locus that are 
expressed in macrophages but not microglia (Butovsky & Weiner, 2018; Zarruk et al., 2017). 
Others have created chimeric mice with GFP-tagged bone marrow derived macrophages 
injected in the blood of animals, and they perceived macrophages infiltrated the brain 
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following ischaemic injury, and were distinguished from resident microglia (Schilling et al., 
2003). 
A specific marker of microglia only (TMEM 119) was chosen in order to assess possible 
macrophages infiltration. TMEM 119 is expressed by resident microglia but not peripheral 
macrophages (Bennett et al., 2016; Satoh et al., 2016). TMEM 119 was decreased with 
ischaemia suggesting that a population of the Iba1 stained cells are peripheral macrophages 
(Fig 3.10, 3.11, 3.12 and 3.21). However, recent findings suggested that there is decreased 
TMEM119 expression in microglia after ischaemia (Rajan et al., 2018). Thus, the result 
observed could be due to macrophage infiltration or changes to the phenotype of resident 
microglia. It has been reported that there is no macrophage infiltration on the three first days 
following 30 or 60 minutes of ischaemia (Denes et al., 2007). However, others had observed 
macrophages in the parenchyma 7 days after ischaemia (Kokovay et al., 2006; Schilling et al., 
2003, 2005; Tanaka et al., 2003; Yamagami et al., 1999). Labelling microglia or macrophages 
by genetic modification is the best technique so far to distinguish them and should be done 
in future studies. 
 
3.5.4. Ischaemia modifies Nrf2 signalling at acute but not chronic response to 15 
minutes ischaemia 
HO1 immunostaining was upregulated with 30- and 60-minutes ischaemia in the peri-infarct 
and core of the 60-minutes ischaemia group (Fig 3.13). Other studies confirmed upregulation 
of HO1 protein in the acute response to ischaemia (Bergeron et al., 1997; Zeynalov et al., 
2009). HO1 protein was increased from 3 and 4 hours after ischaemia in rats and mice 
respectively (Alfieri et al., 2013; Yang et al., 2009). HO1 is expressed by astrocytes and 
microglia (Alfieri et al., 2013; Bergeron et al., 1997; Min et al., 2006), that would explain its 
upregulation at the peri-infarct where microglia and astrocytes are activated and recruited 
(Alfieri et al., 2013). Furthermore, oxidative stress was detected beyond the lesion and 
notably in the cortex during the acute phase (Fig 3.3). Oxidative stress activates Nrf2 
signalling by releasing Nrf2 from Keap1 and thus upregulates its downstream genes (Itoh et 
al., 1997). Furthermore, Keap1 was reduced 2 hours and up to 72 hours after 60 minutes 
occlusion in both peri-infarct and core of the lesion (Tanaka et al., 2010).   
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In the acute response to 15 minutes of ischaemia several Nrf2-related genes were 
upregulated (Fig 3.14). In the cortex, hmox1 and srnx1 were upregulated 4 hours after the 
injury and nqo1, srxn1 and slc7a11 were upregulated at 24 hours. In the striatum, hmox1, 
srxn1 and slc7a11 were upregulated at 24 hours. Other publications have found hmox1, srxn1 
and slc7a11 upregulated from 4 hours after 15 minutes ischaemia (Bell et al., 2011; Bell et 
al., 2011b). Interestingly nqo1 gene was not upregulated in the striatum. One study revealed 
that DMF, an activator of Nrf2-signalling pathway, used with inflammatory LPS on human 
monocytes reduced NQO1 and OSGIN1 (another Nrf2-related gene) mRNA levels (Michell-
Robinson et al., 2016). This mechanism is not well understood so far, post-transcriptional 
changes should be studied and Nrf2 protein translocation to the nucleus is key to new studies 
in that scope. Importantly, the shams in this experiment had 4 hours survival after ischaemia. 
This experiment could be further analysed adding a sham group for each survival time point. 
Nrf2-signalling was no longer upregulated 4 weeks after ischaemia despite persistent 
elevation of oxidative stress and inflammatory conditions (Fig 3.23). Interestingly, srxn1 was 
downregulated in the striatum. Since srxn1 is mainly expressed in neurons (Zhang et al., 
2014), the loss of neuron at 4 weeks in the striatum could lead to a reduction of srxn1. 
Furthermore, srxn1 is regulated by other pathway such as AP-1 and NF-kB (Jeong et al., 2012). 
AP-1 is induced by inflammation and cellular stress (Ameyar et al., 2003) and is upregulated 
following ischaemia notably by its transcription factor c-Fos and c-Jun, themselves 
upregulated following ischaemia (Akaji et al., 2003; Dai et al., 1999). Of note, AP-1 is inhibited 
by Nrf2 inducers Curcumin (Dong et al., 2009). 
Nrf2 gene nfe2l2 was not altered in the cortex and was upregulated in the striatum with 15 
minutes ischaemia in the acute phase. This is consistent with the literature, upregulation of 
Nrf2 protein and mRNA in the ischaemic lesion 24 hours after reperfusion (Zhai et al., 2013). 
On the other hand, Nrf2 gene nfe2l2 was upregulated in the cortex and not the striatum at 4 
weeks (Fig 3.23). Nrf2 is mainly expressed by glia (Zhang et al., 2014). Our results indicate an 
increase of Iba1 and GFAP that thus might cause an upregulation of Nrf2. At 24 hours, nfe2l2 
was upregulated in the striatum, where gfap was upregulated and Iba1 %area was increased. 
Nrf2 gene upregulation was significantly upregulated 4 weeks after ischaemia in the cortex, 
in both cases, gfap gene was upregulated and hence might be linked to nfe2l2 upregulation. 
However, since gfap was also upregulated in the striatum and nfe2l2 was not, the link 
between the two might be more complex. The upregulation of Nrf2 gene nfe2l2 expression 
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can be due to the activation of Nrf2-signalling pathway activity as nfe2l2 gene has itself an 
ARE sequence (Kwak et al., 2002; Raghunath et al., 2018). 
Nrf2-signalling activity mainly returned to baseline 4 weeks after modest duration ischaemia 
despite elevations of oxidative stress and inflammation (Fig 3.23). This result has not been 
reported previously. Sustained activation of Nrf2 can be detrimental as it promotes cancer 
(Kensler & Wakabayashi, 2010) and cancer therapy resistance (Hayes & McMahon, 2009); 
hence the pathway is likely to restore to homeostasis. It would be interesting to study 
whether Nrf2-signalling is robust in response to new oxidative stress challenges and whether 
it could still be activated in the chronic response to ischaemia. So far, there are reports in the 
literature of other age-related mechanisms inhibiting or downregulating Nrf2 signalling via 
c-Myc and Bach 1 (Zhang et al., 2012). Ageing tends to result in increased oxidative stress 
and decreased nuclear Nrf2 and responsiveness in the nervous system but an increase in 
several peripheral organs such as liver and spleen (Suh et al., 2004; Zhang et al., 2015). 
Alternatively, Nrf2-signalling activation could have been more comprehensively studied 
using an Nrf2 biochemical-assay (Atef et al., 2018; Huang et al., 2018), cloning the promoter 
of the ARE sequence on a luciferase vector (Moehlenkamp & Johnson, 1999; Shih et al., 
2003), by studying the fraction of Nrf2 in the nucleus (Chen et al., 2016; Lei et al., 2016), or 
by pre-treating the sections with N-ethylmaleimide to permit the detection of reduced 
glutathione (Miller et al., 2009; Won et al., 2015).  
Another limitation to this work is the that Nrf2 activation was not studied after 30 or 60 
minutes of ischaemia and this could be carried out in the future. 
 
3.5.5. Conclusion 
Following ischaemia, oxidative stress and inflammation were detected 24 hours after the 
injury. Lesion volume, oxidative stress and the glial response were increased with increasing 
duration of occlusion compared to shams. This was paralleled with a significant upregulation 
of the Nrf2-related genes hmox1, nqo1, slc7a11 and srxn1. Interestingly, following 15 
minutes ischaemia with 24 hours survival group there was oxidative stress, increased gfap 
and Nrf2-related genes in the cortex despite minimal neuronal damage. It suggests that the 
cortex underwent hypoperfusion and peri-infarct depolarisation waves. Altogether this acute 
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study confirms that Nrf2-signalling activation was associated with oxidative stress and 
inflammation. 
In the chronic phase, 4 weeks following ischaemia, there was a significant increase in 
oxidative stress and glial response; however, hmox1, nqo1 and slc7a11 were not significantly 
altered, whereas srxn1 was decreased compared to shams. This might indicate a lack of 
responsiveness or activation of Nrf2-signalling for long-lasting oxidative injury. In this group 
of 15 minutes ischaemia and 4 weeks survival, there was minimal neuronal damage or 
oxidative stress in the cortex, but aif1, cxcl10 and gfap genes and GFAP protein were 
upregulated. Altogether, these results demonstrated long-term changes with activation of 
astrocytes and possibly modification of the microglia transcriptome in an area that 
underwent acute oxidative stress. Lastly, the upregulation of nfe2l2 at 24 hours in the 
striatum and at 4 weeks in the cortex suggests that ischaemia modified Nrf2 gene 
permanently and differently throughout the cascade of event following ischaemia. This 
finding contradicts the hypothesis that Nrf2-signalling activation was associated with 
oxidative stress and inflammation and thus is still activated in the long term after an injury. 
To conclude, we have demonstrated that a modest duration of focal ischaemia triggers long 
lasting oxidative stress and inflammation however Nrf2 was only altered in the acute 
response to ischaemia. Therefore, in the next chapter, it was hypothesised that 









4. Protective effect of Nrf2 overexpression in the acute response to 
ischaemia in mice  
4.1. Introduction  
Nrf2 is a transcription factor and master regulator of a battery of antioxidant and anti-
inflammatory genes such as heme oxygenase-1 (HO1), NAD(P)H dehydrogenase quinone 1 
(NQO1), sulfiredoxin 1 (SRXN1) and glutamate-cystine antiporter (xCT; gene slc7a11). In 
physiological conditions, Nrf2 is sequestrated by Keap1 and continuously degraded. As seen 
in the previous chapter, Nrf2-signalling is upregulated in the acute response to ischaemia but 
not at 4 weeks. Its upregulation was found in the striatum and cortex and several papers 
localised it in the peri-infarct (Alfieri et al., 2013; Dang et al., 2012; Srivastava et al., 2013; 
Tanaka et al., 2010). Despite its upregulation in the acute response to ischaemia, oxidative 
stress and glial activation were detected beyond the lesion. 
Nrf2-signalling activators reduce oxidative stress following ischaemia (Alfieri et al., 2013; Li 
et al., 2016; Yao et al., 2016; Jakel et al., 2007; Lin et al., 2016; Scannevin et al., 2012; Zhao 
et al., 2007; Kunze, 2017; Kunze et al., 2015; Liu et al., 2019; Bynum et al., 2015). 
Furthermore, Nrf2-signalling has anti-inflammatory properties, notably through HO1 that 
alters the phenotype of macrophages to anti-inflammatory (Naito et al., 2014). It has also 
been reported that Nrf2 represses the expression of many pro-inflammatory cytokines 
during an inflammatory challenge (Kobayashi et al., 2016). This effect was independent of its 
antioxidant properties as Nrf2 interferes with the transcriptional upregulation of these genes 
by binding directly to their upstream sequence, notably for IL-6 and IL-1β. 
Astrocytes have an important role in the production of antioxidant to protect neurons and 
microglia (Bronstein et al., 1995; Desagher et al. 1996; McNaught & Jenner, 1999; Min et al., 
2006; Tanaka et al., 1999) notably through the glutathione system (Dringen et al., 1999; 
Drukarch et al., 1997; Gegg et al., 2005). Furthermore, Nrf2-signalling is preferentially 
activated in astrocytes (Ahlgren-Beckendorf et al., 1999; Murphy et al., 2001), Nrf2 
adenovirus is selectively taken up by astrocytes and not neurons (Kraft et al., 2004) and Nrf2 
is stable in astrocytes compared to neurons where it is epigenetically repressed (Bell et al., 
2015; Habas et al., 2013; Jimenez-Blasco et al., 2015). Finally, astrocytes are necessary for 
the neuroprotective effect of Nrf2 (Kraft et al., 2004; Lee et al., 2003; Shih et al., 2003). 
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Nrf2 activation in astrocytes had previously been shown to confer protection in mouse 
models of neurodegeneration. Overexpression of Nrf2 in GFAP-positive astrocytes by genetic 
mutation (GFAP-Nrf2 model) has been shown to be protective in a model of Parkinson’s 
disease by reducing glial cell activation (Chen et al., 2009) and can prevent 
neurodegeneration in mouse model of amyotrophic lateral sclerosis (Vargas et al., 2008). 
Interestingly, in models related to ischaemic conditions such as mitochondrial dysfunction 
and cerebral hypoperfusion there was a protection of neurons, white matter and a reduction 
of the glial cell response and inflammatory cytokines in GFAP-Nrf2 mice (Gan et al., 2012; 
Sigfridsson et al., 2018). 
However, this it is unclear whether overexpression of astrocytes can confer protective effects 
following in vivo ischaemia. Therefore, it is hypothesised that overexpression of Nrf2, 
selectively in astrocytes, attenuates neuronal damage following in vivo ischaemia by reducing 
oxidative stress and inflammation. 
 
4.1.1. Aims 
The aim of the current study was to determine if overexpression of Nrf2 in GFAP expressing 
astrocytes is neuroprotective during the acute response to 60 minutes of ischaemia 
compared with wild-type littermates by reducing oxidative stress, inflammation and 
modifying glial cell activation. 
• To determine potential effect of Nrf2 overexpression in astrocytes after ischaemia in 
the acute phase. 
a. To quantify lesion volume and oxidative stress following ischaemia in GFAP-Nrf2 
model and wild-type. 
b. To investigate possible modulation of inflammation and glial activation/phenotype 
with astrocytic overexpression of Nrf2 after ischaemia. 
c. To determine if Nrf2-related gene expression is increased in the GFAP-Nrf2 model 





4.2. Materials & Methods 
4.2.1. Mice and experimental groups 
GFAP-Nrf2 male mice and C57Bl/6J (wild-type; WT) littermates underwent ischaemia with 
transient middle cerebral artery occlusion (MCAo) for 60 minutes (n=7-15/group) or sham 
surgery and brains were collected at 24 hours for immunohistochemistry and biochemical 
analysis. Group size was chosen based on power calculation performed on previous results 
(presented in chapter 3) to achieve p<0.05 with a 20% effect. All analyses were carried out 
with the experimenter blinded to groups/genotype and mice were allocated to groups in a 
randomised fashion. 
Four animals were excluded from the histological cohort and 4 from the biochemistry cohort. 
These mice were culled early due to a poor response to the surgery. 
  
Table 4-1 Summary of the group size of each group for histologic and biochemistry cohorts.  
Histologic cohorts and the biochemistry cohorts depending on the surgery and the duration of occlusion and the 
survival (time between the ischaemia and the sacrifice) and the genotypes. 
 
4.2.2. Focal cerebral ischaemia 
As previously explained in section 2.2 of the Materials & Methods chapter, a monofilament 
was introduced into the CCA via a small incision and advanced 10mm distal to the carotid 
bifurcation to occlude the MCA (Monofilament 6-0 medium A MCAO suture L34 PK10; 
Doccol). Shams underwent the same procedure without the insertion of the thread. To 
withdraw the thread, mice were re-anaesthetised with isoflurane anaesthesia. Mice received 
0.5ml saline (0.9%) subcutaneously by injection and were transferred to an incubator (30 C) 
for 2 hours. The mice were monitored carefully for the 24 hours survival. All ischaemia 
surgery was undertaken by Dr Jill Fowler. Aseptic techniques were used. 
 
Genotype Initial size Final size Initial size Final size
WT 8 8 8 7
GFAP-Nrf2 8 7 7 7
WT 15 13 12 10
GFAP-Nrf2 16 15 12 11










4.2.3. Histology and immunohistochemistry 
Histology and immunohistochemistry techniques used were performed as described in 
section 2.3 of the Material & Methods. Lesion volume was assessed by drawing areas of 
ischaemic neuronal death observed in Haematoxylin and Eosin stained sections. Oxidative 
stress was detected using 3-nitrotyrosine antibody and then mapped at three coronal levels 
as described in section 2.3, microglia/macrophages and reactive astrocytes were studied 
using Iba1 and GFAP immunostaining respectively and quantified by assessing %area of 
immunostaining in Image J (Fiji, NIH) as described in section 2.3. 3NT mapping, GFAP and Iba1 
immunohistochemistry images were captured by Katharina Nagassima Rodrigues dos Reis. 
Finally, HO1 immunostaining was used to assess HO1 upregulation and as an index of Nrf2 
activation and the immunostaining was quantified as described in section 2.3. 
After observation and analysis of the different markers, the results in the core of the lesion 
were similar between ischaemic wild-type and GFAP-Nrf2 animals. However, a few 
differences were found in the peri-infarct areas. Thus, the results presented in the histologic 
sections are from the peri-infarct analysis.  
 
4.2.4. qRT-PCR  
To study gene expression, qRT-PCR was performed as explained in the Methods section 2.4. 
The animals received 60 minutes ischaemia and survived for a further 23 hours. The results 
of the immunostaining experiments suggested that modification of oxidative stress occurred 
in the peri-infarct area, therefore this area was used for qRT-PCR experiments. Observation 
of the lesion revealed that the striatum was almost completely damaged after 60 minutes 
ischaemia at 24 hours. Thus, only the cortex peri-infarct samples were analysed. 
For this study, glial cell responses were assessed by gfap and aif1 gene analysis. For Nrf2-
related gene expression, nfe2l2, hmox1, nqo1 and slc7a11 genes were performed.  To study 
the inflammatory environment, il-1β, cxcl10 and il-6 genes were analysed to assess the pro-
inflammatory environment and IL-4rα for the anti-inflammatory environment. Furthermore, 
complement component 3 (C3) and amigo2 genes were analysed for pro-inflammatory (A1) 
astrocytes and stat3 for anti-inflammatory (A2). The il-1β, il-4ra, c3, amigo2, il-6, stat3, keap1 
qRT-PCR were experiments were undertaken by Lizi Hegarty under my supervision. For each 
159 
 
animal, the level of gene expression was normalised to the expression of a housekeeping 
gene, 18S.  
 
4.2.5. Statistics 
Data were expressed mean ± S.E.M. using GraphPad Prism software. For parametric analysis, 
two-way analysis of variance (ANOVA) followed by post-hoc Bonferroni test were performed 







4.3.1. Overexpression of Nrf2 gene in GFAP-Nrf2 mice 
In order to confirm the overexpression of Nrf2 in the GFAP-Nrf2 model, levels of the Nrf2 
gene nfe2l2 was performed with qRT-PCR in the cortex and striatum of naïve, uninjured mice. 
There was a 2.5-fold increased expression of Nrf2 gene in this model compared to wild-type 
littermate mice (Fig 4.1). 
 
Figure 4-1 Mice overexpressing Nrf2 in astrocytes (GFAP-Nrf2 mice) have over two-fold increase of Nrf2 gene 
nfe2l2 mRNA expression compared to wild-type (WT). 
There was a significant increase in levels of Nrf2 gene (nfe2l2) in the GFAP-Nrf2 mice compared to wild-type 
(t(8)=4.059, p=0.0036). Samples collected from both cortex and striatum. Animals were 2 to 4-month old. 
 Data presented as mean ± S.E.M. Student’s t-test for gene expression study (N= 5 per group). **p<0.01. 
 
4.3.2. Neuroprotection in mice overexpressing Nrf2 in astrocytes 
The lesion volume after 60 minutes ischaemia was reduced in the GFAP-Nrf2 mice compared 
with wild-type (WT) at 24 hours. No neuronal damage was observed in the shams of both 
genotypes. 
For the total lesion volume, there was a significant effect of surgery (F(1, 39)=162.9, p<0.0001) 
but no effect of genotype or an interaction between surgery and genotype (both F(1, 39)=1.917, 
p=0.1740). Post hoc comparison revealed a reduction in the lesion volume of GFAP-Nrf2 mice 
ischaemic mice when compared with wild-type ischaemic mice (p=0.0486; Fig 4.2 B).  









































In the cortex and striatum, there was a significant effect of surgery (F(1, 39)=159, p<0.0001 and 
F(1, 39)=12259, p<0.0001 respectively) but no effect of genotype and no interaction between 
surgery and genotype (both F(1, 39)=1.176, p=0.284 for the cortex and both F(1, 39)=0.952, 
p=0.335 for the striatum). Post hoc tests revealed there was no alteration between wild type 
and GFAP-Nrf2 mice following ischaemia. 
In other regions comprising hippocampus, thalamus and hypothalamus there was a 
significant effect of surgery (F(1, 39)=67.26, p<0.0001). However there was no genotype effect 
or interaction between surgery and genotype, both F(1, 39)=3.43, p=0.0716. Post hoc 
comparison revealed a reduction in ischaemic neuronal damage between GFAP-Nrf2 mice 
compared to ischaemic wild-type (p=0.0065; Fig 4.2 B). Profiling the lesion throughout the 9 
coronal sections observed revealed that the difference between wild-type and GFAP-Nrf2 
area was mainly observed in the caudal part of the brain, the area comprising the thalamus 




Figure 4-2 Nrf2 overexpression in astrocytes reduced neuronal damage 24 hours after 60 minutes ischaemia. 
(A) Representative coronal line diagrams with neuronal damage in black for the median animals of GFAP-Nrf2 or 
wild-type (WT) genotype. The lesion was mainly comprised in cortex, striatum, thalamus and hypothalamus. 
(B) Quantification of neuronal damage mapping showed a significant effect of the surgery for each region 
(p<0.0001). Post hoc comparison revealed there was a significant reduction of the total lesion in GFAP-Nrf2 mice 
compared to wild-type (p=0.0486). Study of the cortical and striatal lesion showed no differences between GFAP-
Nrf2 and wild-type mice (p=0.148 and p=0.213 respectively). The protective effect of Nrf2 overexpression in 
astrocytes was found in other regions such as thalamus and hypothalamus were the lesion was reduced compared 
to wild-type (p=0.0065). 
(C) Profile of the lesion area in nine coronal sections 24 hours after 60 minutes ischaemia showed the reduction 
was mainly found in the caudal part of the brain, where thalamus and hypothalamus are located. 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
per group). *p<0.05, **p<0.01.  
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4.3.3. Astrocytic overexpression of Nrf2 reduced oxidative stress 
Oxidative stress was studied with 3NT immunostaining. There was increased 3NT 
immunostaining in the cortex and striatum of the ischaemic animals for both genotypes and 
there was minimal immunostaining observed in shams (Fig 4.3 A). By mapping the area of 
3NT immunostaining on three coronal sections for each animal, quantification revealed a 
reduction of oxidative stress in the GFAP-Nrf2 ischaemic animals compared to ischaemic 
wild-type (WT) animals. For each region observed, there was significant effect of surgery 
(total ipsilateral hemisphere F(38)=128.9, p<0.0001; cortex F(1,38)=100, p<0.0001; striatum 
F(1,38)=233, p<0.0001; other regions F(1,39)=81.78, p<0.0001; Fig 4.3 B). There was also a 
significant effect of genotype and an interaction between surgery and genotype for the total 
ipsilateral hemisphere (both F(1,38)=4.13, p=0.0492) and other regions (comprising thalamus, 
hypothalamus and white matter; both F(1,39)=5.54, p=0.0237). There was no effect of the 
genotype or interaction for cortex (both F(1,38)=2.535, p=0.1197) and striatum (both 
F(38)=1.893, p=0.176 respectively; Fig 4.3 B).  
After comparing ischaemic wild-type (WT) to ischaemic GFAP-Nrf2 with post hoc tests, a 
significant reduction was found in the GFAP-Nrf2 group compared to the wild-type group in 
the total ipsilateral hemisphere (p=0.0032), the cortex (p=0.0224) and other regions 





Figure 4-3 Nrf2 overexpression in astrocytes reduced oxidative stress 24 hours after 60 minutes ischaemia. 
(A) Representative images of 3-Nitrotyrosine (3NT) immunostaining showing peroxide nitrite generation in cortex 
and striatum after ischaemia but not in shams.  
(B) Quantification of 3NT immunostaining by mapping the positive staining showed a significant increase of the 
staining with the surgery for each region (total ipsilateral hemisphere F(38)=128.9, p<0.0001; cortex F(1,38)=100, 
p<0.0001; striatum F(1,38)=233, p<0.0001; other regions F(1,39)=81.78, p<0.0001). There was also a significant effect 
of genotype and interaction for the total ipsilateral hemisphere (both F(1,38)=4.13, p=0.0492) and other regions 
(comprising thalamus, hypothalamus and white matter; both F(1,39)=5.54, p=0.0237). There was no effect of the 
genotype or interaction for cortex (both F(1,38)=2.535, p=0.1197) and striatum (both F(38)=1.893, p=0.176 
respectively). There was a significant reduction of the 3NT immunostaining in the GFAP-Nrf2 mice compared to 
shams in the total ipsilateral hemisphere (p=0.0032), the cortex (p=0.022) and other regions (p=0.0006), but not 
the striatum (p=0.0535).  
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
per group). *p<0.05, **p<0.01, ***p<0.001.  
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After comparing the area of neuronal damage and oxidative stress on three coronal sections, 
it was found that oxidative stress extended beyond the area of neuronal damage in the wild-
type animals but not the GFAP-Nrf2 animals (Fig 4.4 A). Two-way ANOVA with repeated 
measures revealed no differences between 3NT-immunostained area and neuronal damage 
area (F(1,26)=2.599, p=0.119), there was a significant effect of the genotype (F(1,26)=11.525, 
p=0.002) and a significant interaction between the marker (oxidative stress and neuronal 
damage) and the genotype (F(1,26)=5.339, p=0.029). Post hoc comparisons revealed a 
significant increase of oxidative stress compared to lesion in the wild-type (p=0.013) but not 
in the GFAP-Nrf2 mice (p=0.613; Fig 4.4 A); in detail for the three regions of the wild-types 
(+0.98 mm: p=0.034, -0.10 mm: p=0.073; -2.06 mm: p=0.016). Oxidative stress was 
significantly increased in the wild-types compared with GFAP-Nrf2 animals in the three 
regions (+0.98 mm: p=0.003, -0.10 mm: p=0.026; -2.06 mm: p=0.007). These results taken 
together proved that the GFAP-Nrf2 animals had oxidative stress in the lesion only in contrast 
to wild-type animals where the oxidative stress was found in an area greater than the lesion 





Figure 4-4 Nrf2 overexpression in astrocytes reduced oxidative stress spread out beyond the lesion 24 hours 
after 60 minutes ischaemia. 
(A) Profile of the staining area and the neuronal damage area in three coronal sections of the ischaemic group 
showed 3NT expression beyond lesion site in wild-type (WT). In the GFAP-Nrf2 mice, 3NT immunostaining was not 
found beyond the lesion. Two-way ANOVA revealed an effect of the genotype (F(1,26)=11.525, p=0.002) and post 
hoc comparisons revealed increased oxidative stress area in wild-types compared to GFAP-Nrf2 (+0.98 mm: 
p=0.003, -0.10 mm: p=0.026; -2.06 mm: p=0.007). Furthermore, oxidative stress area was bigger than lesion area 
for the wild-types but not for the GFAP-Nrf2 animals (+0.98 mm: p=0.034, -0.10 mm: p=0.073; -2.06 mm: p=0.016).  
(B) Schematic of the comparison oxidative stress (by 3NT mapping) and lesion. Oxidative stress was found beyond 
the lesion in the wild-type but not in the GFAP-Nrf2 animals. 
 Data presented as mean ± S.E.M. N= 12 to 13 per group. *p<0.05 and **p<0.01 for the comparison of oxidative 















X Y  to ta l p ro f il  le s io n -3 N T  S E M










L e s io n  W T
L e s io n  G F A P -N rf2
3 N T  -  W T




4.3.4. Nrf2 signalling was boosted in mice that overexpress Nrf2 in astrocytes 
Nrf2 detection using immunohistochemistry is limited at present due to a lack of specificity 
of the commercially available antibodies (Kemmerer et al., 2015). Consequently, to assess 
Nrf2-pathway activation, downstream genes or proteins of this pathway were studied. The 
following immunohistochemical study is based on heme oxygenase-1 (HO1), one of the most 
upregulated protein of Nrf2-pathway activation, previously shown to be upregulated with 
ischaemia (Alfieri et al., 2013) and in response to 60 minutes of ischaemia in the previous 
chapter. 
There was minimal staining of HO-1 in shams of both GFAP-Nrf2 and wild-type genotypes (Fig 
4.5 B). In ischaemic animals for both genotypes, HO1 immunostaining was increased and 
mainly detected at the border of the lesion (Fig 4.5 A). HO1 immunostaining was present in 
the soma of cells that had the appearance of glial cells including processes (Fig 4.5 B).  
In order to quantify this upregulation throughout the brain, mapping of the positive 
immunostaining was transcribed onto coronal line diagrams to allow quantification of the 
area and volume of immunostaining. There was a significant effect of the surgery for the total 
lesion volume and in every brain region (total ipsilateral hemisphere F(1,37)=31.23, p<0.0001; 
cortex F(1,35)=16.83, p=0.0002; striatum F(1,35)=20.89, p<0.0001; other regions F(1,36)=35.99, 
p<0.0001; Fig 4.5 B). There was a significant effect of genotype in the total ipsilateral 
hemisphere (F(1,37)=8.926, p=0.0050), striatum (F(1,35)=6.565, p=0.0149) and other regions 
(F(1,36)=9.958, p=0.0032) but not in the cortex (F(1,35)=3.159, p=0.0842) and a significant 
interaction was detected in every region apart from the cortex (total ipsilateral hemisphere 
F(1,37)=9.097, p=0.0046; cortex F(1,35)=3.159, p=0.0842; striatum F(1,35)=7.439, p=0.0099; other 
regions F(1,36)=9.958, p=0.0032; Fig 4.5 B). Post hoc comparisons revealed a significant 
increase of HO1 immunostaining was found in every region of ischaemic GFAP-Nrf2 mice 
compared to ischaemic wild-type mice (total ipsilateral hemisphere p<0.0001, cortex 





Figure 4-5 Nrf2 overexpression in astrocyte increased HO1 expression, 24 hours after 60 minutes ischaemia. 
(A) Representative images of HO1 immunostaining sections showed an increase in staining with ischaemia at the 
boundary of the lesion particularly on GFAP-Nrf2 animals. Lesion outlined with an orange line. 
(B) Representative images of HO1 immunostaining in the cortex and striatum. HO1 staining was increased with 
ischaemia and further increased with the GFAP-Nrf2 genotype.  
(C) Quantification of HO1 immunostaining by mapping the positive staining revealed a significant increase with 
ischaemia in every region observed (p<0.001). Furthermore, there was a significant increase of HO1 area in GFAP-
Nrf2 animals after ischaemia compared to shams in the total ipsilateral hemisphere (p<0.0001), in the cortex 
(p=0.0147), in the striatum (p=0.0003) and other regions comprising the thalamus and hypothalamus (p<0.0001). 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
per group). *p<0.05, ***p<0.001. 


















































































































































Therefore, there was a striking upregulation was observed in the GFAP-Nrf2 mice compared 
with wild-type mice, especially in the peri-infarct area (Fig 4.5 A). GFAP-Nrf2 mice showed 
increased HO1 immunostaining in both cortex and striatum (Fig 4.5 B).  
Activation of Nrf2-signalling leads to upregulation of Nrf2 downstream genes. Quantification 
of mRNA levels of slc7a11, hmox1 and nqo1 genes revealed no differences between sham 
WT and GFAP-Nrf2 groups.  
Comparing levels of the nfe2l2 gene revealed a significant effect of surgery, genotype and an 
interaction (F(1,31)=19.91, p<0.0001, F(1,31)=54.2, p<0.0001 and F(1,31)=22.9, p<0.0001 
respectively). Post hoc comparisons revealed a significant increase following ischaemia 
GFAP-Nrf2 mice compared with wild type littermates (p<0.0001; Fig 4.6).  
For Nrf2-signalling genes, there was a significant effect of surgery (slc7a11 F(1,31)=36.27, 
p<0.0001; hmox1 F(1,31)=19.52, p=0.0001 and nqo1 F(1,31)=9.962, p=0.0035), a significant effect 
of genotype (slc7a11 F(1,31)=25.92, p<0.0001; hmox1 F(1,31)=7.593, p=0.0097 and nqo1 
F(1,31)=21.97, p<0.0001) and an interaction (slc7a11 F(1,31)=21.96, p<0.0001; hmox1 
F(1,31)=14.45, p=0.0006 and nqo1 F(1,31)=13.2, p=0.0010; Fig 4.6). Post hoc comparison of 
ischaemic GFAP-Nrf2 with ischaemic wild-type mice revealed a significant increase for these 
three genes (slc7a11 p<0.0001; hmox1 p<0.0001 and nqo1 p<0.0001; Fig 4.6). 
Interestingly, in this area (cortex peri-infarct), there were no significant differences between 
wild-type shams and wild-type ischaemia (slc7a11 p>0.999; hmox1 p>0.999 and nqo1 
p>0.999). Furthermore, there was no differences between shams and ischaemic GFAP-Nrf2 
animals (slc7a11 p>0.999; hmox1 p>0.999 and nqo1 p>0.999; Fig 4.6). 
Keap1 gene expression was not modified, there was no effect of the surgery, genotype and 






Figure 4-6 Nrf2 overexpression in astrocyte increased Nrf2-related genes 24 hours after 60 minutes ischaemia 
in the cortex peri-infarct. 
Comparing levels of the Nrf2 gene nfe2l2 and its downstream genes hmox1, nqo1 and slc7a11 revealed an effect 
of the surgery (nfe2l2 F(1,31)=19.91, p<0.0001; hmox1 F(1,31)=19.52, p=0.0001; nqo1 F(1,31)=9.962, p=0.0035; slc7a11 
F(1,31)=36.27, p<0.0001), a significant effect of the genotype (nfe2l2 F(1,31)=54.2, p<0.0001; hmox1 F(1,31)=7.593, 
p=0.0097; nqo1 F(1,31)=21.97, p<0.0001 slc7a11 F(1,31)=25.92, p<0.0001) and an interaction (nfe2l2 F(1,31)=22.9, 
p<0.0001; hmox1 F(1,31)=14.45, p=0.0006; nqo1 F(1,31)=13.2, p=0.0010; slc7a11 F(1,31)=21.96, p<0.0001). Bonferroni 
post-hoc comparison revealed a significant difference between wild-type (WT) and GFAP-Nrf2 after ischaemia for 
each gene (nfe2l2 p<0.0001; hmox1 p<0.0001; nqo1 p<0.0001; slc7a11 p<0.0001;). However, Keap1 gene 
expression was not modified, there was no effect of the surgery, genotype and interaction (F(1,31)=0.018, p=0.89, 
F(1,31)=0.112, p=0.73 and F(1,31)=1.47, p=0.23 respectively). 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 11 
per group).  ***p<0.001. 
 
4.3.5. Reactive astrocytosis was modified with astrocyte specific Nrf2 overexpression 
Astrocyte reactivity was investigated using GFAP immunostaining. In the wild-type shams, 
astrocytes had small cell bodies and long and clear processes with many branches (Fig. 4.7 
A). After ischaemia, GFAP immunostaining was increased, more reactive astrocytes were 
detected, and some astrocytes had disintegrated processes (Fig 4.7 A). Quantification of 
%area of GFAP immunostaining revealed an effect of surgery for the cortex and striatum 
(F(1,39)=29.68, p<0.0001 and F(1,38)=12.83, p=0.0010 respectively; Fig 4.7 B). Interestingly, there 
was an effect of genotype in the cortex (F(1,39)=20.47, p<0.0001) but not the striatum 
(F(1,38)=0.002, p=0.9629; Fig 4.7 B). There was no effect of interaction for the cortex and 
striatum (F(1,39)=0.015, p=0.9012 and F(1,38)=2.802, p=0.1024 respectively; Fig 4.7 B). With post 
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hoc tests, a significant increase was detected in levels of reactive astrocytes in the cortex of 
GFAP-Nrf2 shams compared to wild-type (WT) shams (p=0.0191) and in ischaemic GFAP-Nrf2 
compared to ischaemic wild-type mice (p=0.0007). However, there was no interaction in 
either the cortex or striatum (F(1,39)=0.015, p=0.90 and F(1,38)=2.802, p=0.102 respectively; Fig 
4.7 B). Gene expression for gfap was increased with surgery but was not modified by 
genotype (F(1,31)=73.1, p<0.0001 and F(1,31)=0.019, p=0.89 respectively; Fig 4.7 C) and there 





Figure 4-7 GFAP immunostaining was increased at 24 hours after 60 minutes ischaemia in both cortex and 
striatum and GFAP-Nrf2 sham animals had increased GFAP immunostaining in the cortex. 
(A) Representative images of GFAP immunostaining showed an increase with the ischaemia in the cortex and the 
striatum after ischaemia compared to shams. Some astrocytes had disintegrated processes and swelling and 
vacuolisation of the cell body; they are named clasmatodendrocytes. 
(B) Quantification of GFAP staining by %area in the peri-infarct showed significant increase of surgery for cortex 
and striatum (F(1, 39)=29.68, p<0.0001 and F(1, 38)=12.83, p=0.0010). There was also an effect of genotype in the 
cortex (F(1, 39)=20.47, p<0.0001) with an increase of GFAP %area between the sham groups (p=0.019) and between 
the ischaemic groups (p=0.0007). 
(C) Study of the mRNA expression of GFAP gene gfap showed significant increase with surgery (F(1, 31)=73.1, 
p<0.0001) but no effect of the genotype (F(1, 31)=0.019, p=0.89) in the cortex peri-infarct.  
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
per group for the immunostaining study and N= 7 to 11 per group for gene expression study). *p<0.05, ***p<0.001. 
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4.3.6. Microglial/macrophage response after ischaemia was not altered with 
astrocyte-specific overexpression of Nrf2 
Microglial/macrophage reactivity was investigated with Iba1 immunostaining. After 
ischaemia, microglial/macrophage cell bodies were larger, darker and had thicker processes 
(Fig 4.8 A). Quantification of %area revealed an effect of the surgery for the cortex and 
striatum (F(1,39)=161.6, p<0.0001 and F(1,39)=21.19, p=0.0010 respectively; Fig 4.8 B). There 
was no effect of the genotype in the cortex and striatum (F(1,39)=0.075, p=0.78 and 
F(1,39)=2.206, p=0.145 respectively; Fig 4.8 B) and no interaction in both cortex and striatum 
(F(1,39)=0.049, p=0.82 and F(1,39)=0.038, p=0.845 respectively; Fig 4.8 B). Post hoc tests revealed 
there was no alteration between wild type and GFAP-Nrf2 mice following ischaemia. 
suggesting that overexpression of Nrf2 in astrocytes does not modulate levels of 
microglia/macrophage. Iba1 gene aif1 was not altered with surgery or genotype (F(1,31)=0.59, 





Figure 4-8 Nrf2 overexpression in astrocytes did not alter levels of the microglia/macrophage marker Iba1, 24 
hours after 60 minutes ischaemia. 
(A) Representative images of Iba1 immunostaining showed an increase morphological alteration to the 
microglia/macrophages following ischaemia in the cortex and the striatum compared to shams. The cells had 
larger cell bodies and thicker processes after ischaemia compared to the cells found in shams. 
(B) Quantification of %area of Iba1 staining in the peri-infarct showed significant increase with surgery for cortex 
and striatum (F(1, 38)=161.6, p<0.0001 and F(1, 39)=21.19, p<0.0001). There was no effect of the genotype in the 
cortex (F(1, 38)=0.0755, p=0.784) or the striatum (F(1, 39)=2.206, p=0.1455). 
(C)  Iba1 gene aif1 mRNA expression was not altered by surgery (F(1, 31)=0.595, p=0.446) or genotype (F(1, 31)=0.291, 
p=0.59) in the peri-infarct of the cortex. 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
per group for the immunostaining study and N= 7 to 11 per group for gene expression study).   
 
























































































































































4.3.7. Increase of IL-4rα and cxcl10 genes with astrocyte-specific overexpression of 
Nrf2 
Through genetic or pharmacological approaches, it has been demonstrated that activation of 
the Nrf2-signalling pathway modulates inflammation. Nrf2 genetic global knockout was 
found to increase pro-inflammatory cytokines, decrease anti-inflammatory cytokines and 
increase glial reactivity in a Parkinson’s disease model (Rojo et al., 2010). On the other hand, 
HO1 shifts the phenotype of macrophages to an anti-inflammatory phenotype (Naito et al., 
2014). 
To explain this effect, it has been reported that Nrf2 represses many pro-inflammatory 
cytokines during an inflammatory challenge by interfering with the transcriptional 
upregulation of these genes by binding directly to their upstream sequence, notably for IL-6 
and IL-1β (Kobayashi et al., 2016). There was a significant increase with surgery of the  pro-
inflammatory cytokines, il-1β and il-6 (F(1, 31)=39.31, p<0.0001 and F(1, 31)=15.34, p=0.0005 
respectively) but there was no effect of genotype (F(1, 31)=0.54, p=0.46 and F(1, 31)=1.65, 
p=0.207 respectively; Fig 4.9 A) and post hoc tests revealed there was no alteration between 
wild type and GFAP-Nrf2 mice. 
IL-4 cytokine is a key modulator of the anti-inflammatory microglia/macrophage phenotype. 
Mainly produced by monocytes, microglia and macrophages, it binds to its receptor IL-4rα 
and promotes the M2 anti-inflammatory phenotype (Fenn et al.,2014; Fenn et al., 2012; Liu 
et al., 2016). Interestingly, cells expressing the M2 phenotype upregulate IL-4 and IL-4rα 
genes (Norden et al., 2014). IL-4rα was upregulated with ischaemia surgery (F(1, 31)=9.783, 
p=0.0038). There was no genotype effect (F(1, 31)=1.298, p=0.26) however post hoc tests 
showed that there was a significant increase of IL-4rα mRNA levels in the GFAP-Nrf2 
ischaemic mice compared to ischaemic wild-type (p=0.025; Fig 4.9 B). 
cxcl10 is increased in inflammatory environments and is expressed by reactive astrocytes 
amongst other cell types. cxcl10 mRNA levels were significantly increased with surgery (F(1, 
31)=27.61, p<0.0001) and there was also an effect of  genotype (F(1, 31)=6.621, p=0.0151). 
Together, two-way ANOVA revealed an interaction (F(1, 31)=9.53, p=0.0042). Post hoc 
comparison between ischaemic groups revealed a significant increase in the GFAP-Nrf2 
animals compared to wild-type (p=0.0002; Fig 4.9 C). 
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Reactive astrocytes show transcriptomic changes that can be classified as either neurotoxic 
(named A1) or neuroprotective (named A2; Clarke et al., 2018; Liddelow & Barres, 2017; 
Liddelow et al., 2017). To study pro-inflammatory (A1) astrocyte phenotype, amigo2 and 
complement component 3 (c3) genes were analysed. For these two genes there was a 
significant effect of surgery (c3: F(1, 31)=8.424, p=0.0068 and amigo2 F(1, 31)=8.451, p=0.0067) 
but no effect of genotype (c3: F(1, 31)=0.99, p=0.32 and amigo2 F(1, 31)=0.15, p=0.70; Fig 4.9 D). 
Post hoc tests revealed there was no alteration between wild type and GFAP-Nrf2 mice 
following ischaemia (amigo2: p=0.453 and c3: p=0.455). 
Stat3 gene stat3 is highly upregulated in A2 protective astrocytes and not expressed in A1 
astrocytes, furthermore it is an important gene for glial scar formation. There was a 
significant effect of surgery (F(1, 31)=50.33, p<0.0001) but no effect of the genotype (F(1, 
31)=0.104, p=0.74; Fig 4.9 E). Post hoc tests revealed there was no alteration between wild 
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← Figure 4-9 Nrf2 overexpression in astrocyte increases cxcl10 and IL-4rα genes 24 hours after 60 minutes 
ischaemia in the peri-infract of the cortex. 
(A & B) Levels of pro-inflammatory genes il-1β and il-6 were significantly increased with ischaemia (F(1, 31)=39.31, 
p<0.0001 and F(1, 31)=15.34, p=0.0005 respectively) but not modified in GFAP-Nrf2 mice compared with wild type 
mice (p=0.806 and p=0.092 respectively). 
(C) The anti-inflammatory gene IL-4rα was significantly increased with ischaemia (F(1, 31)=9.783, p=0.0038) and 
post hoc comparisons showed a further increase by Nrf2 overexpression in astrocytes (p=0.025). 
(D) Reactive astrocytes express cxcl10, this gene was increased with ischaemia (F(1, 31)=27.61, p<0.0001) and post 
hoc test revealed that cxcl10 was further increased by Nrf2 overexpression in astrocytes (p=0.0002). 
(E & F) Levels of amigo2 and complement 3 gene c3 were significantly increased with ischaemia (F(1, 31)=8.424, 
p=0.0068 and F(1, 31)=8.451, p=0.0067 respectively). Post hoc tests revealed there was no alteration between wild 
type and GFAP-Nrf2 mice following ischaemia (amigo2: p=0.453 and c3: p=0.455). 
(G) A2 protective astrocytes gene stat3 was significantly increased with ischaemia (F(1, 31)=50.33, p<0.0001 Post 
hoc tests revealed there was no alteration between wild type and GFAP-Nrf2 mice following ischaemia. (p=0.841). 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 11 







There was a significant reduction in ischaemic neuronal damage in mice that overexpressed 
Nrf2 in astrocytes compared to wild-type littermates, and this neuroprotection was 
associated with reduced oxidative stress, increased Nrf2 signalling, increased levels of 
reactive astrocytes and increased il-4rα and cxcl10 gene expression. Altogether, these finding 
provide support for the initial hypothesis that the Nrf2 overexpression in GFAP-positive 
astrocytes is neuroprotective as it reduces oxidative stress and inflammation. 
 
4.4.1. Nrf2 overexpression in astrocytes reduces lesion and oxidative stress induced 
by ischaemia 
Neuronal damage was reduced in the GFAP-Nrf2 animals compared to wild-type littermates; 
however, the reduction was modest (Fig 4.2). This result is supported by other studies that 
show there is an increased infarct volume in Nrf2 deficient mice (Liu et al., 2019; Shah et al., 
2007; Shih et al., 2005; Wang et al., 2012), in addition to worsened ischaemic-induced 
neurological deficits (Liu et al., 2019; Shah et al., 2007). Conversely pharmacological 
activation of Nrf2-signalling reduced infarct volume, improve neurological deficits and 
reduce oxidative stress and oedema (Kunze et al., 2015; Liu et al., 2019; Mao et al., 2018; 
Shih et al., 2005a; Wang et al., 2012; Yao et al., 2016; Zeynalov et al., 2009). Furthermore, 
astrocytes are recognised as the cell that conveys Nrf2 neuroprotective effect as seen in OGD 
challenges and ischaemia (Bell et al., 2011; Kraft et al., 2004; Lee et al., 2003; Shih et al., 
2003). In contrast, Narayanan et al. (2015) did not report increased infarct volume in Nrf2 
knockout mice whereas Wang et al. (2012) did not observe an exacerbation of ischaemia-
induced neurological deficits (Narayanan et al., 2015; Wang et al., 2012). Also mitochondrial 
inhibition is a feature of ischaemia (Schulz et al., 1998; Wojtovich & Brookes, 2008) and 
neuronal damage was also reported to be reduced in GFAP-Nrf2 mice following 
mitochondrial inhibition driven by injection of malonate (Calkins et al., 2010). 
The reduction of neuronal damage in GFAP-Nrf2 mice in the present study was associated 
with reduced oxidative stress (Fig 4.3). Furthermore, oxidative stress spread beyond the 
lesion in the wild-type whereas it was contained in the lesion in GFAP-Nrf2 mice after 
ischaemia (Fig 4.4). This result was confirmed by upregulation of antioxidant Nrf2-related 
genes (Fig 4.6). As found in the literature, Nrf2 is a master regulator of a battery of 
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antioxidant genes and its activation in ischaemic models reduces oxidative stress (Alfieri et 
al., 2013; Li et al., 2016; Yao et al., 2016). With ischaemia and oxidative stress, glial-cells such 
as microglia and astrocytes showed an upregulation of their anti-oxidant defences, notably 
Nrf2 and glutathione (Shih et al., 2003; Vargas et al., 2008; Won et al., 2015). Some glial-like 
cells were immunostained with 3NT, it would have been interesting to counterstain them 
and assess the proportion of astrocytes and microglia/macrophages that underwent 
oxidative stress in both wild-type and GFAP-Nrf2 ischaemic groups. 
The lesion seems to spread from the striatum to cortex and then hypothalamus and thalamus 
as seen with increased duration of ischaemia (Chapter 3 and McColl et al., 2004) or studying 
acute temporal evolution of ischaemia (Yoon et al., 2018). Thus, the results suggest that Nrf2 
overexpression might reduce oxidative stress imbalance and hinder the normal spreading of 
the lesion. 
In the present study a 2.5-fold increase in Nrf2 levels was reported in naïve, uninjured GFAP-
Nrf2 mice and these levels were lower than the 3 to 8-fold increase reported by other groups 
using GFAP-Nrf2 mice (Calkins et al., 2010; LaPash Daniels et al., 2012; Sigfridsson et al., 2018; 
Vargas et al., 2008). However, Nrf2 overexpression was in GFAP-expressing astrocytes only 
and the tissue collected was from a 2 mm thick portion of the cortex or striatum with limited 
number of astrocytes whereas the cited papers used whole brain or the entire striatum or 
region of interest. Astrocytic overexpression of Nrf2 could be analysed by selectively sorting 
astrocytes before measuring Nrf2 gene mRNA levels. This discrepancy can also be due to a 
difference in the background of the strain. In this study, GFAP-Nrf2 mice were obtained from 
a C57Bl/6j background whereas in these papers, GFAP-Nrf2 mice had FVB background. 
Astrocytic Nrf2 overexpression did not modify Nrf2-related gene expression in shams (Fig 
4.6) contrary to the first check on Nrf2 level of expression in unoperated mice (Fig 4.1). One 
potential explanation is the difference of anatomical regions sampled between the two 
figures; cortex peri-infarct after sham or ischaemia surgery in contrast to a 2 mm slice from 
cortex, corpus callosum and striatum for the naïve mice. These two regions have different 
amounts of GFAP-positive cells and this region was quite small compared to the areas 
collected for the naïve animals that include corpus callosum which is enriched in GFAP-
expressing cells. Importantly, Nrf2 levels do not inform on the activation of Nrf2-signalling. 
Alternatively, the distinction of nuclear or cytoplasmic location of Nrf2 by western blot could 
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have informed more about the activation of Nrf2-signalling (Chen et al., 2016; Lei et al., 
2016).  
Nrf2 is known for its antioxidant master regulator role, and it was found that overexpression 
of Nrf2 in astrocytes increased Nrf2 and Nrf2-dependent gene expression after ischaemia (Fig 
4.5 and 4.6). Increased levels of Nrf2-related genes were reported in other studies that used 
GFAP-Nrf2 mice (Calkins et al., 2010; Gan et al., 2012; Sigfridsson et al., 2018). Interestingly, 
in the cortex peri-infarct, there was no increase or very little in Nrf2-related gene expression 
in wild type mice in response to ischaemia (Fig 4.6). Also, HO1 immunostaining was 
upregulated in the rim of the lesion in ischaemic wild-type animals but it did not extend too 
much further (Fig 4.5). This suggests that in the cortex peri-infarct there was minimal 
upregulation of Nrf2-related genes in wild-type animals after 60-minutes ischaemia, despite 
finding increased oxidative stress beyond the lesion. It could be that studying an earlier 
timepoint such as 2 or 4 hours may have revealed a difference in levels of Nrf2 genes between 
ischaemic and sham animals. Using the same procedure, a paper showed upregulation of 
Nrf2-related proteins in the peri-infarct (Tanaka et al., 2010). However, this paper did not 
give details on the analysed area (cortex or striatum? at the frontier or outside the lesion?) 
and counted cells were positive for thioredoxins, glutathione and HO1 immunostaining. 
These results also suggest that in GFAP-Nrf2 mice, levels of Nrf2-related gene expression 
were minimally altered compared with wild-type mice in the cortex peri-infarct of sham mice 
(Fig 4.6). It would be interesting to use ARE-hPAP reporter to localise Nrf2-signalling activity 
(Calkins et al., 2010; Chen et al., 2009; Vargas et al., 2008). 
In physiological conditions, Nrf2 is sequestered by Keap1 and constantly degraded (Itoh et 
al., 1997). Some papers uses Keap1 knockout to upregulate Nrf2-signalling activation (Itoh et 
al., 2004; Kobayashi et al., 2016). Interestingly, Keap1 was neither changed with ischaemia 
compared to shams nor with astrocytic Nrf2-overexpression compared with wild-type (Fig 
4.6). This was contrary to findings that Keap1 is reduced from 2 hours to 72 hours after 60 
minutes of  ischaemia (Ling et al., 2015; Tanaka et al., 2010). However, these papers analysed 
the core of the lesion where cells were lost and different timepoint to the present study. It 
would be interesting to study the expression of Nrf2-related genes in the striatum in the 




4.4.2. Nrf2 overexpression and the effects on reactive astrocytes and 
microglia/macrophages after ischaemia 
3.2.1.6. Increased astrocyte marker GFAP after ischaemia and in GFAP-Nrf2 mice 
As seen in chapter 3, 60 minutes of ischaemia increased the %area of GFAP immunostaining 
and this was likely due increased levels of reactive astrocytes (Fig 4.7). Astrocytosis was also 
increased in the cortex peri-infarct of GFAP-Nrf2 compared to wild-type mice after ischaemia 
(Fig 4.7). Increased GFAP immunostaining can be due to morphological changes or increased 
cell number. Morphological changes are often linked to activation, but in that case, GFAP 
immunostaining was also increased in GFAP-Nrf2 shams compared to wild-type shams. 
Astrocytosis is caused by increased cytokines produced by injured neurons and activated 
microglia but also oxidative stress (Liddelow et al., 2017; Sofroniew, 2009; Swanson et al., 
2004). This result has not been reported previously. Other papers using this model found no 
differences between wild-type and GFAP-Nrf2 sham control for their GFAP protein level or 
%area (Calkins et al., 2010; Gan et al., 2012; Sigfridsson et al., 2018). Interestingly a number 
of disease models of mitochondrial dysfunction, Parkinson’s disease and cerebral 
hypoperfusion model all show increased levels of reactive astrocytes detected with GFAP 
that were dampened by astrocytic overexpression of Nrf2 (Calkins et al., 2010; Gan et al., 
2012; Sigfridsson et al., 2018). However, of pertinence to the current study, one paper found 
that following knockout of Nrf2 mice there were decreased GFAP-positive cell number 24 
hours after ischaemia compared to wild-type and that pharmacological activation of Nrf2 
with Ginseng or DMF increased GFAP-positive cells in a Nrf2-dependent manner (Liu et al., 
2019). They conclude that Nrf2 activation might play a role in the activation and proliferation 
of astrocytes. 
A count of GFAP positive cell bodies (Dr Jill Fowler, personal communication) revealed a 
similar trend to %area, there was increased number of GFAP-positive cells in GFAP-Nrf2 mice 
compared with wild-type in both shams and ischaemia. Ischaemia increases the number of 
astrocytes by proliferation, however this is effect is reported to occur during the first week 
following the injury and not at 24 hours (Bardehle et al., 2013; Barreto et al., 2011; Oki et al., 
2010). This result raises the hypothesis that GFAP-Nrf2 model increases GFAP-cells by 
promoting their production of GFAP and thus increasing their reactivity or that Nrf2 
promotes astrocyte survival. 
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In the recent years, the concept of clasmatodendrocytosis has re-emerged with growing 
interests in astrocytes and their key role in brain pathology. Clasmatodendrocytosis was 
observed with in vitro models of ischaemia such as anaerobic glycolysis (Friede & Van 
Houten, 1961); acidic Ringer’s solution coupled with mitochondrial inhibition (Hulse et al., 
2001); with in vivo models of ischaemia (Davies et al., 1998), hypoperfusion (Hase et al., 2017) 
and was found in post-stroke AD post mortem (Chen et al., 2016). Counting of 
clasmatodendrocytes had been performed by Jill Fowler. No clasmatodendrocytes had been 
found in shams. For the wild-type ischaemic animals, 10 out of 13 animals presented 
clasmatodendrocytes whereas only 4 out of 15 GFAP-Nrf2 ischaemic animals had 
clasmatodendrocytosis. Nrf2 impact on clasmatodendrocytosis has not been reported 
previously. Altogether, these results suggest that astrocytic overexpression of Nrf2 might 
increase the survival of astrocytes. 
Many papers highlight a protective role of astrocytes after an injury (Bhatia et al., 2019; Liu 
et al., 2017; Shinozaki et al., 2017; Zamanian et al., 2012). Astrocytes have many protective 
roles during ischaemia (Barreto et al., 2011; Becerra-Calixto & Cardona-Gómez, 2017; Takano 
et al., 2009) notably by modulating inflammation (Cekanaviciute & Buckwalter, 2016; 
Trendelenburg & Dirnagl, 2005) reducing oedema (Thrane et al., 2014), upregulating 
neurotrophic genes (Zamanian et al., 2012), gaining phagocytic function (Morizawa et al., 
2017) and upregulating antioxidants (Bronstein et al., 1995; Desagher et al. 1996; MCNaught 
& Jenner, 1999; Min et al., 2006; Tanaka et al., 1999). More specifically, reduced astrocyte 
reactivity is associated with increased lesion volume in IL-4 knockout mice (Xiong et al., 
2011). Altogether, these papers and reviews stress the idea that reactive astrocytes have a 
protective role following ischaemia and that their survival is beneficial. 
 
3.2.1.7. UCCAo model might initiate early changes in astrocytes after ischaemia 
An increased in the %area of GFAP immunostaining in sham GFAP-Nrf2 animals compared 
with wild-type mice was also detected in the present study. One possible explanation is that 
the sham procedure used in this work, known as unilateral common carotid artery occlusion 
(UCCAo) will reduce CBF and has been used as a vascular cognitive impairment model 
(Zuloaga et al., 2015). It has been reported that UCCAo decreased anti-inflammatory 
cytokines and increased pro-inflammatory cytokines with increased Iba1 staining, however 
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one limitation of this paper is that Iba1 levels were not quantified (Yoshizaki et al., 2008); 
others have found increased %area and density for both Iba1 and GFAP (Zuloaga et al., 2016). 
However, these results were found at 30 days and 3.5 months and it is unclear if this occurs 
at an earlier time point. No increase in levels of reactive astrocytes were detected between 
the contralateral and ipsilateral hemispheres of sham mice in the previous chapter as 
quantified by Lizi Hegarty of Jill Fowler’s lab. Importantly, a study of the astrocyte 
transcriptome has found changes in the contralateral side of ischaemic animals compared 
with shams without seeing any differences in their GFAP immunostaining (Rakers et al., 
2018). Furthermore, there was an upregulation of IL-1β, TNFα and CXCL10 protein levels 24 
hours after 15 mins of UCCAo. However, this paper reported ischaemic damage in the cortex 
and hippocampus whereas we do not detect neuronal damage in sham UCCAo mice (Silva et 
al., 2015). Another paper found an upregulation of il-1β at 1 and 3 days, il-6 at 2 hours and 2 
months, and a downregulation of il-4 at 1 and 3 days and il-10 at 1 day, without neuronal 
damage following cerebral hypoperfusion model UCCAo, the model used for the sham of the 
present study (Yoshizaki et al., 2008). 
Taken together, these results suggest that UCCAo procedure may modify astrocytes and 
cytokine production. It is possible that these changes could occur as early as 24 hours and 
were not detectable by immunohistology. Possibly, astrocytic Nrf2-overexpression might 
exacerbate these early modifications leading to an upregulation of GFAP immunostaining. It 
would be interesting to further study GFAP-Nrf2 mice astrocyte and inflammation following 
UCCAo and compare it to naïve animals. 
 
3.2.1.8. Microglia/macrophages were increased with ischaemia but not altered by 
overexpression of Nrf2 in astrocytes. 
Ischaemia caused an increase in the %area of Iba1 immunostaining that was not modified by 
astrocytic overexpression of Nrf2 (Fig 4.8). Similarly, other disease models that report 
protective effects in GFAP-Nrf2 mice did cause differences in Iba1 protein level or %area 
(Calkins et al., 2010; Sigfridsson et al., 2018). However, an increase of Iba1 mRNA in a model 
of Parkinson’s disease was dampened by astrocytic overexpression of Nrf2 (Gan et al., 2012).  
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Ginseng or DMF dampened ischaemia-induced microgliosis at 6 and 24 hours after ischaemia 
compared to vehicle treated ischaemia controls (Liu et al., 2019), an effect that was lost in 
Nrf2 knockout mice. In another paper, DMF modestly reduced the microglia/macrophage 
marker Iba1 in a model of chronic cerebral hypoperfusion (Fowler et al., 2017). Conversely, 
Nrf2-signalling activator sulforaphane increased Iba1-positive cells in the peri-infarct but not 
in the core after ischaemia (Pekna et al., 2012). 
As discussed previously in the chapter 3, ischaemia induced an increase in %area of Iba1 
immunostaining that was due to possible morphological changes and increased cell number. 
Further investigation of these changes would be interesting such as counting Iba1-positive 
cells, co-labelling them with TMEM 119 or studying broad transcriptomic changes by using 
RNA-sequencing in a single-cell study.  
 
3.2.1.9. Cytokine expression modified with Nrf2-overexpression in astrocytes 
Inflammation after ischaemia is mainly driven by glial cells and infiltrating immune cells. In 
the past few years new concepts have emerged of diverse or polarised phenotypes for 
astrocytes and neutrophils paralleled to microglia. A discreet communication between these 
cells by second messenger cytokines contributes to the inflammatory state and gives 
direction to the immune response. Microglia activation can modify astrocytes at a 
transcriptomic level (Liddelow et al., 2017; Rothhammer et al., 2018; Shigemoto-Mogami et 
al., 2018) and vice versa (Min et al., 2006; Norden et al., 2014; Ovanesov et al., 2008). These 
changes were operated by means of microglia-astrocyte interactions (for review Jha et al., 
2018). To distinguish the phenotypes, plethora of markers were developed, and methods 
have been refined, notably analysing transcriptomic changes on multi-cells samples or on 
single cell. It would be interesting to study alterations to transcriptomic changes of these cell 
types in the current study using RNA-sequencing. 
IL-4 signalling, found on monocytes, microglia and macrophages (Zhang et al., 2014) is a key 
player in the anti-inflammatory response. There is increased neuronal damage in IL-4 
knockout mice together with increased pro-inflammatory cytokine production and 
decreased anti-inflammatory responses, leading to increased cognitive impairment 
compared to wild-type mice (Liu et al., 2016). Furthermore, IL-4 knockout  also reduces levels 
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of reactive astrocytes following ischaemia (Xiong et al., 2011). IL-4rα KO reduced IL-4 
production (Lee et al., 2018; Noben-Trauth et al., 1997). Following ischaemia, IL-4 and its 
receptor IL-4rα are both upregulated at acute and chronic stage (Lee et al., 2018; Liu et al., 
2016). IL-4 KO is associated with reduced anti-inflammatory responses and impaired 
behavioural recovery after ischaemia (Liu et al., 2016). The KO of IL-4rα increases apoptosis 
and reduces cell viability following ischaemia (Lee et al., 2018). In the present study, 
astrocytic overexpression of Nrf2 increased levels of il-4rα. Other studies report that Nrf2 
and HO1 alter microglia phenotype from pro-inflammatory to anti-inflammatory using Nrf2 
pharmacological activators or oxidative challenge (Han et al., 2016; Kadl et al., 2010; Min et 
al., 2006; Naito et al., 2014; Wang et al., 2018). Upregulation of il-4rα is in accordance with 
papers showing that Nrf2 activation by DMF increases IL-4 levels (Han et al., 2016) and that 
Nrf2 KO decreases IL-4 in a Parkinson’s disease model (Rojo et al., 2010). Altogether, these 
results uphold the idea of microglia-astrocyte interactions and confirm the possible anti-
inflammatory effect of Nrf2. However, it should be noted that the upregulation of IL-4ra in 
the present study was modest and anti-inflammatory effect could be further investigated by 
analysing microglial transcriptome.  
Reactive astrocytes show transcriptomic changes that can be classified as either neurotoxic 
with upregulation of pro-inflammatory complement cascade (named A1) or neuroprotective 
(named A2; Clarke et al., 2018; Liddelow & Barres, 2017; Liddelow et al., 2017). There were 
no changes in astrocytic A1 or A2 specific genes amigo2, C3 and stat3 in the present study. 
An increase in cxcl10 (a ‘pan reactive’ gene present in both neurotoxic and neuroprotective 
astrocytes in Liddelow et al, 2017) was observed after ischaemia and further increased in 
ischaemic GFAP-Nrf2 mice (Fig 4.9). This result could reflect the increased astrocyte 
activation also reported in the present study; however, cxcl10 is also expressed in many other 
cells such as microglia, astrocytes, neurons, leukocytes, macrophages and T cells (Chai et al., 
2015; Harikumar et al., 2014; Klein et al., 2005; Nakamichi et al., 2004; Singh et al., 2008). 
Recent studies show increased CXCL10 in the inflammatory environment (triggered with LPS) 
due to the presence of activated microglia and astrocytes, however there was very little 
CXCL10 within activated microglia alone suggesting a major role of reactive astrocyte in this 
production of CXCL10 (Shigemoto-Mogami et al., 2018). This paper also found that the 
presence of astrocytes did not modify IL-1β or TNFα levels. Therefore, this result associated 
with increased GFAP immunostaining might hence denote increased levels of reactive 
astrocytes with Nrf2 overexpression. It would have been interesting to further study 
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astrocyte phenotype and transcriptome by using RNA-sequencing on isolated astrocyte and 
microglial populations. Another interesting study would have been to study their morphology 
by creating 2D or 3D models of their shape and measure the length and thickness of their 
processes as this reveal different subclasses (Clark et al., 2019; Wagner et al., 2013). 
Upregulation of cxcl10 in our GFAP-Nrf2 model was surprising as some reported CXCL10 
levels were decreased with pharmacological activators of  Nrf2  (Cheng et al., 2018; Kang & 
Lee, 2012) and unchanged with Keap1 KO (Draheim et al., 2016). CXCL10 is expressed in the 
pro-inflammatory environment and Nrf2 is known to increase anti-inflammatory and 
dampen pro-inflammatory cytokines. CXCL10 is expressed by reactive astrocytes and can 
attract microglia (Cross & Woodroofe, 1999; Rappert et al., 2004). This was not confirmed in 
the present study as Nrf2 overexpression in astrocytes increased cxcl10 mRNA levels but did 
not modify %area of the microglia/macrophage marker Iba1. As explained previously, 
increased CXCL10 was found with LPS-reactive astrocytes (Shigemoto-Mogami et al., 2018) 
and after ischaemia (Zamanian et al., 2012). For GFAP-Nrf2 animals, astrocyte activation is 
increased by Nrf2 overexpression and CXCL10 increase can either be due to increased 
astrocyte levels or by a direct effect of Nrf2 overexpression.  
Nrf2 is reported to repress IL-6 and IL-1β cytokine expression during an inflammatory 
challenge by binding directly to their upstream sequence  and repressing their transcription 
(Kobayashi et al., 2016). This finding was not in accordance with our results. However, the 
model we used had an overexpression of Nrf2 in the astrocytes, whereas Kobayashi et al 
(2016) were using a myeloid-cell specific Keap1 knockout. Furthermore, IL-1β is mainly 
produced by microglia and IL-6 is mainly produced by endothelial cells (Zhang et al., 2014). 
To distinguish the glial cell phenotype, a plethora of markers have been developed, and 
methods have been refined, notably analysing transcriptomic changes on multi-cell samples 
or on single cells. The current study is limited by the number of genes investigated; most 
papers studying astrocyte or microglia transcriptomic phenotype use RNA-sequencing as the 
heterogeneity of this activated population is a range of diverse response (Anderson et al., 
2014; Boisvert et al., 2018). This heterogeneity can be defined with regional (Lanjakornsiripan 
et al., 2018) and injury specificities (Lin et al., 2017) but also with aging (Boisvert et al., 2018). 
Furthermore, the sample analysed in the present study comprises a mix of microglia, 
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astrocytes and many other cell types, bringing a difficult conclusion to which cell is being 
modified. 
 
4.4.3. Other possible protective effects of Nrf2 overexpression in astrocytes 
4.4.3.1. BBB leakage and oedema reduced by Nrf2  
Nrf2 activators such as DMF, sulforaphane or Curcumin reduce BBB breakdown or oedema 
after ischaemia (Alfieri et al., 2013; Kunze et al., 2015; Li et al., 2016; Liu et al., 2019; Yang et 
al., 2009; Yao et al., 2016). Only two of these publications used Nrf2 KO to determine if these 
drugs acted via an Nrf2 dependent mechanism (Liu et al., 2019; Yao et al., 2016). It would 
have been interesting to investigate BBB integrity and leakage by mapping IGg or HRP 
immunostaining after ischaemia with the GFAP-Nrf2 model or by staining aquaporin4 or by 
measuring the expression of tight junction markers such as claudin1, occludin or ZO1. 
4.4.3.2. Infiltration of peripheral immune cells  
Because other studies report that Nrf2 reduces BBB breakdown and modifies inflammation 
(Alfieri et al., 2013; Kunze et al., 2015; Li et al., 2016; Liu et al., 2019; Yang et al., 2009; Yao 
et al., 2016), it has been suggested that it would reduce peripheral immune cell infiltration. 
One paper shows reduced neutrophil and T-cell infiltration 14 days after ischaemia with DMF 
treatment, along with infarct reduction and decreased neurological deficits (Lin et al., 2016). 
However, this paper did not challenge their protective effects with silencing or knock down 
of Nrf2. It would be interesting to study levels of peripheral immune cell infiltration in the 
currently study by using microglia specific marker TMEM 119, neutrophil or another 
peripheral immune cell marker. 
 
4.4.4. Other limitations 
4.4.4.1. Modest neuroprotection of Nrf2-overexpression in astrocytes 
In this work, neuronal damage was modestly reduced in the GFAP-Nrf2 mice compared to 
their wild-type littermates after ischaemia (Fig 4.2). This model is developed in accordance 
with previous research showing an astrocytic specific protective effect of Nrf2 (Kraft et al., 
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2004; Lee et al., 2003; Shih et al., 2003) and the GFAP-Nrf2 model attenuates neuronal 
damage and neurodegeneration after mitochondrial dysfunction and in Parkinson’s and 
amyotrophic lateral sclerosis models (Calkins et al., 2010; Chen et al., 2009; Gan et al., 2012; 
Vargas et al., 2008). Despite the use of different disease models, these studies were 
undertaken on mice with a FVB background, whereas the present study was undertaken on 
mice with a C57Bl/6J background; FVB mice show more potent overexpression of Nrf2 and 
important gliosis reduction.  
Knockout of the same gene in different mouse strains and sub-strains can exert different 
physiological effects (Doetschman, 2009; Linder, 2006). Notably in ischaemia research, 
different behavioural outcomes and infarct size have been reported in different mice strains 
(Rosell et al., 2013; Zhao et al., 2017). Finally, Nrf2 knockout showed lower antioxidant 
expression in female and old male compared to young male (Pellegrini et al., 2017). 
Models overexpressing Nrf2 in endothelial or microglial cells, cell types also known to contain 
higher levels of Nrf2 would be useful to study in the context of ischaemia. 
New research emerged developing cocktails of treatments. For ischaemia notably, 
overexpression of Nrf2 coupled with the overexpression of an astrocytic glutamate reuptake 
agent and of a catalyser for glutamate degradation led to drastic improvement and recovery 
of the motor functions after ischaemia (Molcho et al., 2018). 
 
4.4.4.2. Research on ischaemia and aging 
Ischaemia occurs mainly in elderly patients that present with comorbidities. Most preclinical 
research is carried out on young animals, limiting translation to clinical trials. Many 
differences in the cellular response to ischaemia are notable in aged compared to young 
animals (Popa-Wagner et al., 2007). Aged animals have increased oxidative stress and 
decreased antioxidant (Buga et al., 2008; Li et al., 2005; Roberts et al., 1997; Sieber et al., 
2014; Zhang et al., 2018). Furthermore, Nrf2 signalling and its responsiveness is decreased 
with age (Suh et al., 2004; Zhang et al., 2015). However, no papers have studied the potential 
beneficial effect of Nrf2 activation following ischaemia with aged animals. It would be very 
interesting to test whether GFAP-Nrf2 aged animals have reduced ischaemic-induced 




This study suggests that Nrf2-overexpression in astrocytes is potentially neuroprotective 
through an increase in reactivity and survival of GFAP-positive cells, but also by boosting 
antioxidant pathways and upregulating il-4rα and cxcl10 genes it may reduce the spread of 
the lesion. It confirms our hypothesis that Nrf2-overexpression in GFAP-cells attenuates 
neuronal damage following ischaemia by reducing oxidative stress and inflammation.  
In order to improve this study, more genes could be analysed, but also a single-cell approach 
would greatly reduce possible confusion as most cytokines are produced by a multitude of 
cells.  
To conclude, we have demonstrated that Nrf2 overexpression in astrocytes decreased 
ischaemia-induced oxidative stress and neuronal damage, but also modified astrocytes and 
inflammatory response. Therefore, in the next chapter, the potential protective effect of 
astrocytic overexpression of Nrf2 in a chronic model of ischaemia was investigated along its 





5. Astrocytic overexpression of Nrf2 does not protect neurons and 
does not alter neurological function or cognitive deficits in the 
chronic response to a modest duration of ischaemia 
5.1. Introduction  
In the previous chapter, boosting Nrf2 specifically in astrocytes protected neurons 24 hours 
after 60 minutes of focal cerebral ischaemia. The neuroprotective effect of boosting Nrf2 was 
paralleled by reduced oxidative stress, increased levels of reactive astrocytes and increased 
il-4rα and cxcl10 mRNA expression. 
Neurological deficits have been reported following hours or days after focal cerebral  
ischaemia, however neurological function has been shown to improve at later time points (7 
to 28 days; Macrez et al., 2011; Omura et al., 2006; Titova et al., 2011; Yang et al., 2011; Yao 
et al., 2016). Neurological deficits at 3 and 7 days after focal cerebral ischaemia can be 
improved with by boosting  Nrf2 signalling pharmacologically with DMF (Yao et al., 2016). 
Nrf2 activation in vivo decreases inflammation and improves spatial memory in a mouse 
model of Alzheimer’s disease (Dumont et al., 2011; Kanninen et al., 2009). In a model of 
chronic cerebral hypoperfusion, spatial working memory assessed by an 8 arm radial arm 
maze was impaired compared with sham mice, however overexpressing Nrf2 specifically in 
astrocytes protected against these cognitive deficits (Sigfridsson et al., 2018). 
Novel object recognition (NOR) is a sensitive test to detect cognitive deficits in the first weeks 
after focal cerebral ischaemia (Wang et al., 2012; White et al., 2012; Yabuki & Fukunaga, 
2013; Zhu et al., 2015). This test has two phases, familiarisation of the mouse with two 
objects followed by a retention test with one novel object and one familiar. Naïve or sham 
animals spent more time exploring the novel object whereas ischaemic animals do not prefer 
the novel object. Glutathione treatment improves cognitive NOR memory in ischaemic 
animals (Yabuki & Fukunaga, 2013). Although the protective effects of boosting Nrf2 in vitro 
(Shih et al., 2003; Kraft et al., 2004; Murphy et al., 2002) and in vivo (Kraft et al., 2004) have 
been reported to occur via an astrocytic dependent mechanism, the effects of boosting 
astrocytic Nrf2 on cognitive and neurological deficits after focal cerebral ischaemia have not 




It is hypothesised that overexpression of Nrf2 in the GFAP-positive astrocytes could 
attenuate neurological deficits, neuronal damage and improve cognitive function 4 weeks 
following modest duration of ischaemia by reducing oxidative stress and inflammation.  
The specific aims are: 
• To investigate the potential protective effects of Nrf2 overexpression in astrocytes 
after ischaemia in the chronic response (4 weeks recovery). 
a. To determine if ischaemia induces deficits in neurological function and novel 
object recognition memory and to determine whether Nrf2 overexpression 
in astrocytes modifies these behavioural deficits. 
b. To determine if boosting Nrf2 in astrocytes can protect neurons and reduce 
oxidative stress 4 weeks after ischaemia. 
c. To investigate possible modulation of inflammation and glial 
activation/phenotype with astrocytic overexpression of Nrf2 after 
ischaemia. 
d. To verify Nrf2-related gene expression is increased in the GFAP-Nrf2 model 






5.2. Materiel & Methods 
5.2.1. Mice and experimental groups 
Male GFAP-Nrf2 mice and C57Bl/6J (wild-type; WT) littermates underwent ischaemia 
(transient middle cerebral artery occlusion for 15 minutes) (n=12-15/group for histology 
cohort and n=6-10/group for biochemistry cohort) or sham surgery and brains were collected 
at 4 weeks (see table 5.1). In order to study behaviour and cognition after ischaemia, a period 
of 4 weeks of survival after the ischaemia was chosen. As 60 minutes of focal cerebral 
ischaemia is severe, it induces a large area of neuronal damage in the hemisphere and mice 
can often recover poorly. However, the characterisation in chapter 3 demonstrated elevated 
oxidative stress and inflammation following a more modest duration of ischaemia (15-
minutes) in the acute and chronic response. Thus, in the current experiments, 15 minutes of 
ischaemia with 4 weeks survival was investigated. Group sizes were determined using power 
calculations performed on previous result (presented in chapter 4): 15 animals per group are 
needed to achieve p<0.05 with a 20% effect (total lesion volume reduced of 19.576% in the 
GFAP-Nrf2 mice compared wild-types). 
Two criteria of exclusion throughout the thesis has been used: (1) Lack of damage in the 
striatum following MCAo and (2) presence of infarction (pan necrosis of cells) defined as 
cluster of infiltrated cells and glia in the core of very large lesion. In this study, 3 animals of 
the histology cohort were excluded: 2 wild-type MCAo (1 infarcted and 1 with no lesion in 
the striatum) and 1 GFAP-Nrf2 MCAo (infarcted). Additionally, 5 animals in the histological 
cohort had to be culled early as they had a poor response to the surgery, or they exceeded 
20% weight loss, and 2 for other non-ischaemia related health problems. In the biochemistry 
cohort, 3 animals had to be culled due to poor response to the procedure and 1 animal 
exceeded 20% weight loss. 
All analyses were carried out with the experimenter blinded to groups and mice were 





Table 5-1 Summary of the group size of each group after exclusion for histologic and biochemistry cohorts. 
Histologic cohorts and the biochemistry cohorts depending on the surgery and the duration of occlusion and the 
survival (time between the ischaemia and the sacrifice) and the genotypes. 
 
5.2.2. Focal cerebral ischaemia 
As previously explained in section 2.2 of the Materials & Methods chapters, a monofilament 
was introduced into the CCA via a small incision and advanced 10mm distal to the carotid 
bifurcation to occlude the MCA (Monofilament 6-0 medium A MCAO suture L34 PK10; 
Doccol). Shams underwent the same procedure without the insertion of the thread. To 
withdraw the thread, mice were re-anaesthetised with isoflurane anaesthesia. Mice received 
0.5ml saline (0.9%) subcutaneously by injection and were transferred to an incubator (30 C) 
for 2 hours. The mice were weighed daily and monitored at least twice a day for the first 72 
hours, and then daily, in order to assess the severity of the ischaemia injury. All ischaemia 
surgery was undertaken by Dr Jill Fowler. Aseptic techniques were used. 
 
5.2.3. Sensorimotor and cognitive function tests 
The methods used for assessing behaviour are described in section 2.5 of the materials and 
methods. Neurological deficits were assessed at 1, 3, 7, 10, 14, 21 and 28 days post-ischaemia 
using a neuroscore test based on a protocol from De Simoni et al., 2003 and Orsini et al., 
2012. Scores range from 0 to 36, with a score of 0 indicating no deficit and a score of 36 
indicating maximal impairment (See table 2.4). The score represents the sum of the results 
obtained in diverse categories. 
Novel Object Recognition (NOR) was performed in a modified rat Y-Maze to minimize stress 
caused by open apparatus as detailed in section 2.5. Briefly, the animal was habituated to 
the maze by using the “starting arm” that was closed to the rest of the maze (see Fig. 2.4). 
Genotype Initial size Final size Initial size Final size
WT 15 14 7 7
GFAP-Nrf2 12 12 6 6
WT 19 15 12 10
GFAP-Nrf2 16 11 11 9
4 weeks survival









During the familiarisation and retention phases, the maze was opened, and two objects were 
placed in the two other arms. The trial began by placing the mouse in the “starting arm” and 
let free to explore the rest of the maze and the two objects. Each trial was 10 minutes long 
and video recorded. A pilot test showed that the animals were interested in the object mainly 
during the 3 first minutes. As a result, the 3 first minutes of exploration were used. The 
analysis was based on the time spent exploring the objects. A discrimination index (DI) was 
used to normalise the time spent on the novel object compared to the total time spent in the 
apparatus. An animal that spent less than 10 seconds to explore each object during the 10 
minutes of familiarisation would be excluded. In the study, no animals were excluded 
following this rule. One animal was excluded as it did not explore the object during the first 
3 minutes during the 4th week experiment.  
𝐷𝐼 =
(Time on Novel object − Time on Familiarised Object)




Histology and immunohistochemistry techniques used were performed as detailed in section 
2.3 of the Methods. Lesion volume was assessed by drawing areas of neuronal death and 
tissue damage after assessing Haematoxylin and eosin staining, NeuN and MAP2 
immunostaining. Oxidative stress was detected using 3-nitrotyrosine immunostaining and 
then mapped as undertaken for the lesion but using only 3 coronal levels, 
Microglia/macrophages and reactive astrocytes were studied using Iba1 and GFAP 
immunostaining respectively and quantified assessing %area in Image J (Fiji, NIH). After 4 
weeks, the peri-infarct boundary was less obvious, therefore all the results presented in this 
section are from the core of the lesion. GFAP and Iba1 immunohistochemistry were 
undertaken by Lizi Hegarty. 
 
5.2.5. qRT-PCR  
To study Nrf2 related and inflammatory related gene expression, qRT-PCR was performed as 
explained in the Methods section 2.4. Because 15 minutes of ischaemia caused neuronal 
damage that mainly affected the striatum, the samples analysed in this section are from the 
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striatum. For this study, cxcl10, il-1β, il-4rα and c3 genes were analysed to study 
inflammation. For Nrf2-related gene expression, nfe2l2, hmox1, nqo1 and slc7a11 genes 
were performed. For each animal, the level of expression was normalised compared with the 
housekeeping gene 18S. 
 
5.2.6. Statistics 
Data were expressed mean ± S.E.M. using GraphPad Prism software. For parametric analysis, 
two-way analysis of variance (ANOVA) followed by post-hoc Bonferroni test was performed 
to correct for multiple comparisons. To analyse neuroscore, two-way ANOVA with repeated 
measures were performed with SPSS (v24.0). To analyse discrimination and preference for 
the novel object in the NOR test, one-sample t-test was used to compare the results to zero, 





5.3.1. Nrf2 overexpression in astrocytes impaired cognitive functions and did not 
modify neurological function 
Ischaemia impairs sensorimotor functions. To assess recovery from ischaemia and the 
potential effect of Nrf2 overexpression in astrocytes, a neuroscore scaling from 0 to 36, with 
0 no deficit to 36, maximal impairment, was performed at different time points throughout 
the experiment. Different categories regrouped essential sensorimotor tests: grooming (hair, 
eyes and coat), sensorial response (whisker stimulation), posture and gait, spontaneous 
activity, symmetry, circling and gripping. 
For each mouse, even shams, the score was different from 0 on the first days after the 
surgical procedure (Fig 5.1). Overall, ischaemic animals had significant increased neuroscore 
compared to shams (F(1, 56)=16.729, p<0.0001). There was no effect of the genotype (F(1, 
56)=0.062 p=0.805; Fig. 5.1) and no interaction (F(1, 56)=0.941, p=0.336), however, post hoc 
comparisons revealed a significant decrease of the neuroscore for the GFAP-Nrf2 ischaemic 
animals compared to ischaemic wild-types at 7 days (p=0.046). No significant differences 
were detected between the groups at other timepoint. 
 
Figure 5-1 After modest duration (15 minutes) ischaemia, animals present neurological deficits and recovered 
quickly. 
Neurological deficits were assessed at 1, 3, 7, 10, 14, 21- and 28-days post-ischaemia. Scores range from 0 to 36, 
with a score of 0 indicating no deficit and a score of 36 indicating maximal impairment.  
Ischaemia caused a significant increase in neuroscore compared to shams (F(1, 56)=16.729, p<0.0001). There was 
no effect of the genotype (F(1, 56)=0.062 p=0.805) and no interaction (F(1, 56)=0.941, p=0.336). Comparison of the 
different time points showed a significant difference between wild-types (WT) and GFAP-Nrf2 animals after 
ischaemia at day 7 (p=0.046). There was no significant difference between the groups at any other time point.  
Data presented as mean ± S.E.M. Two-way ANOVA with repeated measures followed post hoc comparisons with 
Bonferroni (N= 11 to 15 per group). *p<0.05. 
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To test the cognitive function of the animals after ischaemia, novel object recognition (NOR) 
memory was assessed. This test has previously been used to detect cognitive deficits after 
ischaemia (Wang et al., 2012; White et al., 2012; Zhu et al., 2015). It assesses the ability of an 
animal to recognise a novel and remember a familiar object and thus assesses learning and 
memory (Leger et al., 2013). The 10-minutes trials of familiarisation and retention were 24 
hours apart therefore assessing long term memory (Dudai, 2002; Montarolo et al., 1986). 
Quantification of the object preference was based on the time spent exploring the objects, 
using a discrimination index (DI) to measure the time spent on the novel object (N) compared 
to the time exploring the familiar object (F) and normalised on the total time exploring: DI = 
(N - F)/(N + F).  
In a pilot experiment designed to test different durations of retention wild-type naïve animals 
tested showed a preference for the novel object with a DI close to 0.2, meaning 60% of the 
time spent exploring the novel object, and 40% on the familiar (pre-test on 5 wild-types: 
mean 0.195±0.081; Fig. 5.2) which is expected performance from naïve mice (Alachkar et al., 
2019; Becerril-Ortega et al., 2014; Dong et al., 2019; Yabuki & Fukunaga, 2013). 
 
Figure 5-2 Novel object recognition on wild-types mice. 
The novel object recognition task was designed to test the ability of the animal to remember an object. The animal 
was free to explore an object and its twin during a familiarisation trial. After a 24-hour retention period, the animal 
was free to explore the familiar object or a novel object. As animals naturally prefer novelty, the animal spent 
more time exploring the novel object. The analysis was based on the time spent exploring the objects, using a 
discrimination index (DI) to measure the time spent on the novel object (N) compared to the time exploring the 
familiar object (F) and normalised on the total time exploring: DI = (N - F)/(N + F). Animals were 2 to 4-month old. 
 
On the first week after ischaemia, mice had recovered from the surgery and no animals were 
excluded for lack of exploration. Analysis of the DI with two-way ANOVA revealed no 
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significant effect of surgery (F(1, 48)=0.309, p=0.581) nor of genotype (F(1, 48)=1.799, p=0.186) 
or an interaction (F(1, 48)=0.426, p=0.517; Fig 5.3).  
At the end of the experiment, 4 weeks after ischaemia, analysis of the differences between 
groups revealed a significant effect of the surgery (F(1, 47)=5.541, p=0.0228) but there was no 
effect of the genotype (F(1, 47)=3.806, p=0.057) nor an interaction between surgery and 
genotype (F(1, 47)=1.538, p=0.221). Post hoc comparisons revealed no differences between the 
two genotypes following ischaemia (p=0.056). 
 
 
Figure 5-3 Cognitive deficit was observed 4 weeks after 15 minutes ischaemia compared to sham controls. 
(A) There was no effect of surgery F(1, 48)=0.309, p=0.581 nor of genotype F(1, 48)=1.799, p=0.186 1 week after the 
ischaemia.  
(B) There was an effect of the surgery F(1, 47)=5.541, p=0.0228 but there was no effect of the genotype F(1, 47)=3.806, 
p=0.057 at 4 weeks after the ischaemia.  
Results above the dotted line represent a discrimination of the two objects with a preference for the novel object. 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 11 to 
15 per group).  
 
The performance of both sham and ischaemic GFAP-Nrf2 mice seemed impaired on the NOR. 
A group of naïve animals, uninjured wild-type and GFAP-Nrf2 animals (n=3 to 7) were tested 
with 3 weeks apart to reproduce the experimental procedure (Fig 5.4). No differences were 
found between wild-types and GFAP-Nrf2 animals at both time points (baseline: p=0.58; 3 
weeks later: 0.24). 
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Figure 5-4 Discrimination of the novel object compared to the familiar was performed twice on naïve animals 
of both genotype with three weeks apart.  
Results above the dotted line represent a discrimination of the two objects with a preference for the novel object. 
Data presented as mean ± S.E.M. (N= 3 to 7 per group). One-sample t-test to test the difference from zero (i.e. no 
preference for any object) with #p<0.05. Animals were 2 to 4-month old. 
 
5.3.2. Neuronal damage was not altered by astrocytic overexpression of Nrf2  
As described in Chapter 3, 15 minutes of ischaemia caused neuronal damage that was mainly 
detected in the striatum (Fig 5.5 A). Lesion volume was assessed by mapping the lesion onto 
coronal line diagrams. Quantification with two-way ANOVA showed that there was a  
significant effect of surgery, ischaemia increasing neuronal damage in each region (Total 
lesion F(1, 48)=74.05, p<0.0001; cortex F(1, 48)=8.653, p<0.0001; striatum F(1, 48)=134.4, p<0.0001; 
other regions F(1, 48)=14.96, p=0.0003). There was no effect of genotype (Total lesion F(1, 
48)=0.08, p=0.77; cortex F(1, 48)=0.14, p=0.70; striatum F(1, 48)=0.77, p=0.38; other regions F(1, 
48)=1.80, p=0.18) nor an interaction effect (Total lesion F(1, 48)=0.12, p=0.72; cortex F(1, 48)=0.14, 
p=0.70; striatum F(1, 48)=0.77, p=0.38; other regions F(1, 48)=1.80, p=0.18; Fig. 5.5). Post-hoc 
comparisons showed no differences between GFAP-Nrf2 and wild-type ischaemic animals in 
the total lesion (p>0.99), the lesion in the cortex (p>0.99), in the striatum (p=0.44) or the 







Figure 5-5 Nrf2 overexpression in astrocytes did not modify neuronal damage 4 weeks after modest duration 
of ischaemia (15 minutes). 
 (A) Representative line diagram with neuronal damage in black from the median animal of GFAP-Nrf2 and wild-
type (WT) genotype. The lesion was mainly comprised in the striatum. 
(B) Quantification of neuronal damage mapping showed a significant effect of the surgery for each region 
(p<0.0001). Nrf2-overexpression did not modify the total lesion (p>0.99), the lesion in the cortex (p>0.99), in the 
striatum (p=0.44) or the other regions (p=0.130). 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 11 to 
15 per group).  
 
  





































































































5.3.3. Oxidative stress in response to ischaemia was unchanged in Nrf2 
overexpressing mice compared to wild-type controls 
Oxidative stress was assessed using 3NT immunostaining and mapped on line diagrams. The 
staining was mainly found in the striatum and only rarely in the cortex (Fig 5.6 A and B). 
Quantification revealed an effect of the surgery for each region (total ipsilateral hemisphere 
F(1, 48)=61.47, p<0.0001; cortex F(1, 48)=7.388, p=0.0091; striatum F(1, 48)=79.34, p<0.0001), no 
effect of the genotype (total ipsilateral hemisphere F(1, 48)=0.13, p=0.72; cortex F(1, 48)=0.12, 
p=0.73; striatum F(1, 48)=0.296, p=0.59) and no interaction (total ipsilateral hemisphere F(1, 
48)=0.13, p=0.72; cortex F(1, 48)=0.11, p=0.75; striatum F(1, 48)=0.296, p=0.59; Fig 5.6 B). 
After mapping the lesion and 3NT areas of 3 coronal sections it was possible to compare the 
genotype (wild-type versus GFAP-Nrf2), marker (3NT area of expression versus neuronal 
lesion area) and the regions (+0.98, -0.10, -2.06 mm to Bregma). Using a two-way ANOVA 
with repeated measure by implementing the region variable, there was no effect of the 
genotype (F(1, 52)=0.983, p0.326), nor of the marker (F(1, 52)=0.507, p=0.480), however there 
was a significant interaction between genotype and marker (F(1, 52)=145.622, p<0.001; Fig 5.6 
C). Interestingly, there was an effect of the region (F(1, 52)=111.283, p<0.001) and an 
interaction between region and genotype (F(1, 52)=6.027, p=0.005; Fig 5.6 C). Post hoc analysis 
indicated that there was no difference between wild-types and GFAP-Nrf2 in oxidative stress 
(p=0.568) or in the lesion (p=0.412) but also for each region (Fig 5.6 C). Therefore, it means 
that the difference was dependant on the interaction of all factors without any factor being 





Figure 5-6 Nrf2 overexpression in astrocytes does not modify oxidative stress marker 3NT 4 weeks after 15 
minutes ischaemia. 
 (A) Representative images of 3-Nitrotyrosine (3NT) immunostaining showed peroxide nitrite generation in the 
striatum after ischaemia but not in shams.  
(B) Quantification of 3NT immunostaining by mapping the positive staining showed a significant increase of the 
staining with the surgery for each region (total ipsilateral hemisphere F(1, 48)=61.47, p<0.0001; cortex F(1, 48)=7.388, 
p=0.0091; striatum F(1, 48)=79.34, p<0.0001), no effect of the genotype (total ipsilateral hemisphere F(1, 48)=0.13, 
p=0.72; cortex F(1, 48)=0.12, p=0.73; striatum F(1, 48)=0.296, p=0.59) and no interaction (total ipsilateral hemisphere 
F(1, 48)=0.13, p=0.72; cortex F(1, 48)=0.11, p=0.75; striatum F(1, 48)=0.296, p=0.59). 
(C) Profile of the staining area and the neuronal damage area in three coronal sections of the ischaemic groups 
showed 3NT expression mirroring lesion area and slightly more elevated oxidative stress and neuronal damage in 
caudal brain for the GFAP-Nrf2 mice compared to wild-types. Using Two-way ANOVA with repeated measure, 
there was no effect of the genotype (F(1, 52)=0.983, p0.326), nor of the marker (F(1, 52)=0.507, p=0.480), however an 
interaction between genotype and marker was found significant (F(1, 52)=145.622).  
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
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5.3.4. Nrf2-signalling was increased in the GFAP-Nrf2 mice 
To determine if Nrf2-signalling was boosted in GFAP-Nrf2 mice and in response to ischaemia, 
Nrf2 gene nfe2l2 and downstream genes hmox1, nqo1 and xCT gene slc7a11 were studied 
with qRT-PCR in the striatum. For each gene, there was no effect of surgery (nfe2l2 F(1, 
28)=0.92, p=0.34; hmox1 F(1, 28)=0.17, p=0.68; nqo1 F(1, 28)=1.77, p=0.19; slc7a11 F(1, 28)=3.959, 
p=0.0565) and no interaction (nfe2l2 F(1, 28)=0.522, p=0.476; hmox1 F(1, 28)=1.094, p=0.304; 
nqo1 F(1, 28)=1.044, p=0.316; slc7a11 F(1, 28)=0.325, p=0.573; Fig 5.7). However, for each gene 
there was an effect of genotype (nfe2l2 F(1, 28)=54.46, p<0.0001; hmox1 F(1, 28)=12.12, 
p=0.0017; nqo1 F(1, 28)=46.15, p<0.0001; slc7a11 F(1, 28)=44.79, p<0.0001), with a significant 
increase in the GFAP-Nrf2 animals compared to wild-types (Fig 5.7). Bonferroni post-hoc 
corrections revealed a significant difference between wild-type and GFAP-Nrf2 in shams 
(nfe2l2 p<0.0001; hmox1 p=0.0127; nqo1 p=0.0016; slc7a11 p=0.0009), and after ischaemia 
for nfe2l2, nqo1 and slc7a11 (p<0.0001), but not for hmox1 (p=0.135; Fig. 5.7). 
 
 Figure 5-7 Nrf2 overexpression in astrocyte increases Nrf2-related genes in the striatum 4 weeks after 15 
minutes ischaemia. 
Nrf2 gene nfe2l2 mRNA levels and downstream genes hmox1, nqo1 and slc7a11 were not altered by surgery 
(nfe2l2 F(1, 28)=0.92, p=0.34; hmox1 F(1, 28)=0.17, p=0.68; nqo1 F(1, 28)=1.77, p=0.19; slc7a11 F(1, 28)=3.959, 
p=0.0565). However, for each gene there was an effect of the genotype (nfe2l2 F(1, 28)=54.46, p<0.0001; hmox1 
F(1, 28)=12.12, p=0.0017; nqo1 F(1, 28)=46.15, p<0.0001; slc7a11 F(1, 28)=44.79, p<0.0001). There was no 
interaction (nfe2l2 F(1, 28)=0.522, p=0.476; hmox1 F(1, 28)=1.094, p=0.304; nqo1 F(1, 28)=1.044, p=0.316; slc7a11 
F(1, 28)=0.325, p=0.573). 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 6 to 10 
per group).  *p<0.05, **p<0.01, ***p<0.001. 
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5.3.5. Nrf2 overexpression did not alter levels of reactive astrocytes 4 weeks after 
modest duration ischaemia (15 minutes) 
Astrocytosis was studied with GFAP immunostaining. GFAP staining was present on shams, 
showing sparsely distributed astrocyte cell bodies and processes (Fig. 5.8 A). Ischaemic 
animals presented increased GFAP staining; in the cortex, more cell bodies were visible, and 
in the striatum, a maelstrom of processes and cell bodies were seen in the core of the lesion 
(Fig. 5.8 A). Quantification of the staining was undertaken with %area; it revealed a significant 
effect of surgery with increased staining after ischaemia (cortex F(1, 48)=17.41, p=0.0001; 
striatum F(1, 48)=306.1, p<0.0001; Fig. 5.8 B). There was no effect of the genotype (cortex F(1, 
48)=0.014, p=0.905; striatum F(1, 48)=0.196, p=0.659) and no interaction (cortex F(1, 48)=0.085, 
p=0.772; striatum F(1, 48)=0.788, p=0.379; Fig. 5.8 B). Post hoc tests revealed there was no 
alteration between wild type and GFAP-Nrf2 mice following ischaemia. 
 
Figure 5-8 Astrocytic Nrf2-overexpression does not modify astrocyte reactivity after 15 minutes ischaemia 4 
weeks post-injury. 
(A) Representative images of GFAP immunostaining showing an increase with the ischaemia in the cortex and the 
striatum after ischaemia compared to shams. Some clasmatodendrocytes were observed in the lesion. 
(B) Quantification of reactive astrocytes (%area of GFAP immunostaining) showed that there was a significant 
increase in reactive astrocytes with ischaemia surgery for cortex and striatum (F(1, 48)=17.41, p=0.0001 and F(1, 
48)=306.1, p<0.0001). There was no effect of the genotype in the cortex or striatum (F(1, 48)=0.014, p=0.905 and F(1, 
48)=0.196, p=0.659 respectively) and no interaction (cortex F(1, 48)=0.085, p=0.772; striatum F(1, 48)=0.788, p=0.379). 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
per group for the immunostaining study and N= 7 to 11 per group for gene expression study).  
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5.3.6. Astrocytic overexpression of Nrf2 increased microglia/macrophages response 4 
weeks after mild ischaemia 
In order to study microglia/macrophage activation, Iba1 immunostaining was used. Iba1 
staining was present on sham and ischaemic animals with cell bodies and processes covering 
the parenchyma (Fig. 5.9 A). Ischaemic animals presented increased Iba1 staining in the 
striatum, where most of the neuronal damage was, processes and cell bodies were thicker 
and darker (Fig. 5.9 A). Quantification of the staining of % area immunostaining was 
undertaken. There was a significant effect of surgery with increased staining after ischaemia 
(cortex F(1, 48)=6.225, p=0.0161; striatum F(1, 48)=37.05, p<0.0001; Fig. 5.9 B). Interestingly, 
there was an effect of the genotype in striatum (F(1, 48)=7.169, p=0.0101) with a significant 
increase in GFAP-Nrf2 animals compared to wild-types after ischaemia (p=0.0005), and an 
interaction (F(1, 48)=8.742, p=0.0048). There was no effect of the genotype in the cortex (F(1, 





Figure 5-9 Nrf2 overexpression in astrocytes modifies microglia/macrophage levels 4 weeks after modest 
duration ischaemia (15 minutes). 
(A) Representative images of Iba1 immunostaining showing an increase with ischaemia in the striatum.  
(B) Quantification of Iba1 immunostaining by analysing %area of immunostaining showed a significant increase 
with surgery in the cortex and striatum (F(1, 48)=6.225, p=0.0161 and F(1, 48)=37.05, p<0.0001). There was an effect 
of the genotype in striatum (F(1, 48)=7.169, p=0.0101) with a significant increase in GFAP-Nrf2 animals compared 
to wild-types (WT) after ischaemia (p=0.0005) and an interaction (F(1, 48)=8.742, p=0.0048). There was no effect of 
the genotype in the cortex (F(1, 48)=0.0002, p=0.988) and no interaction (F(1, 48)=0.016, p=0.898). 
Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 7 to 15 
per group for the immunostaining study and N= 7 to 11 per group for gene expression study). ***p<0.001. 
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5.3.7. Nrf2 overexpression in astrocytes reduced c3 gene expression after ischaemia 
but did not modify the expression of cxcl10, il-1β or il-4rα genes 
A few relevant markers of inflammation, known to be modulated by Nrf2, were investigated. 
Pro-inflammatory gene il-1β was significantly increased 4 weeks after ischaemia 
(F(1,28)=15.71, p=0.0005), but there was no significant effect of the genotype or interaction 
(F(1,28)=0.66, p=0.42 and F(1,28)=0.605 p=0.44 respectively; Fig 5.10). IL-4rα is a key player of 
the anti-inflammatory response; its gene expression was significantly increased with 
ischaemia (F(1,28)=23.61, p<0.0001), but there was no significant effect of the genotype or 
interaction (F(1,28)=0.08, p=0.78 and F(1,28)=0.177, p=0.677 respectively; Fig 5.10). CXCL10 is 
produced mainly by reactive astrocytes in an inflammatory environment. Cxcl10 gene 
expression was significantly increased 4 weeks after ischaemia (F(1,28)=22.28, p<0.0001), but 
there was no significant effect of the genotype or interaction (F(1,28)=0.39, p=0.54 and 
F(1,28)=2.933, p=0.097 respectively; Fig 5.10). Reactive astrocytes with a neurotoxic phenotype 
(A1) produce complement component 3 gene c3; analysis of its expression revealed a 
significant increase with ischaemia 4 weeks after the injury (F(1,28)=10.34, p=0.0033). 
Furthermore, there was a significant effect of genotype (F(1,28)=4.955, p=0.034) and an 
significant effect of the interaction between surgery and genotype (F(1,28)=5, p=0.0335). Post 
hoc tests revealed there was a significant reduction in c3 mRNA levels the GFAP-Nrf2 





Figure 5-10 Nrf2 overexpression in astrocyte decreases complement 3 (c3) gene but not cxcl10, il-1β or il-4rα in 
the striatum 4 weeks after 15 minutes ischaemia. 
There was a significant increase in mRNA levels of pro-inflammatory gene il-1b, anti-inflammatory gene IL-4rα , 
reactive astrocytes gene cxcl10 and A1 specific gene complement 3 gene c3 4 weeks after ischaemia (il-1β 
F(1,28)=15.71, p=0.0005; il-4rα F(1,28)=23.61, p<0.0001; cxcl10 F(1,28)=22.28, p<0.0001; c3 F(1,28)=10.34, p=0.0033). 
There was an effect of the genotype for c3 (F(1,28)=4.955, p=0.034) with a significant reduction in the GFAP-Nrf2 
compared to wild-type (WT) animals after ischaemia (p=0.0033), but no effect for the other genes (il-1β 
F(1,28)=0.66, p=0.42; il-4rα F(1,28)=0.08, p=0.78; cxcl10 F(1,28)=0.39, p=0.54). 
 Data presented as mean ± S.E.M. Two-way ANOVA followed by post hoc comparisons with Bonferroni (N= 6 to 10 
per group).  ***p<0.001. 
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In conclusion, Nrf2 overexpression in astrocytes did not modify neuronal damage and 
oxidative stress in the chronic response to a modest duration of focal cerebral ischaemia. 
However, GFAP-Nrf2 mice had decreased neurological deficits at 7 days after ischaemia, pro-
inflammatory c3 gene expression was decreased and microglia/macrophages reactivity was 
increased at 4 weeks when compared with wild type mice. Importantly, cognitive deficits 
seemed increased in GFAP-Nrf2 animals.  
Altogether, these findings refute the original hypothesis that Nrf2-overexpression in 
astrocytes would be neuroprotective and improve cognition in the chronic response 
following ischaemia as it failed to reduce neuronal damage and oxidative stress but also 
further impaired discrimination of the novel object; however, it had other beneficial effects, 
it reduced inflammatory related c3 expression  and neurological deficits. 
 
5.4.1. Neurological deficits improved at 7 days in the GFAP-Nrf2 animals 
In this chapter, it was determined that there were early deficits in neurological function 
assessed with neuroscore. The first day following the surgery, shams and ischaemic animals 
had neurological deficits however it was very mild for shams and they recovered within a few 
days, whereas it took more than a week for ischaemic animals to recover (Fig. 5.1). This is 
supported by other research; ischaemic animals presented general sensorimotor 
impairments following the injury but then recovered after the first week (Deng et al., 2016; 
Macrez et al., 2011; Omura et al., 2006; Orset et al., 2007; Titova et al., 2011). Interestingly, 
these papers reported results for long duration of ischaemia (from 50 minutes to permanent) 
apart from one that showed locomotor activity recovery 48 hours after thrombin injection 
(Orset et al., 2007). Specific unilateral sensorimotor functions are impaired for much longer 
and possibly permanently due to the presence of striatal and/or cortical lesion (Yang et al., 
2011).  
 Quantification of the neuroscore data did not show an overall effect of the genotype, 
however at day 7 GFAP-Nrf2 ischaemic animals had reduced neurological deficits than their 
ischaemic wild-type littermates (Fig 5.1). Other studies have shown that Nrf2 activation by 
pharmacological or transgenic means is beneficial as it can decrease neurological deficits (Lin 
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et al., 2016; Shih et al., 2005; Yamauchi et al., 2016; Yao et al., 2016). With the present data, 
the protection at 7 days cannot be explained as no data have been collected on oxidative 
stress, inflammation, neuronal damage at this time point. To investigate this effect, a new 
experiment must be designed with 15 minutes ischaemia and 7 days survival. 
 
5.4.2. Novel object recognition (NOR) to test cognitive function 
The result of the NOR showed no effect of the surgery after the first week but an effect at 4 
weeks (Fig. 5.3) suggesting that cognitive functions were impaired in the longer term after 
ischaemia. Others reports cognitive impairment at 7 days (Doyle et al., 2015; Wang et al., 
2012; White et al., 2012), with improvement at 21 days (Wang et al., 2012) or at later time 
points (1 month; Zhu et al., 2015) for novel object recognition memory impairments after 
ischaemia. These papers have severe ischaemia procedures and it can cause chronic 
impairments on cognitive function from 7 days to 2 months (Ryan et al., 2006). Concomitant 
with our findings, Guégan and colleagues performed permanent distal MCAo and showed 
impairments on the Morris water maze at 5 weeks but not during the first week (Guégan et 
al., 2006). The severity is thus an important discrepancy regarding the lesion location and 
thus the impact on cognitive function. Our findings indicate that the lesion is present in the 
striatum, however pathology was present in the cortex for a few animals. These papers 
described above all have cortical and striatal lesions, with only one of the papers stating that 
the lesion impacted the hippocampus (Wang et al., 2012). Contrary to the previous cited 
literature, ischaemic wild-type animals were able to discriminate the novel object compared 
to the familiar object at 4 weeks (Fig. 5.3). This might be due to either the time point, as other 
publications found cognitive impairment after ischaemia at 7 to 12 weeks (Doyle et al., 2015). 
Therefore, if a later timepoint had been examined, there may have been an increased 
memory impairment. The lack of impairment following ischaemia wild type mice at 4 weeks 
could also be related to the difficulty of the task. The mice had 10 minutes during the 
familiarisation to observe the familiar object as recommended by other papers (Leger et al., 
2013; Yabuki & Fukunaga, 2013). However, a few others investigated 5 minutes of 
familiarisation and were still able to have mice discriminate (Wang et al., 2012; Zhu et al., 
2015). By decreasing the duration of the familiarisation, it increases the difficulty of the task 
and possibly its sensitivity. Another alternative is to remove the mouse from the apparatus 
after 20 to 38 seconds exploring the objects (Leger et al., 2013; White et al., 2012). It also 
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exists other protocols that complexify the task by putting two different objects during the 
familiarisation or by doing two habituation sessions with different objects (Asiminas et al., 
2019). 
It is interesting to note that GFAP-Nrf2 animals had better neurological scores at 7 days than 
the wild-types after ischaemia and that is paralleled with decreased discrimination of the 
novel object at the same time point for GFAP-Nrf2 compared to wild-types despite the 
surgery. In summary, Nrf2-overexpression in astrocytes causes worsened cognition for both 
focal (MCAo) and global (UCCAo) ischaemia at 7 days and improving neurological outcomes 
at 7 days of ischaemia. Together, these findings suggest both detrimental and beneficial 
effect, with unclear mechanism. In order to investigate this effect, a study of the synaptic 
proteins at 7 days after ischaemia and UCCAo should be conducted on the different region 
underlying these functions. 
It has been reported that cognitive deficits after ischaemia are attenuated following 
pharmacological activation of Nrf2 (Mao et al., 2018). Another paper showed improvements 
on the NOR with glutathione treatment after ischaemia (Yabuki & Fukunaga, 2013). However, 
our results showed impaired recognition for GFAP-Nrf2 animals after ischaemia at 1 and 4 
weeks (Fig 5.3). Sustained activation of Nrf2-signalling can be detrimental for cancer and 
diabetes, cardiac myopathy and obesity (Kensler & Wakabayashi, 2010; Dodson et al., 2015; 
Kannan et al., 2013; Loboda et al., 2016; Seo & Lee, 2013). However, none of these 
publications explain a possible modification of the cognition by Nrf2. Nrf2 is repressed early 
in cortical neurons and this is key to their development and synaptogenesis, as otherwise, 
forced Nrf2 expression in neurons during the early days of development lead to reduced 
synapses, retarded electrophysiological maturation and outgrowth of dendritic arborescence 
(Bell et al., 2015). This mechanism is interesting but not relevant for the present work, as 
Nrf2 was overexpressed in GFAP-positive astrocytes only. Of the different Nrf2-related genes 
expressed when Nrf2 is activated, some reports identified detrimental effect of HO1. Like 
Nrf2, HO1 is linked to tumour aggressiveness and cell proliferation in cancer (Alaoui-Jamali 
et al., 2009; Deininger et al., 2000; Hara et al., 1996). A recent review outlined the 
detrimental effects of HO1 (Schipper et al., 2019). For example,  repeated or sustained 
production of HO1 could modify mitochondrial iron uptake, permeability and lead to 
mitochondrial damage (Schipper et al., 2019). Blockage of HO1 in an AD model led to 
decreased inflammation and improved learning (Gupta et al., 2014). Importantly, a few 
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studies conducted on a suppressor of HO1 activity found there was reduced trauma-induced 
neuronal damage, decreased necrosis and oedema in cerebral hypoperfusion model (Kadoya 
et al., 1995; Panizzon et al., 1996). In terms of cognition, two papers have found that HO1 
overexpression was linked to learning and memory deficits via synapse protein reduction and 
increased Amyloid-β and Tau (Li et al., 2015; Si et al., 2018). However, in the present study 
HO1 was found increased in GFAP-Nrf2 shams compared to wild-type shams but not 
increased when comparing GFAP-Nrf2 ischaemic animals to wild-types animals; and learning 
abilities were reduced in GFAP-Nrf2 ischaemic animals and not GFAP-Nrf2 shams. In a mouse 
model of chronic cerebral hypoperfusion, GFAP-Nrf2 animals presented less impairment in 
the radial arm maze at 8 weeks compared to wild-type hypoperfused mice (Sigfridsson et al., 
2018). However, in this paper, control groups of sham operated GFAP-Nrf2 animals and wild-
type animals had differences in their learning patterns as it appeared that GFAP-Nrf2 mice 
made more re-visiting errors in the second part of the trial. In this paper they suggested that 
this effect was due to overwhelming antioxidant production as basal level maintenance of 
ROS is important for homeostasis (Angelova & Abramov, 2018; Ye et al., 2015). Particularly 
fine tuning of ROS production and regulation is critical as both high and low ROS levels impact 
at different time point the physiological development of nervous system cells (Olguín-
Albuerne & Morán, 2018; Schippers et al., 2012) notably neurons (Kennedy et al., 2012). As 
reductive stress is detrimental for cells (Kornienko et al., 2019; Pérez-Torres et al., 2017), we 
can infer that severe inhibition of ROS might be detrimental for cognition. There is very few 
researches conducted on this subject, but it has been demonstrated that overexpression of 
antioxidant SOD was detrimental for long-term memory (Hu et al., 2006; Lee et al., 2014; 
Thiels et al., 2000) as it inhibited hydrogen peroxide elevation, required for long-term 
potentiation. Furthermore, ROS are essential for vascular homeostasis and function, immune 
response, haematopoiesis (Vara & Pula, 2014). In order to investigate this possibility, an 
investigation of synaptic protein expression could be conducted after ischaemia in GFAP-Nrf2 
mice. 
 
5.4.3. Neuronal damage unaltered with overexpression of Nrf2 in astrocytes 
Infarct volume was similar between wild-type and GFAP-Nrf2 animals (Fig. 5.5), suggesting 
no neuroprotective effect of Nrf2-overexpression in astrocytes at 4 weeks after modest 
duration ischaemia. This result is contradicted by the previous chapter and other studies that 
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reported improved survival, reduced neuronal loss and reduced lesion after mitochondrial 
dysfunction with Nrf2 overexpression in astrocytes (Calkins et al., 2010; Chen et al., 2009; 
Gan et al., 2012; Vargas et al., 2008).  
Interestingly, as the lesion was comparable for GFAP-Nrf2 mice and their wild-type 
littermates, the cognitive impairment seen in GFAP-Nrf2 mice 4 weeks after ischaemia 
cannot be explained a worsening of neuronal damage. Thus, any impairment that was 
observed in the novel object recognition was not due to neuro-motor deficits but caused by 
cognitive impairment. 
Nrf2-signalling activation by pharmacological approach or genetic modification of Nrf2 
expression have been shown to exert protective effects on ischaemic neuronal death in 
numerous papers, however a few papers did not find a protective effect (Kunze et al., 2015; 
Narayanan et al., 2015). These papers investigated the protective effect of two 
pharmacological compounds and used Nrf2 knockout model to test whether these 
compounds had Nrf2-dependant protective effect. Narayanan and colleagues found that 
untreated Nrf2 knockout had similar lesion volume and oxidative stress levels than the wild-
types (Narayanan et al., 2015). This result contradicts others showing a worsening of 
neuronal damage with Nrf2 knockout and thus suggesting a neuroprotective effect of Nrf2 
following ischaemia (Liu et al., 2019; Shih, et al., 2005a; Wang et al., 2012; Wu et al., 2017; 
Yao et al., 2016). Kunze and colleagues failed to find a reduction of the lesion using DMF, 
however DMF reduced the oedema. Using Nrf2 siRNA towards endothelial cells, the 
protective effects of DMF on oedema were lost, suggesting an Nrf2-dependant mechanism 
(Kunze et al., 2015). However other publications reported that DMF reduced neuronal 
damage (Lin et al., 2016; Liu et al., 2019; Yao et al., 2016) and this may be related to dose as 
neuroprotective effects are reported for using 45 mg/kg or more, compared to Kunze et al. 
using only 15 mg/kg. 
In chapter 3, it was demonstrated that lesion volume observed at 24 hours and 4 weeks after 
15-minutes of ischaemia was comparable in wild type mice, suggesting that there is no 
progression of the lesion, although it should be noted that this was not compared in a 
contemporaneous, randomised manner. In the previous chapter, it was shown that astrocytic 
overexpression of Nrf2 was neuroprotective, and it was suggested that this neuroprotective 
effect concerned the hypothalamus and thalamus, regions that have damage only after 60-
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minutes or longer ischaemia. Of all the literature cited previously that demonstrated 
neuroprotective effects of boosting Nrf2, ischaemic models were either permanent or 60-
minutes or longer ischaemia that contrast with our 15-minutes long ischaemia in current 
chapter. It raised the hypothesis that Nrf2-overexpression in astrocytes is protective after 
severe ischaemia as it reduced the spreading of the lesion. The lesion is reported to be 
developed in the first 18 hours after the onset (Hartings et al., 2003; Heiss, 2000), thus it is 
salvageable in that time.  
Another hypothesis is that Nrf2 may have differential effect depending on the anatomical 
area, as neurons and astrocytes are very heterogeneous through the different part of the 
brain (astrocytes: Lin et al., 2017; Morel et al., 2018; Lanjakornsiripan et al., 2018; neurons: 
Watakabe et al., 2006; Zeng et al., 2018). The previous chapter showed a neuroprotective 
effect that seemed to affect the hypothalamic and thalamic regions (Fig 4.2). This would 
imply that the neuroprotective effect Nrf2-overexpression in astrocytes is not found in 
striatum but in these regions, however the hypothalamus and thalamus are mainly 
unaffected by a modest duration (15 mins) of focal cerebral ischaemia. However, Nrf2 
overexpression in astrocytes had proven beneficial effects in the striatum following 
mitochondrial inhibition (Calkins et al., 2010).  
Another possibility is insufficient Nrf2 activation (Fig. 5.7). HO1 immunostaining, as an index 
of Nrf2 activation, is only modestly increased by 15-minutes of ischaemia with 24 hours and 
4 weeks survival (Fig 3.14 and 3.23). Also, the effect of 15 mins of ischaemia on Nrf2-signalling 
activation for GFAP-Nrf2 mice at acute timepoints such as 4 and 24 hours has not been 
investigated. As seen in chapter 3, in wild-type mice only hmox1 and srxn1 were upregulated 
at 4 hours after modest duration ischaemia and this was in the cortex, spared from neuronal 
damage and not in the striatum that was the core of the damage in this model. It would be 
interesting to use alternative methods to study spatial and temporal alterations to Nrf2-
signalling activation after 15 minutes of ischaemia, such as luciferase tagging of Nrf2-
signalling activation or in situ hybridation of Nrf2-related genes.  
One interesting difference between 15- and 60-minutes ischaemia at 24 hours was that GFAP 
immunostaining was increased in the severe model but not following the modest duration of 
ischaemia (Fig 3.4). Since Nrf2 overexpression depends on a GFAP promoter in the GFAP-Nrf2 
mice, this difference suggests the possible need of astrocytic reactivity and/or astrocytic 
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oxidative stress for a beneficial effect of Nrf2-overexpression. However, two results 
contradict this hypothesis. First increased gfap mRNA was observed 24 hours after 15-
minutes ischaemia (Fig 3.5). However, there can be discrepancies between protein and 
mRNA levels (Vogel & Marcotte, 2012) and GFAP is prone to many post-translational 
modification (Yang & Wang, 2015). Importantly, a paper reported that the Nrf2-inducer 
Curcumin reduces GFAP protein level but not mRNA levels (Bachetti et al., 2012). Second, the 
oxidative stress marker 3NT was found in a broader area than the lesion, extending to the 
undamaged cortex at 24 hours after 15 minutes of ischaemia (Fig 3.3 B and C). Oxidative 
stress would certainly induce Nrf2-signalling in that case. Co-staining GFAP with oxidative 
stress marker 3NT would potentially elucidate this question, but also studying the effects of 
15-minutes ischaemia on GFAP-Nrf2 animals that survive for 24 hours would help to 
understand potential early activation of Nrf2-signalling in astrocytes. 
In the present study, Nrf2 gene expression was only 4-fold higher than Nrf2 levels in wild-
type mice. Previous work on this model found very strong Nrf2-signalling activation in 
primary astrocytes cultures and in different brain regions (cortex, brain stem, spinal cord) 
using luciferase luminescence or by measuring 8-fold increase in GFAP-Nrf2 mRNA levels in 
spinal cord astrocytes compared to wild-types (Johnson et al., 2008; Vargas et al., 2008). Nrf2 
overexpression was specific to GFAP-positive astrocytes that were very few and scattered in 
the cortex and striatum of shams or 15-minutes ischaemia. That would explain such a small 
Nrf2 gene expression rate in the mRNA of the multi-cell sample from the parenchyma. Areas 
with increased astrocytic GFAP such as in 60-minutes ischaemia will benefit of the Nrf2 
overexpression to protect from neuronal damage. The GFAP-Nrf2 mice used were 
heterozygous. It would be possible that homozygous model would present further increased 
Nrf2 overexpression and thus increase potential beneficial effects and reduced variability, 
however it remains uncertain if this would alter neuronal damage after a modest duration of 
focal ischaemia (15 minutes).  
 
5.4.4. Increased Nrf2-signalling in GFAP-Nrf2 animals compared to wild-type animals 
Antioxidant genes nqo1 and slc7a11 were both upregulated in the GFAP-Nrf2 animals with 
or without ischaemia (Fig. 5.7). For each Nrf2-related gene, there was no effect of the surgery 
confirming previous results in chapter 3 in the chronic state, that although wild-type 
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ischaemic animals had oxidative stress, Nrf2-related genes were equals to shams (Fig. 3.23). 
For each gene, there was an effect of the genotype with increased gene expression in Nrf2-
overexpressing mice, confirming the validity of the model. 
Interestingly, hmox1 was upregulated in GFAP-Nrf2 sham animals and unchanged with 
ischaemia, but Bonferroni post-hoc corrections revealed no differences between GFAP-Nrf2 
and wild-type animals comparing ischaemic groups. HO1 is slightly downregulated after 
ischaemia in the GFAP-Nrf2 animals and that could be due to homeostatic regulation of its 
production as HO1 can be detrimental as previously explained (Schipper et al., 2019; Gupta 
et al., 2014;  Kadoya et al., 1995; Panizzon et al., 1996; Li et al., 2015; Si et al., 2018). 
 
5.4.5. Oxidative stress was unchanged in GFAP-Nrf2 animals compared to wild-type 
littermates after modest duration ischaemia 
In this chapter, the oxidative stress marker 3NT was observed 4 weeks after ischaemia and 
unchanged with Nrf2-overexpression in astrocytes (Fig 5.6). There was no difference 
between GFAP-Nrf2 animals and wild-types when comparing the lesion or the genotype 
following ischaemia (Fig 5.6 C). Many papers showed efficiency of Nrf2 in reducing oxidative 
stress during acute time points. Chronic studies of the response to ischaemia are rarely 
carried out. It is even so the case for the impact of boosting Nrf2 signalling on chronic 
ischaemia. Two papers showed a neuroprotective effect of Nrf2 activation paralleled with 
increased antioxidant activity and decreased free radicals at 7 and 11 days post-ischaemia 
(Yabuki & Fukunaga, 2013; Yao et al., 2016). 
 
5.4.6. Astrocyte reactivity unchanged in GFAP-Nrf2 animals compared to their wild-
type littermates 
In this chapter, astrocytes immunostained with the GFAP antibody were increased with 
ischaemia and formed a glial scar 4 weeks after ischaemia (Fig. 3.17). However, there was no 
alteration in levels of reactive astrocytes when comparing GFAP-Nrf2 mice with wild-type 
controls 4 weeks after ischaemia (Fig. 5.8). This contrasts with previous findings where 60 
minutes ischaemia led to increased astrocytosis in GFAP-Nrf2 animals at 24 hours (Fig. 4.7). 
This discrepancy could be due to many possible factors that varied between this chapter and 
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the previous one. In the acute response to 60 minutes ischaemia, neuronal damage and 
astrocytosis were observed in the cortex (Fig. 3.2 and 3.4), however there was markedly less 
neuronal damage in the cortex after 15 minutes ischaemia at the same time point (Fig. 3.2 
and 4). This suggest that early astrocytosis due to severe ischaemia can be modified by Nrf2-
overexpression in astrocytes, but that long term astrocytosis is not impacted as it lacks the 
early effect on reactive astrocytes. 
Furthermore, in chapter 4 the peri-infarct was investigated whereas in the present chapter, 
the core of the lesion has been quantified. This potentially explains the discrepancy. As 
previously explained, the peri-infarct and core were homogenous, and it was difficult to 
distinguish them at 4 weeks. In chapter 3, peri-infarct and core analysis of GFAP and Iba1 
markers gave the same results at 4 weeks and thus it suggests the discrepancies were not 
due to this difference (see Appendix 8.2.1, Fig 8.1). 
As discussed in chapter 4, other studies have reported that reactive astrocytosis induced in 
neurodegenerative disease models was dampened with Nrf2-overexpression in astrocytes 
(Calkins et al., 2010; Gan et al., 2012; Sigfridsson et al., 2018). It is possible that 
overexpression of Nrf2-in astrocytes modified astrocytosis before 4 weeks and that GFAP 
levels went back to wild-type levels after that. To test this hypothesis, a longitudinal study of 
astrocytes should be designed, using for example in vivo multi-photon techniques that allow 
for temporal, longitudinal studies of cellular modification in the same animals. 
Using GFAP immunostaining is the best technique to study reactive astrocytes as this protein 
is linked to their morphology (Lebkuechner et al., 2015; Pekny & Nilsson, 2005). However, 
GFAP-astrocytes constitute only a subpopulation of astrocytes and new markers are 
emerging such as ALDH1L1, a pan-astrocytic marker (Cahoy et al., 2008). In this paper, they 
tested other markers, and found that S100β, commonly reported as an astrocytic marker, 
was found in a wide range of astrocytes, however, it is not specific for astrocytes, as it was 





5.4.7. Microglia/macrophages increased in the striatum of the GFAP-Nrf2 animals 
compared to wild-types 
After 4 weeks of survival, ischaemic animals have increased Iba1 staining that was further 
increased in GFAP-Nrf2 animals compared to ischaemic wild-types (Fig. 5.9). In both cases, 
the staining was found within the glial scar as previously seen in chapter 3 (Fig. 3.18). To 
model multiple sclerosis, cuprizone causes oligodendrocyte loss, demyelination and 
microgliosis. Draheim et al. (2016) boosted Nrf2 by knocking out Keap1 in GFAP-expressing 
astrocytes in this model (Draheim et al., 2016). They found that Nrf2-signalling was increased 
and microgliosis was drastically reduced along with oligodendrocyte rescue and reduced 
axonal damage. They believe that Nrf2-signalling had an impact on microglia reactivity and 
diversification. 
An  increase of Iba1 staining in GFAP-Nrf2 ischaemic animals could potentially be linked to 
increased CXCL10 gene expression in GFAP-Nrf2 ischaemic animals found in the acute phase 
(Fig. 4.9) as CXCL10 is known to attract microglia (Cross & Woodroofe, 1999; Rappert et al., 
2004). However, cxcl10 gene expression was increased with ischaemia but unchanged with 
Nrf2 overexpression in astrocytes compared to wild-types 4 weeks after ischaemia (Fig. 5.10). 
 
5.4.8. Inflammatory-related genes expression 
Pro-inflammatory astrocyte gene c3 was upregulated in ischaemic animals but GFAP-Nrf2 
animals had drastic reduction of this gene expression compared to wild-type (Fig. 5.10). C3 
is part of the complement cascade that promote phagocytosis (Veerhuis et al., 2011). Using 
GFAP-Nrf2 mice, Sigfridsson and colleagues found increased complement cascade 
component C1q and C4 after hypoperfusion and it was dampened with Nrf2-overexpression 
in astrocytes (Sigfridsson et al., 2018). Inhibition or lack of C3 was protective in AD mouse 
models, reducing synapse loss and in ischaemic models reducing neuronal loss (Alawieh et 
al., 2018; Hong et al., 2016; Shi et al., 2017). Importantly, one limitation of this marker is that 
C3 is also produced by microglia (Zhang et al., 2014). Fluorescent-associated cell sorting of 
astrocytes revealed that the production of C3 was specific to neurotoxic and pro-
inflammatory reactive astrocytes (Liddelow et al., 2017).  
In this chapter, cxcl10, il-4rα and il-1b genes were still increased 4 weeks after ischaemia (Fig. 
5.10). Decreased c3 gene expression with Nrf2 overexpression in astrocytes after ischaemia 
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suggests an anti-inflammatory effect. However, cxcl10, il-4rα and il-1b were comparable 
between ischaemia GFAP-Nrf2 mice and ischaemic wild-types. Several papers showed that 
ischaemia first increased anti-inflammatory cytokines for the first hours/days and that they 
later it decline, followed by elevations of pro-inflammatory cytokines (Amantea et al., 2018; 
Hu et al., 2012; Zhang et al., 2018). IL-4rα is increased 4 weeks following ischaemia compared 
to shams. But these papers suggest that anti-inflammatory cytokines peaked early and 
decline which we cannot prove with this work as it requires an analysis of the different time 
point in the same cohort. Interestingly, lack of anti-inflammatory IL-4 worsens cognitive 
functions following ischaemia (Liu et al., 2016). Furthermore, two inhibitors of M1 
polarisation improved cognitive function and reduced infarction (Qin et al., 2017; Zhang et 
al., 2019). But in our case, decreased c3 levels were not paralleled with improved cognitive 
functions. This result is limited as a wide range of genes should be used to assess 
inflammation. 
Results presented in the current chapter  contradict known inhibitory effect of Nrf2 towards 
il-1β gene expression (Kobayashi et al., 2016). In the first chapter, il-1β was unchanged at 24 
hours after 15 minutes ischaemia (Fig. 3.10). In the Kobayashi paper, il-1β expression was 
inhibited by Nrf2 after LPS treatment. It is possible that Nrf2 inhibition on this gene 
expression appears only early after a very large increase of this aforementioned gene. 
However, no effects of boosting Nrf2 signalling on il-1β were reported after 60 minutes of 
ischaemia in chapter 4. Interestingly, LPS and ischaemia are known to confer polarised effects 
on the transcriptome of reactive astrogliosis (Zamanian et al., 2012). Furthermore, Kobayashi 
uses Keap1-Knockout in myeloid cells. However, many papers argue that astrocytes can 
modify microglia activation at a transcriptomic level (Min et al., 2006; Norden et al., 2014; 
Ovanesov et al., 2008). Additionally, Min and colleagues found that reactive astrocytes 
boosted Nrf2-signalling in microglia and notably hmox1 gene (Min et al., 2006). These results 
were observed in vitro and thus might be limited compared to in vivo conditions. 
Severe ischaemia led to increased level of il-4rα at 24 hours and it was further increased with 
Nrf2 overexpression in astrocytes (Fig. 4.9). Modulation of il-4rα in early phase of modest 
duration of ischaemia is however unknown. It would be interesting to study this gene in the 
GFAP-Nrf2 mice 24 hours after 15 minutes ischaemia.  
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Importantly, cxcl10 gene is increased in the striatum of the 15 minutes ischaemia at 24 hours 
(Fig. 3.8) and after 60 minutes ischaemia in the wild-type (Fig. 4.9). Nrf2-overexpression in 
astrocytes further increased cxcl10 levels at that time point. But this gene had comparable 
increase in GFAP-Nrf2 mice compared with wild-types 4 weeks after 15 minutes ischaemia. 
In summary, Nrf2 overexpression in astrocytes caused further increases in cxcl10 and il-4rα 
at 24 hours after 60 minutes of ischaemia but not 4 weeks after 15 minutes of ischaemia. 
Either or both, severity or analysed time point can explain this discrepancy. Thus, two 
hypotheses can be produced: Nrf2 overexpression in astrocytes can modulate cytokine gene 
expression following severe ischaemia but not with modest duration of ischaemia; or Nrf2 
overexpression in astrocytes can modulate cytokine gene at early time point but not in their 
chronic upregulation. To test these, two studies must be designed: cytokine gene expression 
has to be analysed in GFAP-Nrf2 mice compared to wild-types at 24 hours after 15 minutes 
ischaemia, and at 4 weeks after 60 minutes ischaemia.  
 
5.4.9. Conclusions 
In this chapter, Nrf2 overexpression in GFAP-expressing astrocytes reduced learning and 
memory performance compared to wild-types, at 1 week in both shams and after ischaemia, 
and at 4 weeks after ischaemia. This result contradicts the initial hypothesis that Nrf2 
overexpression in astrocytes would improve cognitive decline observed in the chronic phase 
of ischaemia. Unexpectedly, the genotype did not impact on oxidative stress or neuronal 
damage at 4 weeks. However, this finding does not explain the worsening of the cognitive 
function observed in GFAP-Nrf2 mice. Of interest, GFAP-Nrf2 ischaemic animals had 
increased microglia/macrophage staining in the striatum and c3 gene expression was 
reduced compared to ischaemic wild-types. This result supports the hypothesis that Nrf2 
overexpression in astrocytes would modulate inflammation. Finally, neurological deficits 
were decreased with Nrf2-overexpression in astrocytes 7 days after ischaemia.  
Taken together, this chapter showed that the effect of Nrf2 overexpression in astrocytes 
were different from the previous chapter. The severity of the ischaemia, as well as the 
different time point study may explain these discrepancies. To conclude, Nrf2 overexpression 
in astrocytes have diverse beneficial and detrimental effects depending on the injury. 
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Limitations of this work must be addressed, such as the use of a mild ischaemic model with 
possible variability and later cellular changes notably of astrocytes that may have driven the 
potential beneficial effect of Nrf2 as seen in chapter 4. Furthermore, there is a potential 
detrimental effect of continuous Nrf2 activation as seen in reductive stress, diabetes, cardiac 
myopathy and obesity research in the past. The use of young mice is an important limitation 
to translation, especially for neurodegenerative diseases. Comorbidities must be analysed 
and carefully included for future therapeutic trials. Finally, further studies should be 
conducted to understand Nrf2 modulation mechanisms involved in cytokines modulation, 




6.1. Summary and implications 
Ischaemic stroke is an important health condition and a leading cause of death, disability and 
persistent cognitive deficits. Neuronal damage occurs in two waves with the lack of oxygen 
and nutrients at first, and a second wave of oxidative stress and inflammation build-up that 
threatens to extend the primary lesion. There is a vast amount of literature on Nrf2-signalling 
pathway showing beneficial effects in inflammation, oxidative stress and ischaemic 
conditions.  
The first chapter characterised the modifications triggered by ischaemia. It laid a ground of 
knowledge on inflammation and oxidative stress and their effects on Nrf2-signalling 
activation, particularly useful for the next chapters. Results of different occlusion duration 
gave a basis for understanding the lesion spreading. The lesion was contained in the striatum 
following 15 minutes ischaemia, and extended to cortex with 30 minutes ischaemia, and 
further to the thalamus, hypothalamus and hippocampus following 60 minutes occlusion. 
Modest duration of ischaemia (15 minutes) was sufficient to increase oxidative stress, 
astrocytic gfap gene expression and microglia reactivity; and increasing durations of 
ischaemia led to increased neuronal damage, oxidative stress and inflammation.  
Interestingly, areas with no neuronal damage showed signs of inflammation and oxidative 
stress, both in the acute and chronic phase of ischaemia. As this MCAo model is known for 
mimicking penumbra, these modifications are probably an observation of it. Going further, 
these modifications are similar to ischaemic preconditioning in which astrocytes and 
antioxidants (notably Nrf2) are imperative for its neuroprotective effect (Bell et al., 2011a & 
b; Hirayama et al., 2015; Xue et al., 2016). Here was found antioxidant upregulation and 
astrocytic gene gfap upregulated at 1 day. Furthermore, long-lasting changes in those areas 
appear at 4 weeks but not at 1 day such as upregulation of GFAP immunostaining %area, 
cxcl10 gene and microglial/macrophage gene aif1. 
Studying different time points revealed an evolution of Nrf2-signalling upregulation. Nrf2-
signalling was upregulated in the acute phase of ischaemia; however, there was a lack of 
responsiveness in the chronic phase despite maintained oxidative stress and inflammation. 
This effect is possibly due to an auto-regulation mechanism that bring back Nrf2 levels to 
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homeostatic levels. This hypothesis is supported by known detrimental effect of Nrf2 
upregulation on reductive stress (Kennedy et al., 2012; Olguín-Albuerne & Morán, 2018; 
Schippers et al., 2012; Vara & Pula, 2014), carcinogenesis (Kensler & Wakabayashi, 2010) and 
insulin resistance (Fu et al., 2016). 
Nrf2 activators have off-target effects. In this regard, the model used in this thesis can inform 
on the effects of Nrf2 effect exclusively It has been suggested in the literature that the 
protective effects of boosting Nrf2 signalling seem to depend mainly on astrocytes and their 
activation. The creation of a model that induces astrocytic overexpression of Nrf2 (GFAP-
Nrf2) in vivo has been central to addressing these questions and interesting protective effects 
have been demonstrated in a number of different neurodegenerative diseases (Calkins et al., 
2010; Chen et al., 2009; Gan et al., 2012; LaPash Daniels et al., 2012; Sigfridsson et al., 2018; 
Vargas et al., 2008).  
In the second chapter, astrocytic overexpression of Nrf2 caused a reduction of oxidative 
stress, increased astrocyte reactivity and a modification of inflammation with notably il-4rα 
gene expression increased. These changes were paralleled with a modest reduction of 
neuronal damage, suggesting a neuroprotective effect of these modifications. However, the 
modest nature of the neuroprotection would suggest that Nrf2 may need to be targeted in 
other cell types (Liddell, 2017) or in combinations with other neuroprotective targets for a 
more effective stroke treatment (Molcho et al., 2018). 
The neuroprotective effects of Nrf2 are mainly observed in thalamus, hypothalamus and 
hippocampus. From the data collected in the previous chapter, these regions were injured 
following 60 minutes of occlusion but not 30 minutes ischaemia. Taken together, it suggests 
a role of Nrf2 overexpression in astrocytes in the containment of the lesion extension via a 
modification of inflammation/glial response and a reduction of oxidative stress. 
In the third chapter, Nrf2 overexpression in astrocytes did not modify neuronal damage and 
oxidative stress in the chronic response to ischaemia. The neuroprotective effect of Nrf2 after  
ischaemia reported in the literature was mostly achieved using pharmacological activators 
with off-target effects (Abed et al., 2015; Magesh et al., 2012) and with a global effect on 
different cells. It appears that Nrf2 activation in astrocytes is known and thought as sufficient 
to induce neuroprotection (Shih et al., 2003). However, in regard of the findings of this 
chapter, boosting Nrf2 in other cells may be key. Nrf2 has protectant and anti-inflammatory 
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effects on endothelial cells notably (Chen et al., 2006; Jyrkkänen et al., 2008; Zakkar et al., 
2009) and a statement about modulating microglial phenotype by boosting microglial Nrf2. 
Interestingly, GFAP-Nrf2 mice had decreased discrimination at 4 weeks after ischaemia 
compared to their wild-type littermates, and this finding was not associated with increased 
neuronal damage. This discrepancy can be explained by different part of the brain underlying 
this behaviour. Other tests could be developed to encompass the spectrum of behavioural 
disorders observed after ischaemia such as nest building used to assess executive functions 
(Hase et al., 2017). It exists other protocols to the NOR that complexify the task by putting 
two different objects during the familiarisation or by doing two habituation sessions with 
different objects (Asiminas et al., 2019). 
There is potential detrimental role of Nrf2 and its activation notably for cancer, 
cardiomyopathy and reductive stress (Kensler & Wakabayashi, 2010; Hayes & McMahon, 
2009; Dodson et al., 2015; Kannan et al., 2013; Loboda et al., 2016). In the brain, HO1 
expression can be linked to mitochondrial damage (Schipper et al., 2019); inflammation and 
impaired learning in an AD model (Li et al., 2015; Si et al., 2018; Gupta et al., 2014); and 
trauma-induced neuronal damage, decreased necrosis and oedema in a cerebral 
hypoperfusion model (Kadoya et al., 1995; Panizzon et al., 1996). However, in chapter 5, HO1 
is not significantly upregulated in GFAP-Nrf2 mice compared to wild-types after ischaemia, 
suggesting that the detrimental effect of Nrf2 is somewhere else. Nrf2 is repressed early in 
cortical neurons because redox signalling pathways are critical for their development and 
synaptogenesis. Forced Nrf2 expression in neurons during the early days of development led 
to reduced synapses, retarded electrophysiological maturation and outgrowth of dendritic 
arborescence (Bell et al., 2015). This result suggests a homeostatic mechanism that regulates 
Nrf2. Detrimental effect of Nrf2 overexpression in astrocytes observed in the NOR could be 
explained by an overwhelming antioxidant production as basal level maintenance of ROS is 
important for homeostasis (Angelova & Abramov, 2018; Ye et al., 2015). Furthermore, ROS 
are essential for vascular homeostasis and function, immune response, haematopoiesis (Vara 
& Pula, 2014). These results are a reminder that redox signalling pathways play critical 






Table 6-1 Main results from chapter 4 and chapter 5 following ischaemia for wild-type and GFAP-Nrf2 animals. 
 
Furthermore, this study of astrocytic overexpression of Nrf2 showed interaction of astrocytes 
with microglia and neurons. In the chapter 4, astrocytic overexpression in astrocytes reduced 
neuronal damage. In the chapter 5, astrocytic overexpression in astrocytes increased 
microglia/macrophage marker Iba1. This interaction also impacts on inflammatory 
modulation. In chapter 4, cxcl10 and il-4rα were upregulated in GFAP-Nrf2 animals compared 
to wild-types following ischaemia. In chapter 5, pro-inflammatory c3 gene expression was 
decreased and microglia/macrophages reactivity was increased. It was previously shown that 
Nrf2 had anti-inflammatory properties, notably by modulating cytokines and leading 
microglial phenotypes transformation (Kadl et al., 2010; Kobayashi et al., 2016; Liu et al., 
2019; Liu et al., 2017; Naito et al., 2014; Peng et al., 2016). This thesis reinforced that theory 
with opening new understanding in which astrocytes interact with their neighbouring cells 
and on Nrf2 modulation of inflammation. 
The protocol used in this thesis required an occlusion of the common carotid artery (UCCAo), 
mixing global and focal ischaemia (Liu & Mccullough, 2011). Therefore, the sham procedure 
underwent permanent UCCAo. In the chapter 4, sham model UCCAo on GFAP-Nrf2 mice had 
increased astrocyte marker GFAP immunostaining %area compared to sham wild-types. In 
chapter 5, GFAP-Nrf2 animals with UCCAo performed poorly on cognitive task compared to 
their wild-type littermates. In the last decade, growing interest on this method linked it to 
vascular cognitive impairment (Nishino et al., 2016; Silva et al., 2015; Zhao et al., 2014; 
Zuloaga et al., 2015). This model induces a reduction in blood flow (Tajima et al., 2014; 
Urushihata et al., 2018; Zuloaga et al., 2015) and that potentially lead to astrocytic response 
that was exacerbated in GFAP-Nrf2 mice, and to reduced performance on the NOR. 
The results in chapter 4 and 5 showed an important discrepancy (Table 6.1). The severity of 
the injury as well as the survival times are the possible main causes to these discrepancies. 
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The mechanism underlying this difference could be guided by the heterogeneity of astrocytes 
and microglia observed in differential disease models, anatomical areas and injuries 
(astrocytes: Anderson et al., 2014; Lin et al., 2017; Liddelow & Barres, 2017; Pekny et al., 
2016; Zamanian et al., 2012; microglia: Böttcher et al., 2019; Masuda et al., 2019). As glia and 
their response can differ depending on the area observed or the injury caused, it might have 
led to differential response in these chapters. 
Interestingly, the literature on insulin resistance and carcinogenesis open a controversy as 
different methods lead to different conclusions on the account of protective or detrimental 
effects of Nrf2. Nrf2 knockout had the same beneficial effect as Nrf2 activation in insulin 
resistance (Fu et al., 2016; Seo & Lee, 2013). In the same way, Nrf2 inhibition and Nrf2 
hyperactivation were both detrimental for carcinogenesis (Jiang et al., 2010; Kensler & 
Wakabayashi, 2010; Zhang et al., 2010). These discrepancies were born from diverse 
methods, and thus a simple conclusion is difficult to draw. These results first suggest that 
boosting or activating Nrf2-signalling require a control as an excessive upregulation could be 
detrimental. Secondly, that Nrf2 results may produce discrepancies between methods, and 
that a clearer understanding is needed in this regard. 
 
 
Table 6-2 Main discrepancies between chapter 4 and chapter 5 following ischaemia comparing GFAP-Nrf2 to 
wild-type animals. 
For each experiment, the result is the comparison of Nrf2 overexpression in astrocytes with wild-type animals 
following ischaemia. In black is shown that GFAP-Nrf2 animals had similar results to the wild-types. In red are 
noted the significant differences between GFAP-Nrf2 animals and wild-types. 
 
  
MCAo duration 60 minutes 15 minutes
Survival 24 hours 4 weeks
neuroprotection modest none
oxidative stress reduced equal
GFAP expression increased equal
Iba1 expression equal increased
IL-4ra mRNA increased equal
CXCL10 mRNA increased equal
C3 mRNA equal decreased
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6.2. Limitations and future directions 
The different pieces of work of this thesis have highlighted several limitations of the 
experiments.  
For most of this study, cortex and striatum were studied but further studies should be 
focused on the white matter, thalamus, hypothalamus and hippocampus. These brain 
regions are especially important because the neuroprotective effects found in the chapter 4 
seemed to occur in the caudal part of the brain with thalamus and hypothalamus. A study 
designed to include these additional anatomical regions of interest could inform on the 
heterogeneity of neurons, microglia and astrocytes throughout the brain, with the impact of 
Nrf2 beneficial effect depending on this heterogeneity. 
In this work, spatial differences were found (peri-infarct versus core) for a same time point.  
In situ hybridisation could be developed to get further insight of the inflammatory 
modulation and of the Nrf2-signalling activation that is better studied looking at downstream 
gene expression. An alternative could be to collect and analyse the different areas underlying 
ischaemic pathology. Furthermore, histology techniques are now developed to gain 
sensitivity, looking for more specific markers for the different function of microglia, for the 
different subtypes of astrocytes, for the different pro- and anti-inflammatory phenotypes 
(Cahoy et al., 2008; Franco-Bocanegra et al., 2019; Hammond et al., 2019). It could be 
hypothesised that Nrf2 can modify glial phenotypes in different ways depending on the area 
of the lesion, or the anatomical region involved. 
Inflammation was characterised using a few markers and these genes were not analysed with 
cell-specific methods. In the same way, oxidative stress was analysed using only one 
antibody. Due to the heterogeneity of astrocytes and microglia, more genes could be 
analysed, but also a single-cell approach would greatly reduce possible confusion as most 
cytokines are produced by a multitude of cells. Ideally, RNA-sequencing of fluorescent-
associated cell sorting are to date the best techniques to give more detailed overview of 
inflammation (Frigerio et al., 2019; Liddelow et al., 2017; Anderson et al., 2014; Boisvert et 
al., 2018). The Nrf2/HO1 pathway is related to an anti-inflammatory response (Rojo et al., 
2010; Kobayashi et al., 2016; Liu et al., 2017; Peng et al., 2016; Liu et al., 2019) and linked to 
specific modulation of microglia/macrophage phenotypes but their transcriptional signature 
has not been defined yet (Boyle et al., 2012; Kadl et al., 2010; Naito et al., 2014). 
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The magnitude of difference between chapter 4 and 5 in the result is of importance. It would 
be interesting to study GFAP-Nrf2 mice 24 hours after 15 minutes ischaemia and 4 weeks 
after 60 minutes ischaemia. Furthermore, there was an improvement in the neuroscore for 
GFAP-Nrf2 mice at 7 days after 15 minutes ischaemia compared to wild-types. It would be 
interesting to further study this time point by collecting some brains and analyse cellular and 
molecular differences in between these genotypes. There is potentially an effect of both the 
severity and the survival, but also of the area. As seen in chapter 3, increased duration led to 
increased pathology features. Furthermore, ischaemia unfolds a cascade of many features 
that evolve through time.  
Finally, new techniques in magnetic resonance imaging (MRI) and positron-emission 
tomography (PET) have provided important in vivo insight and allow for temporal follow up 
of inflammation, blood flow, lesion and penumbra. In addition, in vivo imaging using multi-
photon microscopy is an important research field and provide increasing studies on temporal 
evolution of any disease model and cellular response (Wu et al., 2017). 
Cerebral ischaemia occurs for 95% of cases in individuals aged 45-years old or older (Grau et 
al., 2001). However, aged animals are frail and following severe procedures like ischaemia 
there are increased levels of mortality and technical difficulties, furthermore maintenance 
and care of these animals is expensive. Thus, research on elder animals is difficult and mainly 
done on young animals. This bias limit translations from preclinical to clinical research. Aged 
animals have reduced Nrf2 signalling (Suh et al., 2004; Zhang et al., 2015) and in case of 
ischaemia have increased oxidative stress (Buga et al., 2008; Li et al., 2005; Roberts et al., 
1997; Sieber et al., 2014; Zhang et al., 2018) and inflammation (Badan et al., 2003; DiNapoli 
et al., 2008; Manwani et al., 2011; Popa-Wagner et al., 2007; Sieber et al., 2011; Sieber et al., 
2014; Titova et al., 2011) worsening ischaemic damage in most cases (DiNapoli et al., 2008; 
Doyle et al., 2012; Manwani et al., 2011; Nguyen et al., 2018; Popa-Wagner et al., 2007). In 
this scope, Nrf2 activation following ischaemia on older animals may have a potential 
beneficial effect. However, it is limited by the long list of comorbidities found on old 
ischaemic patient, such as diabetes, cancer, coronary diseases, hypertension, obesity and 
cardiac diseases. As explained previously, Nrf2 is potentially detrimental in diabetes and 
cardiac myopathy. Thus, therapeutic use of Nrf2-signalling pathway activation for ischaemic 
patient will have to be controlled and reviewed with comorbidity cases. Pharmacological 
compounds that target Nrf2 in the brain will have effects on all organs in the body. 
230 
 
Interestingly, Nrf2-overexpression in astrocytes caused increased levels of the 
microglia/macrophage marker Iba1 at 4 weeks. This result suggests a possible interplay 
between the different glial cells. New studies have emerged with the single-cell dimension, 
giving cell-specific modification (Frigerio et al., 2019; Hammond et al., 2019; Liddelow et al., 
2017). As this piece of work gave differential effect of Nrf2-overexpression in astrocytes, the 
next step would be to gain further understanding in the cell mechanisms at stake using these 
single-cell methods such as fluorescent-associated cell sorting.  
In order to further study the modulation of inflammation seen in this piece of work, cell-
specific analysis could be done using fluorescent-associated cell sorting (FACs) method or by 
tagging and sorting cells using TRAP-BAC mice models. As many genes are modified by 
ischaemia, in the inflammation cascade or around the Nrf2-signalling pathway, RNA-
sequencing method would give a better understanding of the molecular pathways involved.  
Nrf2 overexpression in astrocytes is known for its protective effects on diverse 
neurodegenerative conditions (Calkins et al., 2010; Chen et al., 2009; Gan et al., 2012; LaPash 
Daniels et al., 2012; Sigfridsson et al., 2018; Vargas et al., 2008). However, Nrf2 activation in 
multiple cell types seems to be important to achieve protection for other pathologies (Liddell, 
2017). This would explain that the neuroprotective effect found in the chapter 4 was modest 
and that there was no neuroprotection in the chapter 5. Beneficial effects of Nrf2-signalling 
activation after ischaemia have been demonstrated using pharmacological compounds that 
possibly have Nrf2-independent effects on are on a global multi-cells scale (Thomas W 
Kensler & Wakabayashi, 2010; O’Mealey et al., 2017; Schulze-Topphoff et al., 2016; Zagorski 
et al., 2017). Coupling Nrf2-signalling activation with other drugs targeting other protective 
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8.1. Reagent recipes 
Phosphate buffer 
Phosphate buffer (PB) was made 10-times concentrated by dissolving 2.57 g of mono-sodium 
phosphate (NaH2PO4; Sigma) and 11.95 g di-sodium phosphate (Na2HPO4; Sigma) in distilled 
water to make up for 1 litre. This solution was then filtered and was diluted a tenth in order 
to be used. 
 
Phosphate buffer saline 
Phosphate buffer saline (PBS) was made 10-times concentrated by dissolving 2.57 g of mono-
sodium phosphate (NaH2PO4; Sigma) and 11.95 g di-sodium phosphate (Na2HPO4; Sigma) in 
distilled water. After adjusting the pH to 7.4, 90 g of sodium chloride was added, and the final 
solution was filled with distilled water to make up for 1 litre. This solution was then filtered 
and was diluted a tenth in order to be used. 
 
Tris buffer 
Tris buffer (TB) was made 10-times concentrated by dissolving 60.6 g of Trizma HCl (Sigma) 
and 13.9 g of Trizma base (Sigma) in distilled water to make up for 1 litre. This solution was 
then adjusted for a 7.6 pH and filtered. In order to be used, this solution was diluted a tenth.  
 
Paraformaldehyde 4% 
After heating 800 ml of PB at 60°C, 40 g of P6148 paraformaldehyde (Sigma) was added to 
the hot PB and let to stir for 15 minutes. After cooling down, the final solution was filled with 




8.2. Glial response in the peri-infarct compared to the core of chronic ischaemia and 
compared with lesion 
8.2.1. Peri-infarct results in the chronic phase of ischaemia were a mean value of core 
and healthy for Glial marker GFAP and Iba1 
 
Figure 8-1 GFAP immunostaining quantified with %area was increased in the peri-infarct 4 weeks following 
ischaemia. 
Quantification of GFAP immunostaining by assessing %area revealed significant differences between shams and 
15 minutes ischaemia in the cortex peri-infarct (t(14)=3.635, p=0.0027) and the striatum (t(14)=6.414, p<0.0001).  
Data presented as mean ± SEM. Student’s t-test (N= 7 to 9 per group). **p<0.01, ***p<0.001.  
 
 
Figure 8-2 Iba1 immunostaining quantified with %area was increased in the peri-infarct 4 weeks following 
ischaemia. 
Quantification of Iba1 immunostaining by assessing %area revealed significant differences between shams and 15 
minutes ischaemia in the striatum (t(14)=3.278, p=0.0060), but not in the cortex peri-infarct (t(14)=1.989, p=0.0666) 
and 
Data presented as mean ± SEM. Student’s t-test (N= 7 to 9 per group). **p<0.01.  
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8.2.2. Correlations of the lesion volume with GFAP and Iba1 marker in the chronic 
response to ischaemia 
 
Figure 8-3 GFAP %area in the cortex peri-infarct is correlated with the lesion volume at 4 weeks but not the 
core. 
Study of GFAP immunostaining %area compared with lesion volume revealed significant a positive correlation in 
the peri-infarct (R=0.7338, p<0.0001) but not in the cortex core (R=0.1544, p=0.3908). 
Regression curve after Rho of Pearson correlation study (N= 7 to 9 per group).  
 
 
Figure 8-4 Iba1 %area in the cortex is correlated with the lesion volume at 4 weeks 
Study of Iba1 immunostaining %area compared with lesion volume revealed significant a positive correlation in 
the peri-infarct (R=0.5333, p=0.0014) and core (R=0.5252, p=0.0017). 
Regression curve after Rho of Pearson correlation study (N= 7 to 9 per group).  
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8.3. Astrocytic overexpression of Nrf2 did not modify cerebral blood flow 4 weeks 
after ischaemia 
In order to verify cerebral blood flow (CBF) reduction in our model, laser speckle technique 
was used. The laser speckle software created a map of the blood flow with pseudo colours, 
ranging from blue (low) to red (high; Fig 8.4 A). This technique presented difficulties as the 
wound on the skull had to be reopened 4 weeks after the first reading and the scar 
compromised the reading of a few animals (13 animals excluded: 4 sham wild-type, 3 sham 
GFAP-Nrf2, 4 ischaemic wild-type and 2 ischaemic GFAP-Nrf2). The quantification is 
presented with ipsilateral CBF normalised to the contralateral CBF levels, with contralateral 
being 100%. Sham animals presented similar CBF readings before and 4 weeks after surgery. 
There was a significant  effect of the surgery with decreased CBF in the ipsilateral side of 
ischaemic animals compared to shams (F(1, 35)=8.19, p=0.0071) and there was no effect of the 







Figure 8-5. Nrf2 overexpression in astrocytes does not modify cerebral blood flow (CBF) reduction observed after 
mild ischaemia 4 weeks post-injury. 
(A) Representative images of the cerebral blood flow (CBF) with intensity colours (from blue low CBF to red high 
CBF). Ischaemia reduces the CBF in the ipsilateral side (right hand side), four weeks after the injury. 
(B) Quantification of CBF in the ipsilateral side to the lesion, normalised on the contralateral CBF, showed a 
reduction four weeks after 15 minutes of ischaemia (F(1, 35)=8.19, p=0.0071). There was no effect of genotype (F(1, 
35)=0.102 p=0.75).  
Dotted line indicates contralateral CBF level. Data presented as mean ± SEM. Two-way ANOVA followed by post 
hoc comparisons with Bonferroni (N= 11 to 15 per group). *p<0.05, **p<0.01, ***p<0.001.  
 
Using the same model, Sigfridsson and colleagues found unchanged CBF was reduced 6 
weeks after bilateral common carotid artery stenosis but not altered between Gfap-Nrf2 and 
wild-type mice (Sigfridsson et al., 2018). Other authors modulating Nrf2 in models of 
ischaemia did not find an effect on CBF (Shah et al., 2007; Yang et al., 2018; Wu et al., 2017). 
Interestingly, cognitive functions were impaired in GFAP-Nrf2 animals at 4 weeks after 
















































ischaemia. This result is unlikely related to the cerebral blood flow modulation as GFAP-Nrf2 
mice had comparable CBF levels to wild-type ischaemic animals. It suggests that this effect is 
independent of CBF modulation. 
However, this result is limited by the comparison technique used to assess the perfusion is a 
comparison to contralateral side and not baseline. This method was preferred as many 
technical problems were encountered and some animal reading had to be excluded.  
 
 
 
